ShRNA targeting UBE3A-ATS to restore paternal UBE3A gene expression in happy puppet syndrome
By carrying shRNA to target UBE3A-ATS with AAV or lentiviral vectors, the paternal UBE3A gene was activated, and the problem of missing UBE3A protein expression in Happy Puppet Syndrome was solved, and neuronal function was improved and disease symptoms were alleviated.
Patent Information
- Application Number
- CN202380026099.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-29
AI Technical Summary
Patients with Happy Puppet Syndrome (AS) have lost maternal allelic function of the UBE3A gene, which leads to the loss of UBE3A protein expression. It is difficult for the prior art to effectively restore UBE3A expression to improve disease symptoms.
Improve UBE3A protein by carrying short hairpin RNA (shRNA) using adeno-associated virus (AAV) or lentiviral vectors, targeting UBE3A-ATS, inhibiting its expression, thereby activating the paternal UBE3A gene, replacing or increasing the missing maternal UBE3A expression, and improving UBE3A protein expression level.
This method can improve AS symptoms with a single treatment, reduce the need for multiple treatments, increase the recovery of neuron resting membrane potential to about -70mV, improve the delay in action potential development and spontaneous synaptic activity, and improve the correlation with base intensity and action potential characteristics. neuronal phenotype.
Smart Images

Figure CN119053703A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 317,154, filed on March 7, 2022, which is incorporated herein by reference in its entirety.
[0003] Government Support Statement
[0004] This invention was made with government support under Contract No. 1R01HD094953 awarded by the National Institute of Health. The government has certain rights in this invention. Technical Field
[0005] The present disclosure relates to compositions and methods for activating expression of a paternally inherited allele of UBE3A in a subject with Angelman Syndrome using short hairpin RNA.
[0006] Reference to a sequence listing
[0007] A sequence listing corresponding to the sequences described herein is filed.
[0008] background
[0009] Angelman syndrome (AS) is a neurodevelopmental disorder that affects ~1 / 15,000 individuals. Individuals with AS have developmental delay, severe cognitive impairment, ataxic gait, frequent seizures, short attention span, absent speech, and characteristic happy demeanor. Neurons derived from induced pluripotent stem cells (iPSCs) from AS patients exhibit depolarized resting membrane potentials, delayed action potential development, and reduced spontaneous synaptic activity. Fink, JJ, TM Robinson, ND Germain, CL Sirois, KA Bolduc, AJ Ward, F. Rigo, SJ Chamberlain, and ES Levine (2017). "Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells." Nat Commun 8: 15038. AS affects a relatively large patient population; a contact registry of >3,000 patients has been established, and there are ~250 new AS diagnoses each year. Individuals with AS require lifelong care.
[0010] AS is caused by the loss of function of the maternal copy of UBE3A, which is a gene encoding an E3 ubiquitin ligase. This loss-of-function mutation can be caused by any type of genetic mutation in the maternal allele. UBE3A is exclusively expressed by the maternal allele in neurons. All individuals with AS have a normal paternal UBE3A allele, which is epigenetically silenced in a cis manner by a long non-coding RNA called UBE3A antisense transcript (UBE3A-ATS) in neurons (Rougeulle et al., 1997, Nat Genet 17, 14-15; Chamberlain and Brannan, 2001, Genomics 73, 316-322). In the AS mouse model, reactivation of the paternal allele was shown to restore UBE3A protein expression and alleviate behavioral defects. The restoration of UBE3A expression in humans is expected to improve the disease, especially if it is restored in infants.
[0011] Overview
[0012] This article provides a new method to treat Happy Marionette Syndrome by inhibiting the silencing of paternal UBE3A and enabling paternal UBE3A to be expressed from its native regulatory elements, thereby replacing or increasing the missing maternal UBE3A. The increase in UBE3A expression in neurons is achieved by terminating the transcription of UBE3A-ATS. Since the native regulatory elements control expression, overexpression of UBE3A is prevented. This approach can improve AS symptoms with a single treatment and eliminate the need for multiple treatments.
[0013] The present invention provides a polynucleotide sequence comprising:
[0014] An expression vector comprising SEQ ID NO: 2 is provided. In an embodiment, the expression vector is an adeno-associated virus (AAV) vector or a lentiviral vector. A pharmaceutical composition comprising the foregoing is provided.
[0015] Provided herein are polynucleotides encoding shRNAs comprising a nucleotide sequence that is at least 85%, at least 90%, at least 95%, or 100% complementary to an RNA encoded by any one of SEQ ID NOs: 3-489. In embodiments, the polynucleotide is SEQ ID NO: 2. In embodiments, the shRNA results in activation or increase in expression of paternal UBE3A. In embodiments, the shRNA results in decreased expression of paternal UBE3A-ATS. An expression vector comprising the shRNA is provided. In embodiments, the expression vector is an adeno-associated virus (AAV) vector or a lentiviral vector. A pharmaceutical composition comprising the foregoing is provided.
[0016] Provided herein is a method for treating Happy Puppet Syndrome, comprising administering a polynucleotide of SEQ ID NO: 2 to a patient in need thereof. In an embodiment, the polynucleotide of SEQ ID NO: 2 encodes an shRNA that results in decreased expression of the paternal UBE3A-ATS. In an embodiment, the polynucleotide of SEQ ID NO: 2 encodes an shRNA that results in activation or increased expression of the paternal UBE3A gene.
[0017] Provided herein is a method for treating Happy Puppet Syndrome, comprising administering to a patient in need thereof a polynucleotide encoding a shRNA comprising a nucleotide sequence that is at least 85%, at least 90%, at least 95%, or 100% complementary to an RNA encoded by any one of SEQ ID NOs: 3-489. In embodiments, the polynucleotide is SEQ ID NO: 2. In embodiments, the shRNA results in activation or increase in expression of paternal UBE3A. In embodiments, the shRNA results in decreased expression of paternal UBE3A-ATS.
[0018] In an embodiment, SEQ ID NO:2 encodes a shRNA capable of inhibiting the silencing of paternal UBE3A. In an embodiment, SEQ ID NO:2 is contained in an expression vector. In an embodiment, the expression vector is an adeno-associated virus (AAV) vector or a lentiviral vector. In an embodiment, a method of inhibiting the silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO:1 is provided, comprising administering to a patient in need thereof an amount of SEQ ID NO:2 effective to cleave the RNA antisense transcript encoded by SEQ ID NO:1.
[0019] In an embodiment, a method for inhibiting silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO: 1 is provided, comprising administering to a patient in need thereof an amount of shRNA effective to cleave the RNA antisense transcript encoded by SEQ ID NO: 1, wherein the shRNA comprises a nucleotide sequence that is at least 85%, at least 90%, at least 95% or 100% complementary to the RNA encoded by any one of SEQ ID NOs: 3-489.
[0020] In embodiments, the shRNA provided herein is encoded by a portion of SEQ ID NO: 2, e.g., with bold nucleotides, which are shortened by one, two, three, or four nucleotides at either end of the bold nucleotides. Similarly, in embodiments, the shRNA provided herein can contain a portion of SEQ ID NO: 2, e.g., with italic nucleotides, which are shortened by one, two, or three nucleotides at either end of the italic nucleotides.
[0021] In an embodiment, the following polynucleotide sequence is provided:
[0022] wherein nnnnnnnn can be CTCGAG (SEQ ID NO:490), TCAAGAG (SEQ ID NO:491), TTCG (SEQ ID NO:492) or GAAGCTTG (SEQ ID NO:493).
[0023] In an embodiment, a polynucleotide sequence is provided, which includes a first part, a second part and a third part, the first part comprises any one of SEQ ID NO:3-489, the second part comprises any one of SEQ ID NO:490, 491, 492 or 493, and the third part comprises a corresponding nucleotide sequence complementary to the nucleotide sequence in SEQ ID NO:3-489. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 Chromosomal mutations in Happy Marionette syndrome are shown.
[0026] Figure 2 A schematic representation of the paternal UBE3A gene is shown.
[0027] Figure 3 The genomic locations of the shRNA targets are shown (solid line annotation). UCSC Genome Browser view of the 15q11-q13 region containing the imprinted SNHG14 / UBE3A locus (dashed line annotation). Location of the shRNA targets within the UBE3A-ATS region (ATS-shRNA2) and the SNORD115 snoRNA cluster.
[0028] Figure 4 is a bar graph showing qRT-PCR analysis of Happy Marionette Syndrome iPSC-derived neurons after treatment with shRNA targeting SNHG14 (551-2, ATS shRNA1-4, ATS shRNA2_3G) or non-targeting control shRNA (scrambled). Two shRNAs (551-2 and ATS shRNA2) knocked down UBE3A-ATS and activated paternal UBE3A.
[0029] Figure 5 is a bar graph showing qRT-PCR analysis of Happy Marionette syndrome iPSC-derived neurons after treatment with shRNA targeting SNHG14 (ATS shRNA2), non-targeting control shRNA (scrambled), or untreated (UTC). ATS shRNA2 knocked down UBE3A-ATS and activated paternal UBE3A.
[0030] Details
[0031] UBE3A is a gene encoding an E3 ubiquitin ligase. The genomic coordinates of UBE3A on the negative strand are hg19chr15:25,582,381-25,684,175. There are three normal isoforms of UBE3A: isoform 1 (accession number X98032); isoform 2 (accession number X98031); and isoform 3 (accession number X98033). In neurons, UBE3A is exclusively expressed by the maternal allele. The paternal UBE3A allele is epigenetically silenced by the long noncoding RNA UBE3A antisense transcript (UBE3A-ATS) encoded by SEQ ID NO:1. The genomic coordinates of UBE3A-ATS on the positive strand are hg19chr15:25,223,730-25,664,609. The following genomic coordinates are of particular interest: hg19chr15:25,522,751-25,591,391 on the plus strand.
[0032] UBE3A-ATS / Ube3a-ATS (human / mouse) is an antisense DNA strand transcribed at the UBE3A locus of a part of a larger transcript called SNHG14 (SNORNA host gene 14). In the central nervous system (CNS), human UBE3A-ATS is exclusively expressed from the paternal allele as a part of SNHG14. The transcript is about 600kb long, starts from SNRPN, and extends through most of UBE3A. SNHG14 (small nucleolar RNA host gene 14) encodes non-coding RNA and belongs to the lncRNA class. SNHG14 is located in the Prader-Willi critical region (critical region) and produces a long splicing maternal imprinted RNA, which starts at one of the several promoters of the SNRPN (small nuclear ribonucleoprotein polypeptide N) gene. The transcript serves as the host RNA of two clusters of C / D box small nucleolar RNA SNORD116 and SNORD115. See Runte et al., 2001, Hum Mol Genet 10, 2687-2700. This RNA extends into the ubiquitin protein ligase E3A (UBE3A) gene and is thought to regulate the imprinted expression of UBE3A in the brain. The promoter of SNRPN is the Prader-Willi syndrome imprinting center (PWS-IC), and about 35kb upstream of PWS-IC is the Happy Puppet Syndrome Imprinting Center (AS-IC). These two regions are thought to control the expression of the entire SNHG14 transcript.
[0033] SNURF / SNRPN is a bicistronic gene that encodes two protein-coding transcripts, SNURF and SNRPN. Both SNURF and SNRPN proteins are localized in the nucleus. SNRPN is a small nuclear ribonucleoprotein, and the function of SNURF is unclear. The transcript initiated at SNRPN / SNURF also encodes the SNHG14 transcript. Within the introns of SNHG14 are the sequences of several C / D box snoRNAs. Box C / D small nucleolar RNA (SNORD) represents a well-defined family of small non-coding RNAs that exert their regulatory functions via antisense-based mechanisms. Most C / D box snoRNAs play a role in non-mRNA methylation.
[0034] Many orphan snoRNAs are generated from two large imprinted chromosomal domains at 15q11q13 and 14q32 in humans. See, e.g., Figure 3 As described above, the imprinted human 15q11q13 region (also known as the Prader-Willi syndrome (PWS) / Happy Marionette syndrome (AS) locus or the SNURF-SNRPN domain) contains several paternally expressed protein-coding genes as well as many paternally expressed neuron-specific snoRNA genes organized as two major repetitive DNA arrays: the SNORD116 and SNORD115 clusters containing 29 and 47 copies of related genes, respectively.
[0035] SNORD115 encodes a small nucleolar RNA (snoRNA) that was found clustered with dozens of other similar snoRNAs on chromosome 15. These genes were found primarily within introns of the SNHG14 transcript, which is paternally imprinted and originates from the PWS / AS region.
[0036] The compositions and methods described herein are intended to target UBE3A-ATS to relieve paternal UBE3A allele silencing. Effective inhibition of UBE3A-ATS by short hairpin RNA (shRNA) described herein results in a decrease in UBE3A-ATS expression levels and a concomitant increase in paternal UBE3A allele expression levels.
[0037] In an embodiment, the compositions and methods herein relate to treating or preventing AS. Patients in need of such treatment or prevention suffer from AS or are at risk of developing AS. As used herein, the term "patients in need thereof" includes any mammals, including humans, in need of these treatments or prevention methods. The subject may be male or female. In certain aspects, patients in need of AS treated according to the methods and compositions provided herein may show improvements in anxiety, learning, balance, motor function, and / or epileptic seizures, or the method may restore the resting membrane potential of neurons to about -70 mV, improve delayed action potential development, increase spontaneous synaptic activity, and may improve additional changes in neuronal phenotypes associated with base strength, action potential characteristics (e.g., shape), membrane currents, synaptic potentials, and / or ion channel conductance.
[0038] In an embodiment, the polynucleotide comprises a first nucleotide sequence encoding a short hairpin RNA (shRNA), which results in reduced expression of the UBE3A-ATS sequence (SEQ ID NO: 1). For example, a portion of the shRNA described herein may be complementary to an RNA sequence encoded by SEQ ID NO: 1 or a sequence contained therein. In an embodiment, the shRNA described herein is an RNA polynucleotide encoded by a first nucleotide sequence. The polynucleotide comprising the first nucleotide sequence may be a DNA polynucleotide suitable for cloning into an appropriate vector (e.g., a plasmid) for culturing and subsequently producing viral particles. Subsequently, the viral particles may comprise a DNA polynucleotide having a nucleotide coding sequence in a form suitable for infection. Therefore, the first nucleotide sequence may be a DNA sequence cloned into a plasmid for viral particle production or encapsulated in a viral particle. Since retroviruses carry nucleotide coding sequences in the form of RNA polynucleotides, retroviral particles (e.g., lentiviruses) comprise RNA polynucleotides comprising a first nucleotide sequence as a corresponding RNA sequence.
[0039] Disclosed herein is a novel shRNA that cuts UBE3A-ATS, thereby reducing UBE3A-ATS expression and then activating the paternally inherited copy of UBE3A in neurons. This provides the UBE3A gene product in cell types that lack the protein in Happy Marionette Syndrome. There is a potential search space of about 60kb in the genomic LNCAT sequence, which can provide potential shRNA targets. However, not every predicted sequence actually reduces UBE3A-ATS and restores UBE3A. Therefore, as shown in some examples herein, it is difficult to predict which sequences will work or not. See, for example, Figure 4 .
[0040] The first nucleotide sequence encodes shRNA. For example, the first nucleotide sequence can be SEQ ID NO: 2 The first nucleotide sequence may also be such a modification that the bold nucleotides in SEQ ID NO:2 are replaced by any one of SEQ ID NO:4-489, and the italic nucleotides in SEQ ID NO:2 are replaced by nucleotides complementary to those in SEQ ID NO:4-489. As used herein, "target" means an effective RNA polynucleotide that can hybridize with a nucleotide sequence (such as a nucleotide sequence transcribed from a nucleotide sequence in a larger genomic sequence of UBE3A-ATS) by hydrogen bonding. The hybridization of an effective RNA polynucleotide with a nucleotide sequence transcribed from a nucleotide sequence in a larger genomic sequence of UBE3A-ATS can result in a decrease in the expression level of UBE3A-ATS in the presence of an effective RNA polynucleotide compared to the expression level of UBE3A-ATS in the absence of an effective RNA polynucleotide. In an embodiment, the effective RNA polynucleotide comprises a nucleotide sequence of an shRNA complementary to an RNA sequence encoded within a larger genomic sequence of UBE3A-ATS. For example, the shRNA comprises a nucleotide sequence complementary to an RNA sequence encoded by SEQ ID NO:3 and SEQ ID NO:4-489. Thus, the effective RNA polynucleotide refers to the effective portion of the shRNA after the shRNA is assimilated into the target organism and processed into a functional state.
[0041] "Reduced expression" refers to a reduction or blockage of the expression or activity of UBE3A-ATS, and does not necessarily refer to a complete elimination of expression or activity. Mechanisms for reducing target expression include hybridization of an effective RNA polynucleotide to one or more target sequences transcribed from one or more sequences within the larger genomic UBE3A-ATS sequence (SEQ ID NO: 1), wherein the result or effect of the hybridization is target degradation or target occupancy, with subsequent arrest of cellular machinery involved, for example, in transcription or splicing.
[0042] Without wishing to be bound by a particular theory, the shRNA herein can inhibit the silencing of the paternal UBE3A by: (1) cleaving the RNA transcript encoded by SEQ ID NO: 1; (2) reducing the steady-state level of the RNA transcript encoded by SEQ ID NO: 1 (i.e., the baseline level when in steady state); and (3) terminating the transcription of SEQ ID NO: 1. For example, cleavage and reduction of the steady-state level of the RNA transcript encoded by SEQ ID NO: 1 can occur via a mechanism involving the RNA-induced silencing complex (RISC). shRNA can utilize RISC. After the vector carrying the genomic material of the shRNA is integrated into the host genome, the shRNA genomic material is transcribed into pri-microRNA in the host. The pri-microRNA is processed into pre-shRNA (pre-shRNA) by ribonucleases such as Drosha and exported from the nucleus. The pre-shRNA is processed by endoribonucleases such as Dicer to form small interfering RNA (siRNA). The siRNA is loaded into RISC, where the sense strand is degraded and the antisense strand acts as a guide to direct RISC to the complementary sequence in the mRNA. When the sequence has complete complementarity, RISC cleaves the mRNA, and when the sequence has incomplete complementarity, RISC represses the translation of the mRNA. Thus, the shRNA encoded by the first nucleic acid sequence increases the expression of paternal UBE3A by reducing the steady-state level of UBE3A-ATS RNA.
[0043] As used herein, the term "nucleic acid" refers to a molecule comprising monomeric nucleotides. Examples of nucleic acids include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), single-stranded nucleic acid, double-stranded nucleic acid, small interfering ribonucleic acid (siRNA) and short hairpin RNA (shRNA). "Nucleotide" means a nucleoside having a phosphate group covalently attached to the sugar portion of the nucleoside. "Oligonucleotide" or "polynucleotide" means a polymer of connected nucleotides, each of which can be modified or unmodified independently of one another.
[0044] As used herein, "short hairpin RNA (shRNA)" includes conventional stem-loop shRNA, which forms a precursor microRNA (pre-miRNA). "shRNA" also includes shRNA embedded in microRNA (shRNA based on miRNA), in which the guide strand and passenger strand of the miRNA duplex are integrated into an existing (or natural) miRNA or into a modified or synthetic (designed) miRNA. When transcribed, conventional shRNA (i.e., not a miR-451 shRNA mimic) forms a primary miRNA (primary miRNA, pri-miRNA) or a structure very similar to natural pri-miRNA. The pri-miRNA is then processed into a pre-shRNA by Drosha and its cofactors. Therefore, the term "shRNA" includes pri-miRNA (shRNA-mir) molecules and pre-shRNA molecules.
[0045] "Stem-loop structure" refers to a nucleic acid having a secondary structure including a nucleotide region (stem portion) of a double-stranded or duplexed body connected by a region (loop portion) that is mainly a single-stranded nucleotide, which is known or predicted to be formed on one side. As known in the art, the loop portion is at least 4 nucleotides long, 6 nucleotides long (for example, the underlined sequence in SEQ ID NO:2), 8 nucleotides long or longer. The terms "hairpin" and "fold-back" structures are also used to refer to stem-loop structures in this article. Such a structure is well known in the art, and the use of the term is consistent with its known meaning in the art. For example, CTCGAG (SEQ ID NO:490), TCAAGAG (SEQ ID NO:491), TTCG (SEQ ID NO:492) and GAAGCTTG (SEQ ID NO:493) are suitable stem-loop structures. As known in the art, the secondary structure does not require accurate base pairing. Therefore, the stem can include one or more base mispairings or protrusions. Alternatively, base pairing can be accurate, that is, does not include any mispairing. In an embodiment, the following polynucleotide sequence is provided:
[0046] Wherein nnnnnnnn can be CTCGAG (SEQ ID NO: 490), TCAAGAG (SEQ ID NO: 491), TTCG (SEQ ID NO: 492) or GAAGCTTG (SEQ ID NO: 493). In an embodiment, a polynucleotide sequence is provided, which includes a first part, a second part and a third part, the first part comprises any one of SEQ ID NO: 3-489, the second part comprises any one of SEQ ID NO: 490, 491, 492 or 493, and the third part comprises a corresponding nucleotide sequence complementary to the nucleotide sequence in SEQ ID NO: 3-489.
[0047] In embodiments, shRNAs may include, but are not limited to, modified shRNAs, including shRNAs with enhanced in vivo stability. Modified shRNAs include molecules containing nucleotide analogs, including those with additions, deletions, and / or substitutions in nucleobases, sugars, or backbones; and cross-linked or otherwise chemically modified molecules. One or more modified nucleotides may be within a portion of the shRNA molecule, or throughout the entire shRNA molecule. For example, the shRNA molecule may be modified, or contain modified nucleic acids in a region at its 5' end, its 3' end, or both, and / or in a guide strand, a passenger strand, or both, and / or in a nucleotide protruding from the 5' end, the 3' end, or both. (See, Crooke, U.S. Pat. Nos. 6,107,094 and 5,898,031; Elmen et al., U.S. Publication Nos. 2008 / 0249039 and 2007 / 0191294; Manoharan et al., U.S. Publication No. 2008 / 0213891; MacLachlan et al., U.S. Publication No. 2007 / 0135372; and Rana, U.S. Publication No. 2005 / 0020521; all of which are hereby incorporated by reference.)
[0048] The shRNA herein comprises a nucleotide sequence complementary to an RNA nucleotide sequence transcribed from a complete genomic UBE3A-ATS sequence (SEQ ID NO: 1), and inhibits the silencing of UBE3A-ATS to paternal UBE3A. In an embodiment, the shRNA comprises a nucleotide sequence complementary to an RNA sequence encoded by SEQ ID NO: 4-489. In an embodiment, the shRNA comprises a nucleotide sequence complementary to an RNA sequence encoded by SEQ ID NO: 3 (5'-GATATCACCTTACAGAAATTA-3', UBE3A-ATS artificial / synthetic target). In an embodiment, the shRNA is encoded by the nucleotide sequence of SEQ ID NO: 2. In an embodiment, the length of the nucleotide sequence contained in the shRNA and complementary to the RNA nucleotide sequence transcribed from the UBE3A-ATS gene is 17-21 nucleotides. The complementary nucleotides may be continuous or may be interspersed with non-complementary nucleotides. In an embodiment, the length of the complementary nucleotide sequence is 21 nucleotides, as indicated by the bold sequence in SEQ ID NO: 2. The shRNA may comprise a nucleotide sequence in which 17, 18, 19, 20 or 21 nucleotides are complementary to nucleotides in SEQ ID NO: 3 or 4-489. The 17, 18, 19, 20 or 21 complementary nucleotides may be continuous or may be interspersed with non-complementary nucleotides. The total length of the shRNA including the loop may be 40-50 nucleotides, e.g., 44-48 nucleotides, e.g., 48 nucleotides.
[0049] Methods for determining whether a sequence can specifically hybridize to a target nucleic acid are well known in the art.In an embodiment, the shRNA polynucleotides provided herein comprise a nucleic acid sequence that can specifically hybridize to an RNA sequence transcribed from UBE3A-ATS (SEQ ID NO: 1).
[0050] The shRNA may comprise an RNA polynucleotide comprising a region of 17-21 linked nucleotides complementary to an RNA target sequence, wherein the RNA polynucleotide region is at least 85% complementary to a region of equal length to a UBE3A-ATS RNA nucleic acid sequence over its entire length. In embodiments, the RNA polynucleotide region is at least 90%, at least 95%, or 100% complementary to a region of equal length to a UBE3A-ATS RNA nucleic acid sequence over its entire length.
[0051] The shRNA may comprise a nucleotide sequence that is at least 85% complementary to an RNA sequence encoded by SEQ ID NO:3 or any one of SEQ ID NOs:4-489 and has an equal length. The shRNA may comprise a nucleotide sequence that is at least 90% complementary to an RNA sequence encoded by SEQ ID NO:3 or any one of SEQ ID NOs:4-489 and has an equal length. The shRNA may comprise a nucleotide sequence that is at least 95% complementary to an RNA sequence encoded by SEQ ID NO:3 or any one of SEQ ID NOs:4-489 and has an equal length. The shRNA or microRNA may comprise a nucleotide sequence that is 100% complementary to an RNA sequence encoded by SEQ ID NO:3 or any one of SEQ ID NOs:4-489 and has an equal length.
[0052] In embodiments, shRNA is a single-stranded RNA polynucleotide. In embodiments, RNA polynucleotide is a modified RNA polynucleotide. Complementarity percentage is used in the conventional sense herein to refer to base pairing between adenine and thymine, adenine and uracil (RNA), and guanine and cytosine.
[0053] Non-complementary nucleobases between the shRNA and the UBE3A-ATS nucleotide sequence can be tolerated if the shRNA remains capable of specific hybridization with the UBE3A-ATS nucleotide sequence. In addition, the shRNA can hybridize within one or more segments of the UBE3A-ATS nucleotide sequence such that intervening or adjacent segments are not involved in the hybridization event (e.g., loop structures, mismatches, or hairpin structures).
[0054] In embodiments, the shRNAs provided herein, or specified portions thereof, are 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to a UBE3A-ATS RNA nucleotide sequence, a UBE3A-ATS region, a UBE3A-ATS segment, or a specified portion thereof, or are at least 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary. The percent complementarity of the shRNA to the UBE3A-ATS nucleotide sequence can be determined using conventional methods.
[0055] For example, an shRNA in which 18 of the 20 nucleobases are complementary to the UBE3A-ATS region and will therefore specifically hybridize will represent 90% complementarity. In this example, the remaining non-complementary nucleobases can be clustered or interspersed with complementary nucleobases and do not need to be adjacent to each other or adjacent to complementary nucleobases. Therefore, an shRNA of 18 nucleobases in length, having four non-complementary nucleobases flanking two regions that are completely complementary to the target nucleotide sequence, has 77.8% overall complementarity with the target nucleotide sequence, and therefore falls within the subject matter disclosed herein. The percentage of complementarity of shRNA to the region of the UBE3A-ATS nucleotide sequence can be routinely determined using BLAST programs (Basic Local Alignment Search Tool) and PowerBLAST programs (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) known in the art. Percent homology, sequence identity or complementarity can be determined, for example, by the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.) using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).
[0056] In an embodiment, the shRNA provided herein or a specified portion thereof is fully complementary (i.e., 100% complementary) to a specified portion of a UBE3A-ATS nucleotide sequence or its SEQ ID NO: 1 transcription product. For example, the shRNA can be fully complementary to a UBE3A-ATS nucleotide sequence or a region thereof or a segment thereof or a sequence thereof. As used herein, "fully complementary" means that each nucleobase of the shRNA is capable of precise base pairing with a corresponding RNA nucleobase transcribed from a UBE3A-ATS nucleotide sequence.
[0057] In embodiments, the shRNA provided herein may contain a portion of SEQ ID NO: 2, e.g., with bold nucleotides, which are shortened by one, two, three, or four nucleotides at either end of the bold nucleotides. Similarly, in embodiments, the shRNA provided herein may contain a portion of SEQ ID NO: 2, e.g., with italic nucleotides, which are shortened by one, two, or three nucleotides at either end of the italic nucleotides. For example:
[0058]
[0059] Similarly, in an embodiment, the sequence set forth in any one of SEQ ID NOs: 4-489 and / or their complementary sequences may be shortened by one, two, three or four nucleotides at either end and incorporated into the shRNA.
[0060] An effective concentration or dose of shRNA can inhibit silencing of paternal UBE3A by UBE3A-ATS by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
[0061] An effective concentration or dosage of shRNA can terminate transcription of UBE3A-ATS by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
[0062] An effective concentration or dose of the shRNA can reduce the steady-state level of UBE3A-ATS by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%.
[0063] An effective concentration or dosage of shRNA can cleave UBE3A-ATS and reduce it by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%.
[0064] An effective concentration or dose of the shRNA can reduce the expression of UBE3A-ATS by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%, and increase the expression of the paternal UBE3A by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%.
[0065] As used herein, the terms "UBE3A-ATS" and "Ube3A-ATS" are used interchangeably and are not capitalized to indicate any particular species or interspecies homologs. "UBE3A" and "Ube3A" are used interchangeably and are not capitalized to indicate any particular species or interspecies homologs. In addition, "UBE3A", "UBE3A", "Ube3A", and "Ube3A" are used interchangeably without italics to indicate nucleic acids or proteins, unless otherwise specifically indicated.
[0066] Viral vectors
[0067] A "vector" is a replicon, such as a plasmid, phage, or cosmid, into which a DNA segment or RNA segment can be inserted so as to cause replication of the inserted segment. Typically, a vector is capable of replication when associated with appropriate control elements. Suitable vector backbones include, for example, those conventionally used in the art, such as a plasmid, a plasmid containing a viral genome, a virus, or an artificial chromosome. The term "vector" includes cloning and expression vectors, as well as viral vectors and integrating vectors.
[0068] It will be apparent to those skilled in the art that the term "viral vector" is used broadly to refer to nucleic acid molecules that include viral nucleic acid elements that typically facilitate transfer of nucleic acid molecules into cells or viral particles (e.g., transfer plasmids), which mediate transfer of nucleic acid sequences and / or integration of nucleic acid sequences into the cellular genome.
[0069] Viral vectors include structural and / or functional genetic elements that are primarily derived from viruses. Desirably, viral vectors are non-toxic, non-immunogenic, easy to produce, and effectively protect and deliver DNA or RNA to target cells. According to the compositions and methods described herein, viral vectors may contain DNA encoding one or more shRNAs described herein. In embodiments, the viral vector is a lentiviral vector or an adeno-associated virus (AAV) vector.
[0070] As used herein, the term "lentivirus" refers to a group (or genus) of complex retroviruses. Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); Vesnamedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). As used herein, the term "lentivirus" includes lentiviral particles. Lentiviruses transduce dividing cells and post-mitotic cells.
[0071] The term "lentiviral vector" refers to a viral vector (e.g., a viral plasmid) comprising structural and functional genetic elements derived primarily from a lentivirus, or portions thereof, including long terminal repeats (LTRs). A lentiviral vector is a hybrid vector (e.g., in the form of a transfer plasmid) having retroviral (e.g., lentiviral) sequences for reverse transcription, replication, integration, and / or packaging of a nucleic acid sequence (e.g., a coding sequence). The term "retroviral vector" refers to a viral vector (e.g., a transfer plasmid) comprising structural and functional genetic elements derived primarily from a retrovirus, or portions thereof.
[0072] Adenoviral vectors are designed to be administered directly to living subjects. Unlike retroviral vectors, most adenoviral vector genomes are not integrated into the chromosomes of host cells. Instead, genes introduced into cells using adenoviral vectors are maintained in the nucleus as extrachromosomal elements (episomes) that last for an extended period of time. Adenoviral vectors can transduce dividing and non-dividing cells in many different tissues in vivo, including airway epithelial cells, endothelial cells, hepatocytes, and various tumors (Trapnell, Advanced Drug Delivery, Reviews, 12 (1993) 185-199).
[0073] The term "adeno-associated virus" (AAV) refers to a small ssDNA virus that infects humans and some other primate species, is known not to cause disease, and only causes a very mild immune response. As used herein, the term "AAV" is intended to include AAV particles. AAV can infect both dividing cells and non-dividing cells, and its genome can be integrated into the genome of the host cell. These features make AAV an attractive candidate for producing viral vectors for gene therapy, although the cloning ability of the vector is relatively limited. In an embodiment, the vector used is derived from adeno-associated virus (i.e., AAV vector). More than 30 naturally occurring AAV serotypes are available. There are many natural variants in the AAV capsid, allowing identification and use of AAVs with properties particularly suitable for specific target cell types. AAV viruses can be engineered by conventional molecular biology techniques, so that these particles are optimized for cell-specific delivery of shRNA DNA sequences, for minimizing immunogenicity, for regulating stability and particle life, for effective degradation, for accurate delivery to the nucleus, etc. Become possible.
[0074] An "expression vector" is a vector that contains regulatory regions. Many vectors and expression systems are commercially available from companies such as Novagen (Madison, Wis.), Clontech (Palo Alto, Calif.), Stratagene (La Jolla, Calif.), and Invitrogen / Life Technologies (Carlsbad, Calif.). An expression vector may be a viral expression vector derived from a particular virus.
[0075] The vectors provided herein may also include, for example, an origin of replication, a scaffold attachment region (SAR) and / or a marker. The marker gene may confer a selectable phenotype to the host cell. For example, the marker may confer biocide resistance, such as resistance to antibiotics (e.g., kanamycin, G418, bleomycin or hygromycin). The expression vector may include a tag sequence that is designed to facilitate manipulation or detection (e.g., purification or positioning) of the expressed polypeptide. Tag sequences, such as green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, c-myc, hemagglutinin or FIag. TM Tag (Kodak, New Haven, Conn.) sequences are usually expressed as fusions with the encoded polypeptide. Such tags can be inserted anywhere within the polypeptide, including the carboxyl or amino termini.
[0076] Additional expression vectors may also include segments of, for example, chromosomal, non-chromosomal, and synthetic DNA sequences. Suitable vectors include pLK0.1 puro, derivatives of SV40, and plasmids such as RP4; phage DNA, for example many derivatives of phage 1, such as NM989, and other phage DNA, such as M13 and filamentous single-stranded phage DNA, vectors that can be used in eukaryotic cells, such as vectors that can be used in insect or mammalian cells, vectors derived from a combination of plasmids and phage DNA, such as plasmids that have been modified to use phage DNA or other expression control sequences.
[0077] The vector may also include a regulatory region. The term "regulatory region" refers to a nucleotide sequence that affects the initiation and rate of transcription or translation and the stability and / or mobility of the transcription or translation product. Regulatory regions include, but are not limited to, promoter sequences, enhancer sequences, response elements, protein recognition sites, inducible elements, protein binding sequences, 5' and 3' untranslated regions (UTRs), transcription start sites, termination sequences, polyadenylation sequences, nuclear localization signals, and introns.
[0078] As used herein, the term "operably connected" refers to the positioning of a sequence to be transcribed in a regulatory region and a nucleic acid so as to affect the transcription or translation of such a sequence. For example, in order to place a coding sequence under the control of a promoter, the translation start site of the translation reading frame of a polypeptide is generally located between 1 and about 50 nucleotides downstream of the promoter. However, a promoter may be located up to about 5,000 nucleotides upstream of the translation start site or up to about 2,000 nucleotides upstream of the transcription start site. A promoter generally includes at least a core (basal) promoter. A promoter may also include at least one control element, such as an enhancer sequence, an upstream element, or an upstream activation region (UAR). The selection of a promoter to be included depends on several factors, including but not limited to efficiency, selectivity, inducibility, desired expression levels, and preferential expression of cells or tissues. The regulation of the expression of a coding sequence can be achieved by appropriately selecting promoters and other regulatory regions and appropriately positioning relative to the coding sequence.
[0079] The vector may also include other components or functions that further regulate gene delivery and / or gene expression or otherwise provide beneficial properties for the targeted cells. As described and illustrated in more detail below, such other components include, for example, components that affect binding or targeting cells (including components that mediate cell type or tissue-specific binding); components that affect cell uptake of vector nucleic acid; components that affect the localization of polynucleotides in cells after uptake (such as agents that mediate nuclear localization); and components that affect polynucleotide expression. Such components may also include markers, such as detectable and / or selectable markers, which may be used to detect or select cells that have taken in vectors and express nucleic acids delivered by vectors. Such components may be provided as natural features of the vector (such as using certain viral vectors with components or functions that mediate binding and uptake), or the vector may be modified to provide such functions. Other vectors include those described by Chen et al. BioTechniques, 34: 167-171 (2003). A large number of such vectors are known in the art and are generally available.
[0080] "Recombinant viral vector" refers to a viral vector comprising one or more heterologous gene products or sequences. Since many viral vectors exhibit size restrictions associated with packaging, heterologous gene products or sequences are usually introduced by replacing one or more parts of the viral genome. Such viruses may become replication-defective, requiring the provision of one or more missing functions in a trans manner during viral replication and encapsidation (e.g., by using a helper virus or a packaging cell line carrying gene products necessary for replication and / or encapsidation).
[0081] In embodiments, the viral vectors used herein will be present in an amount of, for example, at least 10 5The concentration of viral genomes / cell was used.
[0082] Selection of an appropriate promoter can be easily accomplished. Examples of suitable promoters include RNA polymerase II or III promoters. For example, a candidate shRNA sequence can be expressed under the control of RNA polymerase III promoters U6 or H1 or neuron-specific RNA polymerase II promoters (including neuron-specific enolase (NSE), synaptic protein I (Syn) or Ca 2+ / CaM-activated protein kinase IIα (CaMKIIα)).
[0083] Other suitable promoters that can be used for gene expression include, but are not limited to, the 763 base pair cytomegalovirus (CMV) promoter, Rous sarcoma virus (RSV) (Davis et al., Hum Gene Ther 4: 151 (1993)), the SV40 early promoter region, the herpes thymidine kinase promoter, the regulatory sequence of the metallothionein (MMT) gene, the PGK (phosphoglycerol kinase) promoter, the alkaline phosphatase promoter; and animal transcription control regions that exhibit tissue specificity and have been used in transgenic animals; the myelin basic protein gene control region, which is active in oligodendrocytes in the brain, and the gonadotropin-releasing hormone gene control region, which is active in the hypothalamus. Certain proteins can be expressed using their natural promoters. Other elements that can enhance expression, such as enhancers or systems that lead to high levels of expression, such as tat genes and tar elements, can also be included. The assembly or cassette can then be inserted into a vector, such as a plasmid vector, such as pLKO.1, pUC19, pUC118, pBR322 or other known plasmid vectors. See Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory press, (1989). The plasmid vector can also include a selective marker, such as a β-lactamase gene for ampicillin resistance, as long as the marker polypeptide does not adversely affect the metabolism of the organism being treated. The cassette can also be incorporated into a nucleic acid binding portion in a synthetic delivery system such as the system disclosed in WO 95 / 22618.
[0084] The coding sequence of shRNA can be cloned into a viral vector using any suitable genetic engineering technique known in the art, including but not limited to standard PCR, polynucleotide synthesis, restriction endonuclease digestion, ligation, transformation, plasmid purification and DNA sequencing techniques, such as Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY (1989)), Coffin et al. (Retroviruses. Cold Spring Harbor Laboratory Press, NY (1997)) and "RNA Viruses: A Practical Approach" (Alan J. Cann, Ed., Oxford University Press, (2000)). In an embodiment, the shRNA DNA sequence contains flanking sequences at the 5' and 3' ends, which are complementary to the sequences cut by restriction endonucleases on the plasmid and / or vector. As is well known in the art, the flanking sequences depend on the restriction endonucleases used during the restriction digestion of the plasmid and / or vector. Therefore, those skilled in the art can select the flanking sequences at the 5' and 3' ends of the shRNA DNA sequence accordingly. In an embodiment, the target site can be cloned into the vector by nucleic acid fusion and exchange techniques currently known in the art, including Gateway, PCR in fusion, Cre-lox P, and Creator.
[0085] In an embodiment, the expression vector comprises a promoter and a polynucleotide comprising a first nucleotide sequence encoding an shRNA described herein. In an embodiment, the promoter and the polynucleotide comprising the first nucleotide sequence are operably linked. In an embodiment, the promoter is a U6 promoter. In an embodiment, the first nucleotide sequence contained in the expression vector may be SEQ ID NO:2. In an embodiment, the first nucleotide sequence contained in the expression vector may also be a modified SEQ ID NO:2, the bold nucleotides in SEQ ID NO:2 being replaced by any one of SEQ ID NO:4-489, and the italic nucleotides in SEQ ID NO:2 being replaced by nucleotides complementary to those in SEQ ID NO:4-489. In an embodiment, the first nucleotide sequence contained in the expression vector may be any one of SEQ ID NO:490-497. In an embodiment, the polynucleotide comprising the first nucleotide sequence in the expression vector is a DNA polynucleotide. In an embodiment, the first nucleotide sequence of the expression vector is a DNA nucleotide sequence. The shRNA encoded by the first nucleotide sequence of the expression vector may be as described in any of the variations disclosed herein.
[0086] As discussed below, the recombinant viral vector is transfected into packaging cells or cell lines along with the elements required for packaging recombinant viral particles. The recombinant viral particles collected from the transfected cell supernatant are used to infect target cells or organisms to express the shRNA. The transduced cells or organisms are used for transient expression or selected for stable expression.
[0087] Viruses / Viral Particles
[0088] Viral particles are used to deliver shRNA encoding nucleotide sequences targeting UBE3A-ATS RNA. The terms virus and viral particle are used interchangeably herein. Viral particles typically include various viral components and sometimes host cell components in addition to one or more nucleic acids. Nucleic acid sequences can be packaged into viral particles that are capable of delivering shRNA nucleic acid sequences to target cells of patients in need.
[0089] Viral particles can be produced by: (a) introducing a viral expression vector into a suitable cell line; (b) culturing the cell line under suitable conditions to allow production of viral particles; (c) recovering the produced viral particles; and (d) optionally purifying the recovered infectious viral particles.
[0090] Expression vectors containing nucleotide sequences encoding one or more shRNAs herein can be introduced into appropriate cell lines for proliferation or expression using well-known techniques readily available to those of ordinary skill in the art. These include, but are not limited to, microinjection of minute amounts of DNA into the nucleus (Capechi et al., 1980, Cell 22, 479-488), CaPO4-mediated transfection (Chen and Okayama, 1987, Mol. Cell Biol. 7, 2745-2752), DEAE-dextran-mediated transfection, electroporation (Chu et al., 1987, Nucleic Acid Res. 15, 1311-1326), lipofectamine transfection / lipofectamine fusion (Feigner et al., 1987, Proc. Natl. Acad. Sci. USA 84, 7413-7417), particle bombardment (Yang et al., 1990, Proc. Natl. Acad. Sci. USA 87, 9568-9572), gene guns, transduction, infection (e.g., with infectious viral particles), and other techniques, such as those described in Sambrook et al. (Molecular Biology). Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001).
[0091] In embodiments where the expression vector is defective, infectious particles can be produced in a complementing cell line or by using a helper virus that provides non-functional viral genes in trans. For example, suitable cell lines for complementation with adenoviral vectors include 293 cells (Graham et al., 1997, J. Gen. Virol. 36, 59-72) and PER-C6 cells (Fallaux et al., 1998, Human Gene Ther. 9, 1909-1917) commonly used for complementation with E1 function. Other cell lines have been engineered to complement double-defective adenoviral vectors (Yeh et al., 1996, J. Virol. 70, 559-565; Krougliak and Graham, 1995, Human Gene Ther. 6, 1575-1586; Wang et al., 1995, Gene Ther. 2, 775-783; Lusky et al., 1998, J. Virol. 72, 2022-2033; WO94 / 28152 and WO97 / 04119). Infectious viral particles can be recovered from the culture supernatant or from the cells after lysis and optionally further purified according to standard techniques (chromatography, ultracentrifugation in cesium chloride gradients, as described, for example, in WO 96 / 27677, WO 98 / 00524, WO 98 / 22588, WO 98 / 26048, WO 00 / 40702, EP 1016700 and WO 00 / 50573).
[0092] In embodiments, provided herein are host cells comprising nucleic acid molecules, vectors or infectious viral particles described herein. The term "host cell" should be understood broadly without any limitation on tissues, organs or isolated cells of a particular organism (organization). Such cells can be a unique type of cell or a group of different types of cells, and include cultured cell lines, primary cells and proliferating cells.
[0093] Therefore, host cells include prokaryotic cells, lower eukaryotic cells such as yeast and other eukaryotic cells such as insect cells, plants and higher eukaryotic cells such as vertebrate cells, and particularly preferably mammalian (e.g., human or non-human) cells. Suitable mammalian cells include, but are not limited to, hematopoietic cells (totipotent stem cells, leukocytes, lymphocytes, monocytes, macrophages, APCs, dendritic cells, non-human cells, etc.), pneumocytes, tracheal cells, hepatocytes, epithelial cells, endothelial cells, muscle (e.g., skeletal muscle, cardiac muscle or smooth muscle) cells or fibroblasts. For example, host cells can include Escherichia coli, Bacillus, Listeria, Saccharomyces, BHK (baby hamster kidney) cells, MDCK cells (Madin-Darby canine kidney cell line), CRFK cells (Crandell cat kidney cell line), CV-1 cells (African monkey kidney cell line), COS (e.g., COS-7) cells, Chinese hamster ovary (CHO) cells, mouse NIH / 3T3 cells, HeLa cells, and Vero cells. Host cells also include complementing cells capable of complementing at least one defective function of a replication-defective vector (e.g., a defective adenovirus vector) that can be utilized herein, such as those stated above.
[0094] In embodiments, host cells can be encapsulated. Cell encapsulation technology has been previously described (Tresco et al., 1992, ASAJO J.38, 17-23; Aebischer et al., 1996, Human Gene Ther.7, 851-860). For example, transfected or infected eukaryotic host cells can be encapsulated with compounds forming microporous membranes, and the encapsulated cells can be further implanted in vivo. The capsule containing the cells of interest can be prepared using a hollow microporous membrane (e.g., Akzo NobelFaser AG, Wuppertal, Germany; Deglon et al. 1996, Human Gene Ther.7, 2135-2146), which has a molecular weight cutoff suitable for allowing proteins and nutrients to pass freely between the inside and outside of the capsule while preventing implanted cells from contacting the host cells.
[0095] Viral particles suitable for use herein include AAV particles and lentiviral particles. AAV particles carry the coding sequence of shRNA herein in the form of genomic DNA. On the other hand, lentiviral particles belong to the retrovirus category and carry the coding sequence of shRNA herein in the form of RNA.
[0096] Recombinant engineered viral particles, such as AAV particles, artificial AAV particles, self-complementary AAV particles, and lentiviral particles, containing DNA encoding shRNA targeting UBE3A-ATS RNA (or RNA in the case of lentiviral particles) can be delivered to target cells to inhibit silencing of UBE3A by UBE3A-ATS. The use of AAV is a common way of delivering DNA because it is relatively nontoxic, provides efficient gene transfer, and can be easily optimized for specific purposes. In an embodiment, the selected AAV serotype has a natural neurotropism. In an embodiment, the AAV serotype is AAV9 or AAV10.
[0097] Suitable recombinant AAV can be produced by culturing a host cell comprising: a nucleotide sequence encoding an AAV serotype capsid protein or a fragment thereof, as defined herein; a functional rep gene; a minigene comprising at least an AAV inverted terminal repeat (ITR) and an encoding nucleotide sequence; and sufficient auxiliary functions to allow the minigene to be packaged into the AAV capsid protein. The components required for culturing in the host cell to package the AAV minigene into the AAV capsid can be provided to the host cell in trans. Alternatively, any one or more of the required components (e.g., minigenes, rep sequences, cap sequences, and / or auxiliary functions) can be provided by a stable host cell that has been engineered to contain one or more of the required components using methods known to those skilled in the art.
[0098] Unless otherwise indicated, the AAV inverted terminal repeats (ITRs) and other selected AAV components described herein can be easily selected from any AAV serotype, including but not limited to AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV Rec3 or other known and unknown AAV serotypes. These ITRs or other AAV components can be easily isolated from AAV serotypes using techniques available to those skilled in the art. Such AAV can be isolated or obtained from academic, commercial or public sources (e.g., American Type Culture Collection, Manassas, Va.). Alternatively, AAV sequences can be obtained by synthesis or other suitable means with reference to published sequences, such as those available in the literature or available in databases such as, for example, GenBank, PubMed, etc.
[0099] The minigenes, rep sequences, cap sequences and auxiliary functions required for producing the rAAV herein can be delivered to the packaging host cell in the form of any genetic element that transfers the sequence carried thereon. The selected genetic element can be delivered by any suitable method. The method for constructing the embodiments herein is known to nucleic acid manipulation technicians and includes genetic engineering, recombinant engineering and synthetic techniques. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, the method for producing rAAV virions is well known, and the selection of suitable methods is not restrictive. See, for example, K. Fisher et al., 1993 J. Viral., 70: 520-532 and U.S. Patent No. 5,478,745, etc. All citations herein are incorporated herein by reference.
[0100] Selection of these and other common vectors and regulatory elements is routine, and many such sequences are available. See, e.g., Sambrook et al., and references cited therein, e.g., pages 3.18-3.26 and 16.17-16.27, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989). Of course, not all vectors and expression control sequences will function equally well to express all transgenes herein. However, one skilled in the art can select among these and other expression control sequences.
[0101] Pharmaceutical compositions and therapeutic treatments
[0102] The virus containing the desired shRNA coding sequence can be formulated for administration to patients or humans with corresponding needs by any suitable mode of administration. Such formulation includes the use of pharmaceutically and / or physiologically acceptable vehicles or carriers, particularly vehicles or carriers suitable for administration to the brain (e.g., by subcranial or spinal injection). In addition, more than one shRNA herein can be administered in a combined therapy. In a combined therapy, different shRNAs can be administered simultaneously, respectively, sequentially and in any order.
[0103] The pharmaceutical composition herein comprises a carrier and / or diluent suitable for delivery to a human or animal organism by injection. Such a carrier and / or diluent should generally be nontoxic at the dosage and concentration used. It can be selected from those commonly used to prepare compositions for parenteral administration in unit dose or multiple dose form or for direct infusion by continuous or regular infusion. In embodiments, it is isotonic, hypotonic or weakly hypertonic, and has a relatively low ionic strength, such as the ionic strength provided by sugar, polyols and isotonic saline solutions. Representative examples include sterile water, physiological saline (e.g., sodium chloride), bacteriostatic water, Ringer's solution, glucose or sucrose solution, Hank's solution and other physiologically balanced saline solutions (see, e.g., the latest version of Remington: The Science and Practice of Pharmacy, A. Gennaro, Lippincott, Williams & Wilkins). The pH of the composition is appropriately adjusted and buffered so as to be suitable for humans or animals, for example, at physiological pH or slightly alkaline pH (between about pH 8 and about pH 9, wherein pH 8.5 is particularly preferred). Suitable buffers include phosphate buffer (e.g., PBS), bicarbonate buffer and / or Tris buffer. In embodiments, for example, the composition is formulated in 1M sucrose, 150mM NaCl, 1mM MgCl2, 54mg / l Tween 80, 10mM Tris pH 8.5. In embodiments, for example, the composition is formulated in 10mg / ml mannitol, 1mg / ml HSA, 20mM Tris (pH 7.2) and 150mM NaCl. These compositions are stable at -70°C for at least 6 months.
[0104] The pharmaceutical compositions herein can be in various forms, for example, solid (e.g., powder, lyophilized form) or liquid (e.g., aqueous). In the case of solid compositions, the preparation methods are, for example, vacuum drying and freeze drying, which produce a powder of the active agent plus any additional desired ingredients from a previously sterile filtered solution thereof. If desired, such solutions can be stored in sterile ampoules, ready for reconstitution by adding sterile water for ready injection.
[0105] Atomization or aerosolized preparations are also suitable. The method of intranasal administration is well known in the art, including the drops, sprays or dry powder forms of the composition are applied to the nasopharynx of the individual to be treated from a pressurized container or a dispenser (it contains a suitable propellant, for example a gas such as carbon dioxide) or a nebulizer (see, for example, WO 95 / 11664). Enteric-coated preparations such as gastric-tolerant capsules and granules for oral administration, suppositories for rectal or vaginal administration may also be suitable. For non-parenteral administration, the composition may also include an absorption enhancer that increases the mucosal pore size. Such absorption enhancers include sodium deoxycholate, sodium glycocholate, dimethyl-β-cyclodextrin, lauroyl-1-lysophosphatidylcholine and other substances with structural similarity to the phospholipid domain of the mucosa.
[0106] The composition can also include other pharmaceutically acceptable excipients for providing desired pharmaceutical or pharmacodynamic properties, including, for example, changing or maintaining the pH, osmotic pressure, viscosity, transparency, color, sterility, stability, dissolution rate of the formulation, changing or maintaining release or absorption into a human or animal organism. For example, polymers such as polyethylene glycol can be used to obtain desired solubility, stability, half-life and other pharmaceutically favorable properties (Davis et al., 1978, Enzyme Eng. 4, 169-173; Burnham et al., 1994, Am. J. Hosp. Pharm. 51, 210-218). Representative examples of stabilizing components include polysorbate 80, L-arginine, polyvinyl pyrrolidone, trehalose, and combinations thereof. Other stabilizing components particularly suitable for use in plasmid-based compositions include hyaluronidase (which is believed to destabilize the extracellular matrix of host cells, as described in WO 98 / 53853), chloroquine, protic compounds such as propylene glycol, polyethylene glycol, glycerol, ethanol, 1-methyl L-2-pyrrolidone or their derivatives, aprotic compounds such as dimethyl sulfoxide (DMSO), diethyl sulfoxide, di-n-propyl sulfoxide, dimethyl sulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile (see EP 890362), nuclease inhibitors such as actin G (WO 99 / 56784), and cationic salts such as magnesium (Mg 2+ ) (EP 998 945) and lithium (Li +) (WO 01 / 47563), and any derivatives thereof. The amount of cationic salt in the composition herein preferably ranges from about 0.1 mM to about 100 mM, and still more preferably from about 0.1 mM to about 10 mM. Viscosity enhancers include sodium carboxymethylcellulose, sorbitol, and dextrose. The composition may also contain substances known in the art to promote permeation or transport across the blood barrier or membrane of a particular organ (e.g., antibodies to transferrin receptors; Friden et al., 1993, Science 259, 373-377). A gel complex of polylysine and lactose (Midoux et al., 1993, Nucleic Acid Res. 21, 871-878) or poloxamer 407 (Pastore, 1994, Circulation 90, 1-517) may be used to facilitate administration in arterial cells.
[0107] Virus particles and pharmaceutical compositions can be applied to patients in a therapeutically effective amount. As used herein, the term "therapeutically effective amount" refers to an amount sufficient to achieve a desired biological effect. For example, a therapeutically effective amount for treating happy puppet syndrome is sufficient to improve one or more symptoms of happy puppet syndrome as described herein (e.g., developmental delay, severe cognitive impairment, ataxic gait, frequent epileptic seizures, short attention span, speech loss, and characteristic happy behavior). In addition, AS iPSC-derived neurons show depolarized resting membrane potential, delayed action potential development, and spontaneous synaptic activity reduction. Therefore, the therapeutically effective amount for treating AS can restore the resting membrane potential of neurons to about -70mV, improve action potential development delay, increase spontaneous synaptic activity, or improve the other changes in the neuronal phenotypes related to base strength, action potential characteristics (e.g., shape), membrane current, synaptic potential, ion channel conductance, etc.
[0108] The appropriate dosage may vary depending on known factors, such as the pharmacodynamic characteristics of the particular active agent, the age, health and weight of the host organism; the condition or conditions to be treated, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, the need for prevention or treatment and / or the desired effect. The dosage is also calculated based on the particular route of administration selected. The practitioner can further refine the calculations required to determine the appropriate dosage for treatment based on the relevant circumstances. As a general guide, the viral particle-based composition can be administered in, for example, at least 10 5 The composition based on the vector plasmid can be formulated in a dosage form of between 1 μg and 100 mg, for example, between 10 μg and 10 mg, for example, between 100 μg and 1 mg. Administration can occur as a single dose, or as a dose repeated once or several times after a certain time interval.
[0109] The pharmaceutical composition herein can be encapsulated in an ampoule, a disposable syringe or a multi-dose vial made of glass or plastic. In all cases, the composition should be sterile and should be fluid to the extent that it is easy to inject. It should be stable under manufacturing and storage conditions and prevent the contamination of microorganisms such as bacteria and fungi. Sterile injectable solutions can be prepared by: the active agent (e.g., infectious particles) is incorporated into a composition or a combination of components listed above in the required amount, and then filtered and sterilized.
[0110] The viral particles and pharmaceutical compositions herein can be administered by parenteral routes, including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial (e.g., intracerebral or intraventricular) administration. In embodiments, the viral particles or pharmaceutical compositions are administered intracerebrally or intraventricularly. In embodiments, the viral particles or pharmaceutical compositions herein are administered intrathecally.
[0111] In embodiments, the viral particles and pharmaceutical compositions described above are administered to a subject by subcranial injection into the brain or spinal cord of a patient or human being in need. In embodiments, subcranial administration to the brain results in the coding nucleotide sequences described herein being directly administered to brain cells, including glial cells and neurons. As used herein, the term "neuron" refers to any cell in the brain or any cell associated with brain function. The term can refer to any type of neuron, including monopolar, bipolar, multipolar, and pseudo-monopolar. Example
[0112] shRNA vector production and lentiviral preparation
[0113] Oligonucleotides encoding shRNA were cloned into the pLKO.1-puro vector, which drives the expression of small RNA via the U6 promoter (Addgene plasmid #8453). Specifically, the polynucleotides generating shRNAs contained the specific 21 nucleotide sequence to be targeted and its reverse complement, separated by the loop sequence CTCGAG, and with the addition of the 5' flanking sequence CCGG and the 3' flanking sequence TTTTTG for cloning into the plasmid vector. The following oligonucleotides encoding shRNAs were used, as well as the scrambled shRNA control:
[0114] 551shRNA 2 ("551-2") (SEQ ID NO:502):
[0115]
[0116] ATS-shRNA1 (SEQ ID NO: 503):
[0117]
[0118] ATS-shRNA2 (SEQ ID NO: 2):
[0119]
[0120] ATS-shRNA3 (SEQ ID NO: 504):
[0121]
[0122] ATS-shRNA4 (SEQ ID NO: 505):
[0123]
[0124] Clones were verified by Sanger sequencing. Lentiviral particles were generated from cloned shRNAs in HEK293T cells using second-generation lentiviral packaging plasmids (psPAX2, Addgene plasmid #12260; pMD2.G, Addgene plasmid #12259) and concentrated using the Lenti-X Concentration Kit (Takara). Lentiviral titers were estimated using a qPCR kit (Applied Biological Materials) that detects 5'LTR.
[0125] Stem cell culture and neuronal differentiation
[0126] Happy puppet syndrome (AS) induced pluripotent stem cells (iPSC) and human embryonic stem cells (hESC) were maintained in mTeSR-plus culture medium (Stem Cell Technologies) on a Matrigel-coated substrate (Corning) without feeder layer. iPSC / hESC was cultured in a humid incubator at 37 ° C, 5% CO2. Cells were fed daily and passaged every 4-5 days using 0.5mM EDTA. Glutamatergic neurons were generated from iPSC / hESC by doxycycline-induced expression of human neurogenic protein 2 (NGN2) transgene (Fernandopulle et al., 2018, Curr Protoc Cell Biol. 79 (1): e51.). In short, a pair of TALENs targeting AAVS1 were used to stably integrate the doxycycline-induced NGN2 construct into the safe harbor AAVS1 locus of AS iPSC / hESC, and then derive clonal cell lines. Neuronal induction was then performed by culturing these iPSC / hESCs for three days in a neural induction medium consisting of DMEM / F12, N2 supplement, non-essential amino acids (NEAA), L-glutamine (all Gibco products) and 2ug / mL doxycycline. Neurons were then seeded in a cortical neuron culture medium consisting of DMEM / F12, Neurobasal medium, B27 supplement, penicillin / streptomycin (all Gibco products), BDNF (10ng / mL), GDNF (10ng / mL), NT-3 (10ng / mL) and laminin (1ug / mL) for terminal maturation. Human iPSC / ESC-derived NGN2-induced neurons (7-10 days after induction) were transduced with lentiviral particles at an MOI of 10.
[0127] Quantitative RT-PCR (qRT-PCR) analysis
[0128] Neurons were collected for RNA isolation and qRT-PCR 7 days after viral transduction. Total RNA was isolated from iPSC-derived neurons using RNA-STAT60 (AMS Biotechnology) according to the manufacturer's protocol. cDNA was generated using a high-capacity cDNA reverse transcription kit (Life Technologies). Gene expression analysis was performed in at least three replicates. All qPCR assays used were TaqMan gene expression assays (Life Technologies). The Ct value of each gene was normalized to the housekeeping gene GAPDH. Relative expression was quantified as 2^ relative to the calibrator sample. -ΔΔCt .
[0129] Data Summary and Results
[0130] AS iPSC-derived neurons were transduced with lentiviral particles to express selected shRNA sequences targeting the SNHG14 long noncoding RNA. qRT-PCR was used to determine the expression of UBE3A-ATS, SNORD115 host gene and UBE3A in SNHG14-shRNA treated neurons relative to neurons treated with non-targeting control shRNA (scrambled). Figure 4 and Figure 5 Reflects qRT-PCR analysis of AS iPSC-derived neurons after treatment with shRNA targeting SNHG14 (551-2, ATS shRNA1-4, ATS shRNA2_3G) or non-targeting control shRNA (scrambled). Expression of UBE3A-ATS, UBE3A, and SNORD115 was normalized to the housekeeping gene GAPDH and expression is presented relative to scramble-shRNA treated neurons. Error bars represent standard error of the mean, n=3 biological replicates. Figure 4 and Figure 5 As shown in Figure 2, selected SNHG14 shRNAs effectively reduced RNA levels of UBE3A-ATS (55%-60% reduction) and SNORD115 (45%-50% reduction) compared to scrambled controls. This reduction in SNHG14 transcript levels was associated with a robust increase in UBE3A RNA (5- to 9-fold increase over scrambled controls). Although ATS shRNA-1, ATS shRNA-3, and ATS shRNA-4 were predicted to reduce RNA levels of UBE3A-ATS and SNORD115 and increase UBE3A expression, they did not have this effect.
[0131] It should be understood that the foregoing detailed description and the accompanying examples are illustrative only and should not be regarded as limiting the scope of the subject matter described herein, which is limited only by the attached claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention, including but not limited to those changes and modifications related to chemical structures, substituents, derivatives, intermediates, syntheses, compositions, formulations, or methods of use.
[0132] sequence
[0133] SEQ ID NO:1
[0134] Human UBE3A-ATS genome sequence.
[0135] TGAGATGACCTAAACAACTGTGGAGAATCATTGATATATTTCCTTTTTTCACTGTTCATGTTGGGTGAAAATAATC
[0136] TTGTAGTGAAATTCACATGTTCTAAATATTGTTTTTTTACATCTTTATCTGGCACATTCATAACATAGATGTTTCT
[0137] ATACATATTAGTACTGTAATCATACCATATATTATTCTGTTACCCCACTTACTCCTTAAACTTTTAGTTAATTAAA
[0138] GAGTTTTTATAAAGTCCCCCAATAGATTTTTTTTTTTTGAGACATAGTCTCACTCTGTTGCCCAGGCTGGAGTGCA
[0139] GTGGCGTGATTTTGGCTCACTGCAACCTCCCCATCCTGGGTTCAAGCAATTCTCCTGCCTCAGCCTGCCAAGTAGC
[0140] TGGGATTACAGGTGCCTGCCACCACGCCCGACTAATTTTTGTATTTTCAGTAGTGACAGGGTTTCACCATCTTGGC
[0141] CAGGCTGGTCTTGAACTCCTGACCTCGTGATCCACCCGCCTTGGCCTCTCAGAGTGCTAGGATTACAGGCTTGAGC
[0142] CACTGCACCCGGCCAGATTTTAATCTAATTTTATTAGAACAATTCAGTCATATGTTTTTTCATGCTATGTATATGA
[0143] GAGTTCCATTATTCAGATACTAAACAAATGTCTACTGTACATTTACTGTTCTCACTGATGATGCATTAGATAACCA
[0144] TGCACAAAATAAGCCTGGCTGTGGAAACGCTTATTTGTTGGGAGGGTGCTTGTTTGGATCGATGATGAGAATAATT
[0145] GTCTGAGGATGCTGAGGGACTCATTCCAGATGTCAATCTGAGGTCCAGATGTGTGCGGCCCTCCAATAGGACAAATAA
[0146] GACTCTCAGAGCCTGGCTCTATTTGGGGATCCCTCAGTGACAACATAGTACCCCTGTGAGCGTGCCTTTTCTATCT
[0147] CTTCGAAGAGGGCAGTGGCATCCTGTCTTATGAGTCAGTGTGCACTTTAGTGTGCCTAGTGACCCAAGACTTGCTT
[0148] TATTGTAGATAGATACTTACATATAGGAAATATTTCTTAAGTAACAAATGAAAAACTTTAGAAGATTGAATTAAG
[0149] GGTCAAGCAACTGTGATATGTCTGAAAATCTCATTAGTGTTGTGCTGAAAGAAGGAAATATGGCATGCCTCTATTA
[0150] AATAATGACAGTGGAACCAAGTTTATTGCTTTGTTATTTTTACTGTGGAGTATTTTCTAAGATTATTTTTGCTTTT
[0151] TTTTTCTTTCATGTTTTGCTGAGATAGAAGGCCTGGAATCTGATCCTCCACTTCAGAGAACAGGGGTGAGTAGCTA
[0152] AGCCATTATCTTTTGAAATTCATATGTCATGTGCTCTTTGCTAGGTCTTTAGGTCGTTTTGTACATCTTTTCAGAA
[0153] GCTTATTGGAGGACATTTTCATGATATGTCCTTTTCCTCATTGAGACCCTCACCATGTCACCTACACTATTGAATC
[0154] CTTATCATTTCTCTTTTAATTTTAACTCTCTTTTGCTTTTATGGAAAAATGTAGAATTTAAGAGAATTTTTGGCAA
[0155] TTTCATATTGGATCAAAATGTATTGTAGTGAAATCCAGGTGTGCCAAAATATTAACAGATTTTCCCCATCTGTTTA
[0156] ATTATTGGGGTTTCAGAATAGAGACTCCATGGTTTCATAATATCTTTGTGGTCATACTACATTATATTTCTGCTTCT
[0157] AATTTAATTATTAATATTGACTTGAATTAGTCTTTTCCTCATTGTTGCAACAAGGTAAGTTATATAGGAAATTTT
[0158] CTTCTCTTTGATGGCATGTCTGAGATAATCATAGATATAAGACACCTGGCTGGTTTCTAGAATGCATGTAATTTTTA
[0159] TTTCTTGATCTGTGTGTTGAGTACTTGCTGTGATTGCATCATGCAAATACATTGAGCTTTACAATTTTAGTGTATG
[0160] CACTTTTCTACATGTATATTATTCTTCGATAGAAAGTAAAAAAAACTTATCGAACTAGTCAAAATATTGGTTAATA
[0161] CATAAAAAAAGTCTCAAGTAGATTGTGTATTACATGGTGCTTGTTGATTGATGCCCTCATAATAGATCAAGTGGGT
[0162] TCTCTCTTTAGCACAGGGCTTTTTAGCAAATCATGTCATGAGTAGTTACTCAAGTATTTTTATTTTAACACATTTA
[0163] TATTTTTTCTATGTATATTCTTAAATTCTCTTATACTTTTTTCTCTGTTATAAAAACATGCTGAACAATCTCAAGT
[0164] CTTAAGGATTGCAGTATTGTCCCCCACATATTCATGTATTTTGGTACTCAATTCTTTATACTTTCTTTGACAGATCA
[0165] CTTGAACTGGCACATGTCTCTTGTTTTGCAGAGAGGGAATTAATGTGATACCTTCATGCTTTTCTATTCTATGTGC
[0166] TACATAATTGAATATACAAGCAAATATAGTTGTTAAGATTTAGTGTGATTATTTCTACACCACCATGCAAAGAAGTT
[0167] TCTCATATAGATCTTAATAGAGGCCCACATGCATTGTACAGTTTAGAATTTGGGGAAATATTGATGAAGTTGGGTAAA
[0168] GTATAAAGCCAAAGTCAGAACAGTGAACTCCTTGCTTAAGGATTTCCTTGGAGATTACTTAGTCAATACACAACT
[0169] GATAAATTTAAGTGCTTTTCACCTTTGAGTTCTCGACATACTAAAGCTAAAATGTGTTTCAACTTTTAATCCTGC
[0170] TTCCCTGATTTTCCCTTTTTTAGTCTGAGATCAAAGAGTTTCAGCCATAAATTACTGCCAAGAGTAATCACTTCAT
[0171] TTTAAGAAAGCTTAACAATATAGAAGAATATAAAATTATTATGACAGATGTATTTTTAACCTTTTCCCCATGCTT
[0172] TCCAGAGGAAATATGTTTAATCATCTGCCCTATATTAGGAAAAAACTTTCTATGCTAATACAAGTATCTATCAATC
[0173] CATTTATCTTTCTATATAAGATGTATTGATCATAACCAATTAACTTTACTGTAAATGAGCTTTAGATTTGACATTT
[0174] TGGTAGTAATATATGTTGTACAATCTCCTGAGGTCCTATAGGTCTTGAGGTCTCTATGTCAAAAACTATAGATGTG
[0175] CCAGTGTCCTCAGTGAATGTGAAGGACACCACATTTTCCTTAGCCATTTCTTGTTTTCAGAATAATGGTTATCAAC
[0176] ATTTTGCTACTGCAAGATACCATACATTTATAATCGGAATATGCCAGTTTTTATGCACTCATGCCTCTGTTTCTGT
[0177] AGAGCATTCCCAGAATGAGTAATGCTTGAAAATTAGGTCCATGTGATTTCTTTAATGAGTTATAGTCAAATCATGA
[0178] AATATTCAGGTTACCATTATTTCAGTAATGTATTAGAATGTCAAGGTAAAGTTATCTACATTGTATATATACACAC
[0179] AACATAGATATAATTTATACAACATCTATATTTATACAACAGATATATATTTATGTATATATTTATACAACATAAA
[0180] ATATATTTTATTATTTAAACATAAAATATATTTTATTATTTAATATAGATTCTTAAGTGATAAATATGTTTAATAT
[0181] TATTAAAATAGGTTAAAATAGGTTATAGTTAGTACAGTGAAAATTGGCAGCCCTTTTACAAAACATATGCCATAAC
[0182] TATAGCATTTATCACTGACAGTCATACCAGGATAGTCTTTTATTTCCAATCACTTAAATATTCCTAATTGCAAAAG
[0183] AAATTTGAAGACTAAAATTCAGAAGTTTTGAAAGAGCCATTGCCTGGGTAAACTATACAGGTTTCAGTTTTATTTA
[0184] TAATAATTATGAGGCCAGGCGCAGTGGCTCACACCTGTAATCCCAACACTTTGGGAGGCCGAGGCGGGTGGATCAC
[0185] GAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAAAATACAAAAAATTAGCCGG
[0186] GCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTGGTAGGCGGA
[0187] GCTTGCAGTGAGCCGAGATCGCGCCACTGCCCTCCAGCCTGGGAGACAGTGCGAGACTCCGTCTCAAAAAAAAAAA
[0188] TTATGTATATATTTATAAATTAATACTTAATAAATTAATAACTTGTGATAGGCAATGCAAAGATGACAGTAAAAGG
[0189] ACAAAATTGATTAGATTGATAAAGTCCTGTTAACATGAAGAAATTGACCAGGATACCATCCACACTATAAAGTTAG
[0190] AGAAATTTATCAGGACAATTCCCTAAAATACTCTTCTCAATTTTAACATTGTAACAGGAATTTTTAAAATTTTGGT
[0191] ATTATGTGTGTTTCCTTCCAGATAATTTGAACAGATTCATATTTGGTATTTTTAAAAGCCATATCTTTGTCCTTAG
[0192] TGCTGGCAATGTATTCTTGAGAATGAACAAATAAGAGATACGTAAAAGCATAAGAGAAGGTATCAGGTTGAAGTAG
[0193] TCAATCAGTTATACAGAACACAAAGAATTTTATCTTGTATAATGTTTATATAGCTTTATAGAAGTGTGCTGAAAGG
[0194] GCTATAAAACATGGACATTATTATCTCATTGAAAGGTCCAATACGTACTGAAATACATGCTTTTATTTTGAACCAA
[0195] CCACCCTATAAACGTTGTATGGCTTATTTAGATGAGAGCCCAGGTTGTGTGTGTCTGTGTGTGTGTGTGTGTGTGTGT
[0196] GTGTGTGTGTGTGTGTGTGTGTGTACCTGACAGGGAAGCAAGAACATCGAGTTGCCAATGCACTCTGTCTATGGTT
[0197] AGAATCATGCTGAAAACATGGCTCCCCCCAGTTCTGGAATGAGCCCACAGATCAAGCATTCCCCAAAGACATAGCAG
[0198] GCTCAAATCCCTGTGTACACAATATTTTATGATTATCTTATGTCAGTACTTTCAAAGTATACAGTTTGTGTGAAGA
[0199] CAAATCCAATGTCATTTTTCTTGGCTAGCCTATATGTGTGGTAAATCCATTATTTACTTACTTGCTTCCTGAAAAT
[0200] TACAATTAGATTAACAAACTGCAGCAAAGTGGGCATGATGAGATAGAGATTGAAGTGTAAGCTTATGTTAATGATG
[0201] CCCTTGGTTTGGATAAACACATCTAAGAGAAAAATGGAAAAACACACATGGCAGGGAAGCCTTGATAGAGCCAAAA
[0202] TATAGGATTGTATGTAGTAATGCAATCCATAGATGAGCATTTGGCAGTAATATTATTTTTCAGATATGGATAAAAA
[0203] TTGCTTAGGAGAGTAAAGAGAGACAAAGTTGAAAGCAGGTTTATAGTAGGTGTTGTTTTAGTGTTGATCCCTTTTT
[0204] GCTCCAATAATCAAAGTGATAAATATTGAAAATTGATTCATGCAGCATTACTTACTCCATTCTAATTTTTATATAT
[0205] GTCAAAAGTGCCATCTCCCAAACTGTGCTATCCCCTTCAGGAGAAGAGACTCTGCTGAAGTTTATAAGGTTGACAT
[0206] ATTGCCAGCTTCAATAATGTAAAGATGAAGTGTATACTGAATTCTTAATGCAAATAACAACTCTATTGGAAAGTAA
[0207] CCCAGTTATAGAAGTGCTAATTTGTCAGGAGCTGCCTTACCAAGATCATGATGAGTACAGTTATCTCAGGATTCTG
[0208] AAAGATTGTTTTCCGATTTCAACTAGTCTAGCTGAATGTTCCTTGATAGAAAGAGAGGACTTTTAGAATTGGTTCA
[0209] ATATGATGACCTCCTGAATTATCTCACATAGCCCGTTTGTACATGCCTTTCTTTTCTCTCAGAAAATGGCACTATC
[0210] ATAATAGCTTTCTTACACAGACTTCACCTTAGGGTTTTACATTAAGGGAGGGGTCTGGTGTTTCATTTATTTTGAA
[0211] GTATTTGTTGTTGATTGTGTACAGTGCTTGAGTAAAAAATTGAATATAGAAACATCTAGAATATTTTTTTAAAGGA
[0212] TCAGTGTTTATAAAGTGAATTATTAGTGTCAATAATGTTGGGAAAGTTTTAAGAGAATATAGGAAACTTGAACATT
[0213] ACACAACTACAATGGGACCAAATTGTGGGGTCTCATTATAGTTAATATTTATGTATTTTTTTCCAATTGATTTGTG
[0214] TGCTTTTTTCTGCATGTTTTTGGCAGATAGAATGGCTATAACAAGTAACAGCATGTCAGGTAATAAAAATAAGCA
[0215] GAGCCCTATTCCTTTAAAAATCTTCACTGATGGGAGGGCCATAAAATAAGTCTTAATACATTTAAAGAATTAAATT
[0216] CATGTAAACCATGTTAATTTAATTCCACAATGATATTGAATTAGAAATAAGAGGAATATCTCTTGAACATCTCCTA
[0217] AATGTTTGGAAATTTAAATTAGCATTTCTGACCTATTTATTGGTTAAAAAAGATACAAAGAAAGGAAAATTGAAAA
[0218] GTCTTTTGAACTGAATAAAAATAAATATAGAATCTAAAACTTTATGGGATACTGACAAAACAGGATATAGGGAA
[0219] TAATTTATAGCACTGAAATGCCTATATTAGAAAAGAAAAAAGGTTTTAAATCAGTAAATTTGTATTTTACCTTAAG
[0220] AACTTAGAAAAGAACAAATTAACCCAGACTTAAGTAAAATAAAGGCACTAATAAAGATAAGAGCAGAAATCAATG
[0221] AAATATAAAACAACAAAACACAGAGAAAAATTGAGAAAATTTAAAAATAGCCTAGTGAGAAGATATTGATAAACTT
[0222] GTAACCAGACCAATTTAAGAAAAAAAGTCAAAACACAAATACCAATATTTGAAAATGTAGGAGGGCAAATCATTAC
[0223] AGATTCTATGAATACTAAAATGATAATAAGGAAAAATTATTTAAAAGGGGCATGTCAGCCAGGCATGGTGGCTTAC
[0224] CCCTGTAATCCCAGCACTTTGGCAGGCCGAGGTGGGAGGATTGCTAGAGCTCAGGCATTCGAGACCAGCCTGGGCA
[0225] ACATGTTGAAACCTTGTCTACACAAAAAGTACAAAAATTAGCTGGGTGTGGTGTTGCACACTTGTAGTCCCAGTCA
[0226] CTTGGGAGGCTGAGGCGAGAGGATCACTTGAGCCCAGGAGGTTGAGGCTGCAGTGAGCCATGTTTGTACCACTGCC
[0227] CTCCAGCCTGGGTGACAAAGTAAGACCCTATGTAAAAAAAAAAAAATGTATGCCAACATTTTTCAATAACTTAAAT
[0228] GAAATGGAAAAATTCCTTGAAAGACACGAACTACAAAAACTCAGTGAACAAGTAAATAACCTGAATAGCCCTGTAT
[0229] CAAGTAAATTGAATTTGTAGTTAAAAGCCTTCCAACAGAGAAAACTTCAGGTACCTATAGCTTCATATGAAATGAA
[0230] AAAAAAAATACCAATCCTCTACAAGATTCCAGAACATTTAAAAGAAGGGAATATTTCCCAACTTATTCCATTTGGA
[0231] CAGCAATACCCAGGTAAGAAAAAGAGACACAGAAATTTAAAAAGAAGAATATACATTATTCCTTAGGAACATAAAT
[0232] GCAAAGAAATCTAATCAAAATTTTGGCAAATGAAATGTAGAAATACTTTATGACCAAGTGAGAGTTACCCAAAGAA
[0233] TTTAAGGTTGGTTTTATATGTAAAGATCAACCAATATAGGAAAATCACTTCTGGAAAGTCAGAGTAAGAAACTCCA
[0234] AAAATCTACTCCTCCATAAAACCAATAACAGCCTTGATAGAAATAGTTGAAATTAATTTTCCAAAACTTTGGAAAT
[0235] TAACCAAAGGCTTACAAAATTCCAGAGAACATTAATTCAAGAAAAATGGCTGAATCAGTAAGAACAGCCAGCTTTG
[0236] TGGCATTTTAATATGACCCCTTCCCATGCTTTTCTCCCTAGTGCTGAGATAGTCTTAAAAATTAGCAGGATAGCAA
[0237] CCACTGGAGAAGAAAGGTTTGGAAATTTCCCAAAAAGTTCCATCCCCATAGAATTATCACTATTTGACCTCTAAAG
[0238] CCCAATCTATAGGATTTATATTCATTTGGACTGACTCAGAGCTCACTCAGTAAGGAAATCTCAATTTCAAGGTATT
[0239] GGTCAAAAAGAATCCATGGCAATTGTTGACTATCACAACTGCCTGAAGTCTTGGTAACAGTTGGGATAAACAAGAA
[0240] GCTGATCAAAAACTGAAAACTAAAATCTTGGGAATGAGATATCTACAGGATGCTTCAAAAAGCTTTGATACATTCC
[0241] TGTTTATCTAGAAAGCTACATGCAGGCTGGGTGCAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGG
[0242] CGTGCGGATCATGAGGTCAGGAGTTTGAGGCCAGCCTGACCAACATGGTCTCTACTAAAAACACAAAAATTAGCCA
[0243] GGCGTGGTGGCGTGCATCTGTAATCCTAGCTACTCAGGAGGCTGAGACAGGAGAATCGCTTGAACCCGGGAGGCGG
[0244] AGGTTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCCTGGGCGACAGAGCAAGGCTCTGTCTCAAAAAAAAAA
[0245] AAAAAAAAAGCCACATGCATGTAATTGTTTACCTCTGGCTTTCCTTTTATGCTCTGGGCAAGCTAAGGAAGAGTTG
[0246] TGAACTACCTAAGTGCTGAATGGGAACCATAACACACACACACACACACACACACACACACACAGCACCTTAGTAA
[0247] AGGGTGAGAGGCATGTTAGTTAGAAGCATTAAAGGAAATCTCTTTCTAGTCATTATCTGTGCACTAACCTAACTGA
[0248] GCAGAGACTTCAGTATCCACATACTACAGGGCATATAAACTTTACAGAATTAGTCCAGGAAAATCATATCTAAAAA
[0249] AAAAAAAAAGCAGTAACAAAAATAAACTCTGGGAAAGGGGAGAATATGATTTAAAGAGTTGCCACATTATACATAA
[0250] TATGTCTAGTGTTCAACAAAAAATTACGAGACATGCAAAGAAATAGAAAAATATGGCACAAAGAGGATAAGATGAA
[0251] GTCAGTGAAACTATCCTCGAGGAAGACCAGATGTTGGTCTTACTAGACACAGACATTGAACCAGCTATTAAAAATA
[0252] CGTACACAGAACTAAGAAAAACATGTCAAAAGGGTTAAAGAAAGGTATAAAAATAGTGTCTTACCAAATATAGACT
[0253] ACCAATAAAGAGATAGAAATTATAAGAAAAGACAACATGAAAAAATATAAAGCAAAAAAATTAGACAATTGAAACA
[0254] AGAGGGCCTCTATTCGCAGATTTGAGCAGGCAGAAGAAAGAATCAGTGAACTTGAAGATATGTCAACTGAGATTAT
[0255] CCAGTCTGAGCAACAAAGGTGGGAAAAAATGAAGAAAACTGAGCAACAAAGAACTGTAGAACAGCATCTCTCATAC
[0256] CAATGGATACATAAACTGGAGCCCTAGAAGGATGAAAAAAGGAGAAGGAAAGAAAACTTCCCAAATTTTAAGAAAA
[0257] ACATTAATTTATATACCCGAGATGACCAATAAAATCCAATTAAGATAATCTCAAAGAGACCAACACCTATACACAT
[0258] CATAGTCAGCGTGTCAAAAGACAAACATAAGGAGAGAATTCTTGAAGATAGTAAGAAAAAAATTATTCATAACATA
[0259] CACACCATCCTCAATAAGTCTGACAATTGACTTCTCACTGTAAACCATGCAGGCTAAAGGCAATGTACATAACC
[0260] AAGTGATGAATAAAAACCTTCAACCAATCATTCTAGATCCAACAAAACTATTGTTCAAAAAGAAGAAATGAAGA
[0261] CATTCCTAAACAAAATCTCAGAGAAATGTTCTCTATAAGACTTGTCCTAATAGAAATGCTAAAGGAACTCCTTCGG
[0262] TCTGAAATAGAAAGGCACTGGAGAGTAAATCAAATCCACGAGAAGAAATAAAGAGAACCAGTATAAGTAACTACAT
[0263] GTGTAAGTTTAAAACAAAGTATAAATTTATTTTGTTTGTAACATTTGTCTTTTCCTATTTGATTTAAATATAATC
[0264] TCAATTATAAACTTGTGTTGATGGTATTATATAAAGATGTAATTTTGGGTTATAGCACCAAAATGGCAGAATAGGA
[0265] ATTTTCTGTAGGTGTTTCCCACATAAGTATCAATTTTGACAACCATCCATGGGCAAGAGTACCTTGTGGGAGTTCA
[0266] GGAGTTGACAGTAAAACTTCAGCACACCAGAGGAGTAAAGAAATCTAAGAATAGATTCATTGGAAAGGGTATAAAC
[0267] AGTTTCACTTTACCTGCATCACCAACCCCCAAAAGTGGCACAGCTCAGTAACAAGAGCCCATTATTTCTTCCACAG
[0268] AGGAAAAGGAGAGTATAATAAGTAAGTGTCCAGTTTCTCAAGACATACAGGCCCCTGCCCAAGAGATCCACTTTAT
[0269] TTTCATCTCACCCAGAATATTGAGGTGATCAGCAAGGTGGAGTGGTTGGGAGAGGGTAAAAGCAGGAAAGAGAGAT
[0270] GGGGACTCAAACAGCAGCCCATACTTGGAACTGCCATAGATCCTACCAGTTACTTCATGGACTCCATCAGGAACCC
[0271] ACCTATAAGCCACAGGGGATGCATCCCTCCCATCTTGCCAACAAAACCCCGAATGCTCCAAATGCCTCACCCACTC
[0272] TTTGGCTGGCTCCCAAGTGCGCTCCTGTGAAAAGCGAGTGAGTATCTCTGCAGATGGCTTGCAAGCACATGTTGAC
[0273] AGCTGGCTCCACTCTGTAGAACTGGAAAAAAGCTCACATACATGAGAATTTCAGGACACTACCCTAAAAAAAAAAA
[0274] TGAGACTTCAGCACCTGGCCTGGCTTTATGCAACCTAGAGAAGGTGATATGATTTGGCTCTGTGTCCCCACGTAAA
[0275] TCTCATGTCAAATTGTAATCCCCACGTGTTGGACAAGGGACTTGGTGGGAGGTGATTGAATCATGCGGGTGGACTT
[0276] CCCTCTTGCTGTTCTTGTGATAGAGTTGTTATGAGATCCAGTTATTTGAAAGTATGTAGCATGTCCCCCTTCACTC
[0277] TCTTGCACTCCTGCTCCACCTTGGTAAGACTTGCTTGCTACCCCTTTGCCTTCTGCCATGATTGTAAGTTTCCTGA
[0278] GGCCTCCCAGCTATTGCTTCCTGTATGGCCTGCAGAACTGAACTGTGAGCCAATTAAACCTCTTTTCTTCATAAATT
[0279] ATCCAGTCTTAGGTAGTTCTTTATAGCAGTGTGAGAATGGACTAATGCAGAAGGCATACAACCTTTAGAATTTGCC
[0280] CCCTTGAGGGAACAAGATGTGTGAAGCAGGTTCATCCATAGAAAATGTCTGAGAGAACCTCAAAATCCCTAACCTG
[0281] ACTAACTGATGAAAGTGTTTCTCTCCTAAGGCCAGTCAGTAAAGACCAGAGGGGGTGACTGTTTCTTTAAATGCAA
[0282] AGGCAGCAGCACAATAATTCAAGAAACATGAAAAATCAAGAAAACATGACACCACCAGAAGAACACAATCATTTTC
[0283] CAATAACCAACTCCCCAAAAATGGAGATTTACAAATTGGTTTATAATGAATTCAGAACAATTATGTTAAGGAAGCT
[0284] CAGCAAACTAAGGAACACCAATAGACTACTCTGTGAAGTCAGGCAAACAATTCATGAACAAAACTAGAAATTCA
[0285] AAAAAGAGAAAAATTATCTTAAGAAACCCAGAAGTTATGGAGCTAAAGAATACAATGCATGAAATGAAGGAGC
[0286] GTATCAACAGCAAAGTTGATCAAGCATAAGAAAAAAAAAATCTGTGAAACTGAAGACTGGCTATTTGAAATTATTC
[0287] ATCAGAGGATTAAAAAAAAAAGAATGAAAAGAAATAAAGAAGCCTACAGGATGTATAAAACACCATCAAGAGAAC
[0288] TAATATAAGGATTATTGGAGTCATAAAGGAGAAGAGAGAAAAGGGTAGAAAACTTATTTAAGAAATAATGGCTGAA
[0289] AACTTCCAAATCTAGGAAAAGATATGAGCATCCAGGTATATGAAGCTCAAAGATCCCCGTACAGGATACATTCCA
[0290] AAAAGACTTCACCAAAACACATGATAATCAAACTGTCAAAAGCAAAATCAAGACGATGAATAAAACCACAATCACT
[0291] AAGAGGGAGACAGGATTCTTATGTTGTCTATTATTTACATATAATTTCAGTAAATGTTATTGGAAAATTTATAA
[0292] TGTTTTAAAAAAAAAATTTGAAAGCACCGAAAGAAAAGAGACTCATCACATACAGGGAACCCTTTTAAGGCATTC
[0293] AAGAGATTTCTCAGTAGAAACCTTACAAAATAGGAGAGAGAGTGGGATGAACTATACAAGTGCTGCAAGGAAAAAAAT
[0294] GCCAACCAACGCTTTACCTGGCAAATCTGTTCCTCAGAAATGAAGGAGAGAGAAGAACTTTCCTAGACAAACAAA
[0295] GCTGAGGCAGTTCATCACCACTAGACCTGCCTTACAAGACACTATAAGGGGAGTTCTTCAAGCTGAAATGATATGG
[0296] CAATAGTTAGTAATATGAAATGATAAACCTCACTGGTAAAGGAAAGTACATAGTCAAATTTAGAACACTTTGATAC
[0297] TATAATGATGGTGTATAAATAATTTTACTGTGCTATGAAGGTTAAAAGACAAAAGTATTAAAAAAAACCCATAGCT
[0298] GCAATAGCTTGTCAATGCATACTACAGTATAAAAAGATGTAAATTAGAACATTAAAAACATAGCATGCAAGGGTAG
[0299] GGAAGTAAAAGTGTAGTTTTCATATGTAATCAAATTTAATTTGTTATCAGCTTAAAATAAATTGTTATACCTATGT
[0300] TTTATGTAAGTGTCATGGTAACTATAAAGGAAAAACCTCTAGTAGATACACAAAAGAAAAAGAGAAAGGAATCAAA
[0301] ACATAACACTACAGAAAATTATCAAATTACAAAGGAAGACAGCAAGGGAGGAACAAAGTAAAAAGAGCAAGAAAAA
[0302] ATTTAACATAATGAAAACAGTAAGTCCTTACGTGTCAATAATTACTTTAAATGTAAATGGATTAAATTATCCAAAC
[0303] AAAAAAACAGACTGGACAAATGGATTTTAGAAACAACAACAACAACAAACACCGCACACACACACACACACACACA
[0304] AACCACCCAGCCCCAACTATGTGCTGCCTACAAGAGATTTACTTCCACTTTAAGGACACATACAGGCTGAAATTAA
[0305] AAGAACAGAAAAAGATATTGCATGCAGATAGAAACCAGAAGAGAGGAGAGGCATCTATACTTACAGCATACAGAAA
[0306] AGATTTTAAGTTAAAAAACTATATCAAAAGGCTAAGAAGGTCAAAAATGGTGAAGCAGTTAATTGTTCAAGAAGACAT
[0307] AAAAATTGTAAATATTTATACACCCAATATTGAAGCACCTAAATATATAAGGCAAATATTAATACATATAAAAGGA
[0308] GAAATATACAGCAATCAGTAATAGTAGTGAACTTCAGTGCCTCCCTTTCAAAAATGGATAATCCAGACATAAAAT
[0309] CAATAAGGAAACATTTAACTTAAACTTCACTTTAGACCAAATGGATCTAACAGACATTATACTGAACATTTCATCC
[0310] AACAGTGGTAGAATTCACATTCTTCTCAAGCACACATGGAACATTCTCCAGGATAGATTATATGTTAGCTCACAAA
[0311] ATAATATTACAAAATTTAATAAAGCTGAAATATCAATTATTTGCACCACAATAGTATAACACTAGAAATCAAATAA
[0312] CAAGATGGAACTGGAAATTTACAAATATAGCATTAACATATTCCTGAACAACCAATGGGTCAAAGAAAAAAAT
[0313] CAAAATAATTTTGTGACAGCAAAGTAGAAACACAACATACCAAAACATACAGGACACAGCAAAAGCAGTTCTATGA
[0314] GGTAAGCTTATATTGATAAACACATTTAAAAAAGATTTTAAATAAACAACATTACACCTCAAGGAACTACAAGGA
[0315] AGAAAAAAAAACAAGCCCCATGTTATCAAAGGGAAGGAACTAACAAGATCAGACAGAAATAAATGAAACATAGAC
[0316] TAGAAAAACAATAGAGACTATTAATAAAACTTAGAGTTAGTTTTTTAAAAAATAAAATCAACAAACCTTTAGCTAG
[0317] ACTAAAAAAAGAGAAGACTCAAATAAAATAAAAAATGAAAGAGGAGACATTACAACTGATACCACAGACATACAAA
[0318] TTAAGAGAAAACTATATGCCAACATATTAGTTAACTTGCAATGGGTAAATCCCTAGAAACATACAACCTACAAAAA
[0319] CTGAATCATGAAGAAATGGAAGATCTGAACAGATCAATAATGAATAAGGGAATTGAATCAATATTCAAAAATCTCA
[0320] CAAAAAGAAAAGCTCAGGATCAGATGGCTTCACTGGTGAAGACTGCCAACCATTTAAAAAAATTAATACCACTCTT
[0321] TATTAAGCTCTTCCAAAAAAATTGAAGAGGAGAAAACACTTTCAAATTCATTATAAGAGGCCAGTTTTACCTTGAT
[0322] ATCAAAGATTTAAAAAGAACACTTTGAGAAAGGAAAATTACAGGCCAAAACCCTTGATAAATATAGATGCAAAAAT
[0323] GCTCAGCAAAATACTAGCAAACCTAATTCAGCAACACATTATAATGGCATACATCATGACCAAGTGAGATTCATGC
[0324] CTCGGATGCAGGATAGTTCAATATAATCAAATCAACAAATGTTACACTACTTTAACAGAATGAAGGATAAAAATCA
[0325] TATGATCATCTCGATGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAAAATGTTCCTATTTCTCCACATCCTC
[0326] TGCAGCACCTGTTGTTTCCTAACTTTTTACAGATCACCATTCTAACTGGTGTGAGATGGTATCTTATTGTGGTTTT
[0327] GATTTGCATTTCTCTGATGGCCAGTGATGGTGAGCATTTTTCAAGTGTCTGTTGGCTGCATAAATGTCTTCTTTTG
[0328] AGACGTGTCTGTTCATATCCTTCACCTACTTTTTGATGGGGTTGTTTGTTTTTTTCTTGTAAATTTGTTTGAGTTC
[0329] TTTGTAGATTCTGGATATTAGCCCTTTGTCAGATGAGTAGATTGCAAAAATTTTCTCCCATTCTGTAGGTTGTCTG
[0330] TTCACTCTGATGGTAGTTTCTTTTGCTGTGCAGAAGCTCTTTAGTTTAATTAGACCCCATTTGTCAATTTTGTCTT
[0331] TTGTTGCCATTGCTTTTGGTGTTTTAGACATGAAGACAGTGTGGTGATTCCTCAAGGATCTAGAACTAGAAATACC
[0332] ATTTGACCCAGCCATCCTGTTACTGGGTATATACCCAGAGGATTATAAATCACGCTGCTATAAGCCATAAAAAATG
[0333] ATGAGTTCATGTCCTTTGTAGGGACATGGATGAAGCTGGAAACCATCATTCTCAGCAAACTATCACAAGGACAAAA
[0334] AACCAAACACCGCATGTTCTCACTCATAGGTGGGAATTGAACAATGAGAACACATGGACCCAGGAAGGGGAACATC
[0335] ACACACTGGGGATGGTTGTGGGGTGGGGGGAGGGGAGAGGGATAGCATTAGGAGATATACCTAATGCTAAATGACG
[0336] AGTTAATGGGTGCAGCACACCAACACGGCACATGTGCACATATGTAACAAACCTGCACGTTGTGCACATGTACCCT
[0337] AAAACTTAAAGTATAATTAAAAAAAATAATGCTGCTATAAAGACACGTGCACACGTATGTTCATTGCGGCACTATT
[0338] CACAATAGCAAAGACTTGGAACCAACCCAAATGTCCATCAATGATAGACTGGATTAAGAAAATGTGGCACATATAC
[0339] ACCATGGAATACTATGCAGCCATAAAAAAGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAGCTGGAAACCAT
[0340] CATTCTCAGCAAACTATCACAAGGACAAAAAACCAAACACTGCATGTTCTCACTCATAGGTGGGAATTGAACAATG
[0341] AGAACACTTGGACACAGGAAGGGGAACATCACACACTGGGGCCTGTCGTGGGGTCAGGGTAGGGGGAGGGATAGCA
[0342] TTAGGAGATATACCTAATGTAAATGACGAGTTAATGGGTGCAGCACACCAACACAGCACATGTGTGCACATGTACC
[0343] CTAGAACTTAAAGTATAATAAAAAATAAATCATATCATCATCTCAGTAGATTTAGAAAAGCATTTAACAATATTCA
[0344] ACATCCTTCAGAACTAAAAACTCTCAATAAATCAGGTATAGAAAGAATGTGCCTCAACACTATAAAAGCCACATA
[0345] TGACAAACCTGGAGGTAATATACTCAATGGTGAAAAGTAAAGCTTTGACTCTAAGATCAGAACCAAAACAAGGA
[0346] TGTCCATTCTCACCACTTATATTTAACATAGTAGTTGAAATTCTAGCTAGAGCAATTAGGCAAGAAAAAAGGCACC
[0347] CAAGTTGGAAAGAATGAAGTTAAATTGTCTCTGTAGATGACATGATCTTATATATAGAAAACACTAAAGACTCCAC
[0348] CAAAATGCTGTTTTAATTAGAGCTTAAAAAAATAATTCACTAAAGTTGCAGGATACAAAATCAGTATACAAAAATC
[0349] AGTTGCATTTCTAAACACCAAAAACAAGTTATTCCAAAAAATTAAGAAAACAATCCTATTTGTGATATCATCAAAA
[0350] ATAAAATACTAAAGAATACCAAAGAAACTGAAAATAAATGGAAATAAATGGAAAGATAGCCCATGTTCATGGATTA
[0351] GATGAATTAATACTGTTAAAATGTTCATACTACCCAAAGCAACCTACAGATTAAGTGCAATTCCTACTAAAATTCC
[0352] AATGACATTTTTCACAGAAATAGAAAACACACTCCTAAAGTTTGCATGGAACCGCAAAAGACTCAAATAGATGAAG
[0353] CAATTTTGAGCAAGAACAGTAAAGCTGGAGACATCACACTACCTAACTTCAAAATTTTATTAATCAAAACAGCATG
[0354] ACATAAAAACAGACAGAAAAGACCAATGGAACAGAATAGAGAGCCCAGAAATAAACTCACGTTTATAGAGTCAACT
[0355] AATATTCAACGAAGGTGCCAAGAGTACACAATGGGGAAAGTATAGTCTCTACAATAAACAGCACTGGGAAGCAAT
[0356] ATCCAAATGCAAAAGAATGAAATTACACCCTTATCTTATACCATACACACAAATCAAATCAAAATTGATAAAGACT
[0357] TAAATATAAGACCTGAAACCATACAATCTTTAGGCAAAACTCATTGACATTGGTCTTGGCAATGATTTTTTTGAT
[0358] ATGACACCAGAGCACAGGCAACAAAAGCAAACCTAAAACAAGTGGGACCCTAACAAACTAAAAAGTTTCTGCACAG
[0359] CAAAGGAAACAATCAATCATCAGAATTAAAAGGCAATTTATGAAATGGGAAAATGTTTGCAAACCACATATCTG
[0360] ATAAAGGGTTAATATCCAAAAATATATAAGGAATGCATAAAATTCAATAGAAATAAACAAACAAATAATCCAATTT
[0361] TAAAATGGGTGAAGACCTGAATAGAACATTTTTTCAAAGAAGACTTACAGATAGGCAACAGGCATATGAAAAAATG
[0362] CTTGACATCACTAATAATCAGGGAAATGCAAATCAAAGCTCCAGTGAAATACCACCTCCAACTATTAGGATGGCTA
[0363] TTATCAAAAACTCAAAAAGAAAACAAGCTGGGGGAATGTAGAGAAAAGGGAAAAAGAATCCTTATACACTGTTGGT
[0364] GTGAATTTAAACTGGAATAGCCCTTATGGAAAACAGCATGGAGGTTCCTCAAAAAAATTAAAAATAGAACTACTATA
[0365] TGATCCAGCAATTTCACTATTGAGTATATATCCAAATGAATTAAAATCACTGTCTTGAAGAGGTATTTGCACACTC
[0366] ATATTTTATTCAGCATTATTCACAATAGCCAAGACATGGAATCAACCTAAGTGTTCATCAGTAGATGATTAGATAA
[0367] AGAGAACGTGGTATATAGACACAGTGGAATCTATTTAGTGTTCAAAAGAAGGAAATCCAACTTTTAAAATCCTTTT
[0368] AAAAAGTTAAACTCATAAAAACAGAGAGGAGAATGGCGGTTTCCAGGAACTGGAGGGTGGGGAGAATGGGGAGATGT
[0369] TGGTCAAAAGGTACAAACTTTCAGTTATAAAATGAATAAGTTCTAGAGATCTAGTGTACAACAGCATTACTATAGT
[0370] TAATAATAATATTTTTTATACTTGAAATTTGCTAAGAGTAAATATCAATATTCTCAATACACACAAAACAGAACTA
[0371] TCTGAAGGCACTGATATGTTAATTATCTTCATTATATAGTAATCATTTCACAATGTATAATGAATATCAAAACAATAG
[0372] TGTACATCTTAAAATATATACAGTTTTGATTTGTTAATCATACATCAATGAAGCTAGAAAAATGTTGTAATTTTTA
[0373] AAACAATAGTAATATAAATTAGGGTGAAGGAATTGACCTATGTTGGAGAAAGTTTTTGTAAACTATTTAAATTA
[0374] ATTGGTATCCATTCAAGCTAGATTATTTTTAATTGTTAATTTAATTGTAATACTAAGGCAACCACTAAAAAAGCCT
[0375] TTAAAAAAATATAGCACTTGAGGCTGGGCATGGTGGCCCTCAATTATATATAATATATATAATATATATAT
[0376] ATATATAGATGAACAACAATGGGATTTAAATGGTACACTAGAAAATATCTGTTTAACAAAAAGAAAGCAATAG
[0377] TGGAGAAATATAAGAACAAAACCATGTAAGATTTATAGAAAATGAATAGCAAATTGGTTGACCTAAACCCTATCTT
[0378] ATAATTATATTAAAGATAAATGAAATAAATACTACATCAAAAGGCAGAGATTATCAGAATAGAGAAAAAATCCA
[0379] AACCATAATTCAACCTTATGTTATCTGTATTTAGAATTTTAGAGTCAAGACACAAATAGATAGAGTTCCATTTGG
[0380] GCGTGAAAATTTTACCATGCAAAATGTAATTAAAATAGAGCTAGAGCAGCAATACTAATCTGACAAAATATAC
[0381] TTTAACAAAAATTGTTGCTAAAGACAAAAAAGAACATTTTATAATAAGACACAACATTAACATATACACCAA
[0382] AATAGAGCCCAAATATAACAAAAAACTGCTAGATTGAAGAAAAAAATTACTGATTAGTTGTT
[0383] AGGTGTTATAAACTTTTATATATATAXAACCAAGTCAAAAGCAAAAAAAAAAAAACTATATATA
[0384] ATCATACCACCTTAATATATACCATCCAACAATAGATAGACTATTCTCTGAGTGCACATGGATATTCTCTTC
[0385] NATIONAL HELPTAGGCTGTAAAACATCTCTATAATTTAAATTGAAATTGAATTAACTATTCTCTCTG
[0386] ACTGCAAAATTAAACCAATTACAGAAAATGTGGGAAATTCAATGATGGATTTAAAAATACTTCAA
[0387] AGTAACACATCAGAACAAATCAAAGAATTAGAATATTTTTATGAATAACTGAGAACAC
[0388] ATTACCAATTTTGTGGTTGTAGCTAAAGCAGTGCTTCAAGGGAATGTATAAGTATCCCTAAATTTAAAA
[0389] AAATCTCAATCCAATAACCTAATTTTTCACCTTAAGAAATGAGTGAGAGAGACCTAAACCCAAATAACAG
[0390] AAGGAAAATAAAAGATTAGCATGGAGATAAGTAGTGAAAAAAAAATAGAGAAAATTAAAACTTGAA
[0391] AGTTGGTTCTTCTGATATCAGTAAATTGACGTATTATGTTTGACCGAGAAAAAAAGAGAGAAGATTC
[0392] AAGTTACTAGACATAAATGAAAGTATAGATATCACCTTACAGAAATTAAAAGAATTCTAACAGAATATTGTGAAAA
[0393] AGTGAATGTCAAAATTAAATTATATGAGATACACAAATCCCTCTAAAGGCACAAACTACCACAGCTGGTGTAAA
[0394] AACATGAATACACCATTTACAGTTAAAAAGACTGAATAGATAAAAATTTTAAGAAGAAATTGAGTAAGTAATTTAA
[0395] TTTTCAAACTATAATCCCAAGACCAGATGTTTTCATTGGTGAATTCTACCAAACTTTAAAAGGATTAATATCTATT
[0396] TTTCATACACTCTTTCCAGAAAATAGAAAAGGAGGGAACACTCTATAACTCACTGTATGAGGTCCGTATTACCCTT
[0397] ATATCAAGACCAAACATCATAAGAAAAGAAGACTAAAGACTTATGGTTTCTGCTCTGATATGTTTGGAAGTCATCA
[0398] CTACTATTGTCACAAGGAAAAATCTGAACAAACTAAAGTCAACGATTTCTTAAACTAACCATAGAATTGAGGTAAC
[0399] GGGCGAAGACTGGAGATGTAGGCAAATACAAAAAATCACAGTTTATCAGGAGCAGAAACTGCTGAAACCAGCAA
[0400] CTCGTATGAACATGTTAAGTGGTAATTGACAAATTTCTGGAGATTGAATGTGGACTGGATTGAGAGTTAGGAACTC
[0401] CTAAGTGCCCAGTTTTTGATGACCCCACACACTTTTGTAAACTAGACTTCCAAGAGCCCCAGCAAGTTTCTTACAG
[0402] TGAAGACTGCAGAAAAATCCCCTGATGCTTCAGATAGGAGGAAGGGAAAAGCAACTATTTTGAAATAAGCCCAGGG
[0403] GACAAGTAGTTATTCTTAAACACTCTCAGAGCATTTTCTTTCACACGGCAGGGGGCTCCCTGCAAGGGAAGCTACT
[0404] TTGCCTGAGCCTTGTCTGATGTAGGAGAAAAGGAATTGGATGGCTCAAGCTCCATCTAGCCTTTCTGATTTATATA
[0405] AGGGAAGCAAAAAATAGGTTAAGAAACTCTTCTGAAAGTCACACTCAGATTTATTTTATATTTATTTATTTTATT
[0406] ATATTTTTTGAGACGGAGTCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTC
[0407] CACCTCCCGGGTTCACGCCATCTTCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGCGCCCAGCTAATTTTTT
[0408] GTATTTTTAGTAGAGACGGGGTTTCACCACGTTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCACCTGCC
[0409] TCTGCCTCCCAAAGTGCTGGGGATTACAGGCTGAGCCACCGCACCTGGCCTCACAACTCAGATTTAACCATAAGAT
[0410] TATAGAACACTTCTCCTCCCAAAACAGAGATATAGATCAATGGAACAGAACAGAGCCCTCAGAAATAACGCCGCAT
[0411] ATCTACAACTATCTGATCTTTGACAAACCCGAGAAAAACAAGCAATGGGGAAAGGATTCCCTATTTAATAAATGGT
[0412] GCTGGGAAAACTGGCTAGCCATATGTAAAAAGCTGAAACTGGATCCCTTCCTTACACCTTACACAAAAATTAATTC
[0413] AAGATGGATTAAAGACTTAAACGTTAGGCCTAAAACCATAAAAACCCTAGAAGAAAACCTAGGCATTACCATTCAG
[0414] GACATAGGCATGGGCAAGGACTTCATGTCTAAAACACCAAAAGCAATGGCAACAAAAGACAAAATTGACAAACGGG
[0415] ATCTCATTAAACTAAAGAGCTTCTGCACAGCAAAAGAAACTACCATCAGAGTGAACAGGCAACCTACAAAATTTTC
[0416] ACAACCTACTCATCTGACAAAGGGCTAATATCCAGAATCTACAATGAACTCAGACAAATTTACAAGAAAAAAACAA
[0417] ACAACCTCATCAAAAAGTGGGCAAAGGATATAAGCAGACACTTCTCAAAAGAAGACATTTATGCAGCCAACAGACA
[0418] CATGAAAAAATGCTCATCATCACTGGCCGTCAGAGAAATGCAAATCAAAACCACAATGAGATACCATCTCACACCA
[0419] GTTAGAATGGCGATCATTAAAAAGTCAGGAAACAACAGGTGCTGGAGAGGATGTGGAGAAATAGGAACACTTTTAC
[0420] ACTGTTGGTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGATTCCTCAGGGATCTAGAACTAGA
[0421] AATACCATTTGACCCAGCCATCCATTGCTATATATATATATATATACCCAAAGGAACTATAAATCATGCTGCTATA
[0422] AAGACATATGCACAGGTATGTTTATTGCAGCACTATTCACAATAGCAAAGACTTGGAACCAACCCAAATGTCCAAC
[0423] AATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAATACTATGCAGCCATAAAAAAGATGAGTTCA
[0424] TGTCTTTTGTAGGGACATGGATGAAATTGGAAATCATCATTCTCAGTAAACTATCGCAAGGACAAAAACCAAACA
[0425] CTGCATGTTCTCACTCATAGATGGGAATTGAACAATGAGAACACATGGACACAGGAAGGGGAACATCACACTCTGG
[0426] GGACTGTTGTGGGGTCGGGGGAGGGGGAGGGATAGCATTAGGAGATATACCTAATGGTAAATGACGAGTTAATGG
[0427] GTGTAGCACACCAGCATGGCACATGTATACATATGTAACAAACCTGCACATTGTGCACATGTACCCTAAAACTTAA
[0428] AGTATAATAATAATAAAAAAGGCTACCTAAAAAAAAAAAAAAAGAACACTTCTCCTCCCAACACCATATCACCACA
[0429] TCAACCAGGACTCCAGTGTAATAGCAGTGAAATTCTAACTGAAAGAGGTGAAAGACACTGATTGTATTTAAGAAAAGA
[0430] TCTTCTAAGGAAATCCAAAAATAGTAGGGGGAGATCAAAACAAAGATACTAGAGGAAATTGAATATGTGACACCTAT
[0431] AGCTACAAAAAAATTAAACATAACATAGCCCTAACCATATAAACATAAAACCTCACACAAAGACCTATTATCTGAG
[0432] ATTCTGTTGCCTGATACATTGCGTTTTATTTCAATAAAAAAATTAGAGGGTATGTTAAAAAGCAGGAAAAGTTAGT
[0433] CTAAAGAGACAAATTGAGCCTCAGAAGTAGGCTCAGATATGGCAGAGATTTGGCAATTATACCTAGAGTTTAATAT
[0434] AAATGATTAATATAATAAGTGTTCTAACAGAAAAAGGCAACATGCAAGAACGGATGGGTAATGTGATCAGCAAGAA
[0435] GGAACTCTAAGAAAGAAGTCAAAAGGAAATGCTAGGAATAAAAACCTACAAGAAATAAAGAATGCCTGTGATGGG
[0436] TTCCTCAGAGACTGGACAAGGTCAAAGAATCAGTGGATTTGAAAATATGTCAACAAAAACTGCCCCACTGAAATA
[0437] CAAAAGAAAAATAGAATTTTTTAAACGTAACACAATCTCCAAAACAGTGGGACAATTACAAAAGATGTAATGTGCC
[0438] TAATGCAAATGACAGTAGGAGTATAAAGGGAGAAAGGAATAGAAAATCTGAAGTAATAATGGCAGAGAGTTTTCCA
[0439] AATTAATGCTAAACCACAGATACAGCAAGCCCAGAGAACAACAAGGAGGAAATTTAGTAAAGCGTCTGCAACCAA
[0440] GTATGTCATATTCAGACTGACAAAACCAAAGGTGAAGAGAAAATATTGAAAGAAGACAAAGAGGAAAATAAATATC
[0441] AAGAAAATACATACGAAATACATCATACATACATAAGAAATACATCAGACCATACAAGCAAGAAGAGAATGGAGTG
[0442] AAATGTTTAAAATGTTGAAAAAAAAACTATCATTTGCAATTCTGTATCCAGTGAGATTATCTTTCAAAAGTGAAG
[0443] AGGGAAATGGCAGAGAAGTCATCTCCAAGACCTATGGTTTCCCTTTCACAGAAACACTGAAAAATATGAACAAAAGT
[0444] GGTCAGAATTAACTTTCTAAGAATTCTATAAAATGGTAAAATGTTTACACCAGTAAAGCAAATGCTGAATTGAGAA
[0445] GGCAACTTAAAGGGTGAAGAAAACTTCGTATTATTTTTATGTGTCCTTGCCCCACGTCCTTCCCTACCTTAGTCT
[0446] TGAAGATGGCAGCCCACATTTCTACTGTGGGGCTCTGGTTTCTGTTTCTCTGGTTCAAGAGGGAGAATAACAGACCT
[0447] TACTTTTAGTCATTATTATTTCCTTCTTTCTGATTTCCTTGGGTTTATTTTGCTCTTCTTTCTACTTTATTGAAAT
[0448] GAGAACTAAGATTATGATTTGAGACATTTTTCTAATGTAAGCATTTAGTGCTATAAATTTCCATCTCAACACTGCT
[0449] TTAGTCACATCCCACAAATTTTTATATGTTGTAATTTCACTTTCATTTAGTTCTATTTTTAAATTTTTTCTTTTTA
[0450] TACTTCCTCTGACTCACAGATTACTTAGAATTGTGTGTTCAGTTTTCAAGGATATTGTAGATTTTCCTGTTTCTC
[0451] TGTTGTCTAATAGTTCTGTTCCATTTTGTACAGATAGCTCACGCTGTATGATTTCAATTTTTAAAAAATTGTGCT
[0452] TTGTTTTATGGCCCAGATATGGTCTGTGCTGTGAATATTCCATGTTATTATAAAGTATGCCTGTTATATTATTATA
[0453] TATATATAATATATAATTATAAAGCATGCCCGTTTTGTATTGTTAGCAGAGTATTCTAGAAATGTCAATGAGAT
[0454] CTTGTTGGTTGATGGTGCTTTCAGTTCTATATCTTTGCTAATTTTTTTTTTTTTGCTTAGTAGCTATATGAGAT
[0455] TCTGAGAGAGGAAATTGAAGTCTCCAACCATAATTGTGGATTTGTCTATTTCTCCTATCAGTTCTATCAGTTTGTG
[0456] CATCACATATTTGAGGCTCTGTTGTTTGGTGCATACACAAGTGGAATCATTGTGCCCTCTTGGTGGCTTATTTTAT
[0457] GATTATATAGTGCCTATCTTTGGTATTTTTTATTTGCTCTTAAATCTACTTTGTGTTATATTCATATACCCCATTC
[0458] TTTTTTTAAAAAAAATTGTTTGCGTGATACATCTTTTCCATTCTTTAATCTCAGCCTATCTGTGCCATTGAATTTG
[0459] AAGTGAGTTTTCATATAGAGAACATATTATTGAATCATCATTTTAAAAATTCCTTTTGCCAATCTTTTTTATACTG
[0460] AGGTAAAATTGACATAAAATTTATCATTTTAAAGTGTACAATACAGTGGCATTTGGTAATACACATGTTATGCAAC
[0461] GTTAACTCTACCTGGCTCCTAAATGTTTTCATCATCCCCAAGGAAACTTCATACTCATTAAGCAGTTAATTCCC
[0462] ATTCCTTCTCTCGGCCACTGGCATCCGCAAACCTACTTTTCTGTCTCTATGAATTTACCTATTATGGATATTTTGT
[0463] ATAAAATTGAATTATACAATAAGTGACCTTTATGTTTGGCTTCGTTCGCTTCGCATACTATTTTTCGATATTCAACC
[0464] ATGTTGTAGTAGTATCAGTTTTATTTGAATAACTCAATTCTTTTTGTTGTATAGCTAAAAGTTGATTCCTAGGTC
[0465] ATAATGATAATTCTATGTTTAGTTTATTGAATAGCTGCCAAAGTTTTTCCACAGTGGCTCTGTCATTTTAAAATCC
[0466] CACTAGCAATGGATGAGAGTTCCAATATCTCCACATCCTTACCAATATTGTTATTTTATATTTTTATAATTATAAT
[0467] TTTCCTAGTGAATACGCAATGGTATCTCATTGTGTTTTTGGTTTGCCTTTCCCTAATGACTAATGATGTTGAGCAT
[0468] CTTACAATGTACTTGTTAACTATTTGTGTTCTTTAGAGAAATGTCTATTCAAGTGCCTTGTCCATTTTAAAAATCG
[0469] AGTTGTCTTGTTGACTTATGAGTTCTTTAATACAGTAAACGCTTATCAGATATGATTTATAAGTATTTTAACCCAT
[0470] TCTGAAGGTCACCTTTTCACTTTTGTGGTAGACCATTATGCACAAAGGTTTTAATTTTGATAAATCCAATTTATCC
[0471] GCTTTTGTTGTTGTTTTTGTTGTTCGTGCTTTTGCAAAACCTAGTGTCATGAGGTTTTCTCATTATCTTTGGAGAA
[0472] TTTTATAGTTTGGGTCTATACATGTAGATTATTGATCTAATTTCCATTAATTTGTGTGTATGCTACGAGGTAGGGG
[0473] TCCAAATTCAATTTTTGCATTGAATTGAAAATTCATATTTTCAGTTTCAAATTTCAACTGCATATTCAGTTGTTGC
[0474] AGCACAATTTGTTGAAGAGATCATTCTTTACCACAGGGAATGATCTGGGACCCTTGTCAAAAATCAATTGATCATA
[0475] GATGTATGGGATTATTTCAGACTTTAGATCTTGTTCCATGAATATGCCTATTTTTATGCCAGCACTGCAGTATTTT
[0476] CATTACTGTAGCTTTATCATAAATTTTGAAATCAGGAAGTATGTATCCTCCAAGTGTGATTTTCATTTGCTAGAGT
[0477] GTTTTGACTATTGGGGTCTTTGCAATTCCATATGAATTTCAGAATTGGCTTTTCATTTAAAAAAATGGTAGTTGA
[0478] GATTTTCATAGGAATTATATTGAATCTACAGATCACTTTGGGTAGTATTGCCATCTTAACAATATTGTATTCCAAT
[0479] CCATAAACACGGATGTATTGCCATTCATATCTTTTTTCTTTTCTTTCGGCAACATTTAGTATATGACACTTGTAA
[0480] CTCCTTGGTTAAATTTATACCTAAGCATTTTATCCTTTCTGATGCTGTTTAAATGGAATTATTTTATTAATTTCTC
[0481] TTTTAGATGGCTTGTTGCAGGTGTATAGAAATAGAACTGATTATTGTGCTTTTATTGAATTATCTGAAACTTTGCT
[0482] GCATTTATTAACTCTAGTAGGTTTTTTTTTTCTTTAAAAGTTGTCTATATATCTTGCTCTGTGAATAGATAATTTTA
[0483] CTTCTTGATCTCCAATATGGATGCCTTTCTTTCTTTTCTTACCTAATTGCTGTAGCTAGAATTTTCAGTATAATG
[0484] TATGATAGAAGTTGTTCACAACTATCCTTGTCTTCTTTCTGATCCTAGGGGTATAGCTTTCAGTCTTTCACCATTA
[0485] AGCACAATGTTAGCTGTGGGGTTTTCTTAGATGCCATTTAATATATTAAGGAAGTGCTCTGCTATTTCTAATTGGT
[0486] TGAGTATTTTTATTATAAAAATGGTGTTAGATTTATGACTTTATGTACTGCATAATTGAGATTATCATGTGGTCTT
[0487] TTCATTCGATTAATGTGGTATATTTTATGATTTTCATATGTTGATCCACCTTTATATTCTTGGGGCAAATCCCACT
[0488] GTGTACACGGGTTTTTTAGGGTCTCCTAATTTTCTTCATTCTTTTTCTTTTCTCTCCCTGAGACTGAATAACGTTA
[0489] ACTGACCTATCTTCAAGTTTACTATTTTTTCTTCTGCTGTTCAAATCTGCTTGAACCTATAGAGTGAATTTTTCAT
[0490] TTTACTTATTGAACTTTTCAGCTCCAAAATTTCTCTTTGGCTACTTTGTATAATATCTATCTCTCTATAGATATTC
[0491] TCTATTTGGAAAGACATTTTTCTCCTGGTTTTCTTTACTTATTTGTATTTTTTAAAGTCTTTAAGCATATTTGAGA
[0492] CAGTTGATTTAAGTATTTGTGTACTAAGTCCATTGCCTAAGCTTTTGCATAGAGATTTTATATTATTTCTTTTTT
[0493] TTCTGTGAACAGGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGAAAACTGGACATTTTGAGTAGTATAAA
[0494] CGTGGCTATTTTAGAAATAATTTTCCTCCCTCCTTAGGTTTTGTTTCCACTTGTTGCATGTTGCTGTTGTTTGCTC
[0495] ATTAGTGACTTTTCTAAAGTATTTTGAAAAGTCTGTGTTCTTGATCATGTGGGTCCATTGAATTCTGTATTCTGTT
[0496] AATTTCATAGTCAGCTAGTGTTCTGAAAGTTCCCTTAAGTGCATAGAGCCAATAAAAGAAAAAGAAAAGAAACACA
[0497] GAAAAAGAAAAGAGGAAAAAAGGAGGGAAAGAGATTTAAAAAAATAATGTCGGTTGGGCATGGTGGCTCATGCCTG
[0498] TAATCCCAGCACTTTTGGGAGGCCGAGGCAGGCAAATCACTTAAGGTTGACCATCCTGGCCAACACGGAGAAACCT
[0499] TGTCTCTACTGAAAATATAAAATTAGCCGGGCATGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGA
[0500] GGTAGGAGAATCACTTGAACTCGGGAGGTGGAGGTTGCAGTGAACTGAGATCACACCACTGCACTCCAGCCTGGGC
[0501] AACAAGAATGAAACTCCATCTCAAAAAAAAATAATAATAATAATGCCTTTGCCGATTTGCTCTGTGTTTGGGCCCT
[0502] CATTCAATGCCTAGTCAGGCCATTTACAACTCTCTCTTAACTTTCACTACCTGCTTGTGTACTGACTGAAGGCCAC
[0503] CTATAGGTGAAAGCTTAACATCATCTCAGATCTTTTTGGACCATGAATCCTACCCTGGGTATGCACATGATCTTCT
[0504] TAATTTCCCAGTAGATGCAAGAGTTTTAGTGTTTTAAAAGTCCTTATTCCCTCATCTATCTTCTTTTCTGACCTTT
[0505] TTCAGTCTGCTTATTGTTCATCTGAACTGACATCCTTTGCCCCAAGCGGCTGTGGCAAAAACTTTTACCTTTAAAT
[0506] GCTTTCACCACAAGCCACTTGGGAAGCTGCCCCAGACCTGGGACTGCTCTGACCCTGATGAAACAAAGACAAGACC
[0507] TTGTACAGCCAGGCAGCCATAAGACAAGTCCATACCCAAACCACAGTTCTTTCAGAATAAGGTCTATATTGGATTC
[0508] TCTGGCCCTAGTAACCAGCATGAGTCTGGGCTTGCCATCTTCATGGCCACTTGTCTTAGTTTGCTAGGGCTGCCAT
[0509] AACAAAATATGAGAGACTGAGTGGCTTAAACAAGAGAAATTTATTTTTTCACAATTCTGAAGACCAGAAGTCCATT
[0510] ACTCTGAAATCTCTCTCCTTGGCTTGCAGATACTGCCTTCTTGCCGTGTCCTCACACAGCCTTTTCTCTGTGTACA
[0511] CATCCCTGGTGTTTTTTAAGCCTGTCCAAATTTTCTGTTCTTCTGAGGACACCAATCAGATTGGATTAGCGACCAC
[0512] CCATATGATCATTTTACCTTAAGTACCTCTTCAAAGGTATCAGAGTAGTATATTTGCTACAGTTGATGAACCTGCA
[0513] TACAACATCATCACTTGAGGTCTGCAGTTTACATTAGAGTTCATCGTTAGTGTTATATATTCTAGGGTTTGTTTTG
[0514] TTTTGAGACAGAACAGAGTCTTGCTGTGTTACCCAGGCTGGAGCGCAGTGGTACAATCTCATTGCTACCTCTGCTT
[0515] CCCAGATTCAAGCAATTCTCATACCTCAGCCTCCTAAGTAGCTGGAACTACAGGCGCACACCACCATGCCCAGCTA
[0516] ATTTTCGTATTTTTAGTGGAGATGGGGTTTCACCATGTTGGCCAGGCAGGTCTTGAACTCCTTGCCTCAAGTGATC
[0517] TGCCCGCCTCAGCCTCCCCCAGTGTTGGGATAACAGGCATGAGTCACCATGCCTGGCCTTATTCTATGGGTTTTGA
[0518] AATGTATAATGACATGTATCCATCGTTGTAGTATTAGATAGAATAGCTTCATTACCCTAAAAGTCTTCTTTGCACT
[0519] GGGTTGAGTTTTAAAAGCTCTTTGATTATTTTATGACAGTTCCTTATTAGATATATCTTTTGCAAGTATTTTTATC
[0520] AGTCTGTGGTTATCTTGTCTTTTACAGAGCAGTAATTTTTAATTTTAATAAAATCCAATTTGTCAATTACTTATCT
[0521] CATATGACTCTGGTGTTACATCTAAAATGTTACCACCATACTCAAGGTCACCTAGGTTTTCTCTAGGAATTTTATG
[0522] GTTTTGCATTTTACATTTGGTGTATGACCCATTTGAAGTTAATTTTTGTGAGGTTGTAAGGTCTGTGCCTAGATTC
[0523] ATTTTTTTTTTTTTTGGCATGTTACTTCAGTATTCATAAGAAACATTGTTCTGTAATCTTCTTTCTTATAGTATCT
[0524] TAGTCTTGCTTTAGTTTTTGGGCAATGCTGGCCTCACTGAATAAATTCAAAGTGTTCCCTCCTCTTCAATTATTTG
[0525] GAAAAGTTTGAGAAAGACTATTGTTAACTGTTTTCTAAATTTTTGGTGGAATTTACCAGTGAACCAACTGGTCCTA
[0526] GGCTTTTCCCAGTAGGTGGTTTTGATTATGCTTTCAATCTCTTTACAAGTTACACATCTATACAGACTTTTATAA
[0527] TTCAGTCTTGGTAGGTTGTGCGTATTTAGGAATCTGACCACTTCATCTAAGTTATTCCAATTAGTTGGCATGCAATT
[0528] ATTCGTAGTTCTCTGAATAATCATTTTTATTTCCACAAAATTGGTAATATCCCAGTTTCCATTTTTTATTTCATTG
[0529] AATCTTCTTTTTTCTTAGCTAATCTAGCTAAATGTTTGCCAATTTTGTTGATCTTTTGGAAGAACCAACTTTTGAT
[0530] TTATTAATTTTCTCTACTCTTTTTCTGTTCTTTATATTATTTATTTCCACACTAATCTTTACTATTTTCTTCCTTC
[0531] TGTTGGCCTTTAATTTTTTTTTTTTAATTTTTAAGGTGTAAATTTAGGTTGAGAAATTTTTTAAATGAAAGCATTT
[0532] AGAGCTATAAATTTTCCTTCTGGTGTTCCTTTCACTACCTGCCATAAATTTTGATATGTTGAGTTTTTGTTTGTCT
[0533] TGGAGTATTTTCTAATTTGTCTTCTAATTTCTTCCTTGACCTATTGGTTATTTAAATGTATTTAATTTTTGCATAT
[0534] TGTGGATTTCCCAGTTTTTCCTTCTGTTATTGATTTCTAGTTTTATTCCATTGTGATCACAGAAGATATTTTGTATA
[0535] ATCGCAGTCTATTAACATTTATTAAGTCTTTGGCCTAACAGAGGATCTATGTTGGAGAATGTTCCAAGTGCAATT
[0536] GAGAATACTATTCTGGTGCTATTAGGTGAAGTATTCTCTATATGTCTGTTAAGTCCAATTCATCTATAGTGTTGAC
[0537] GTTTCCTGTTCCTTACTGATTTTCTGACTTATTATTCTATCCATTATTATTAAGGGAGTGGTAAAGTCTCTATTAT
[0538] TGTAGAACTCTCTGTTTTTCAAGTCTATCAATATTCTGTTTCATATATTTTGGAGCTCTGTTTGCTGCATATGTGTT
[0539] TACAATTGTTATATCTTCTTGGCAAATTGACCAGTTTCATCAACATAAAATATAATTCTTATTGTCTTCTAACAGT
[0540] TTATTTTTCTTTTTACATAAAGCCTATTTTATCTGATCTTAGATTCCCTCACACTCCACCCCAGCACGCTTTTGGT
[0541] TACATTTACATAATATATCTTTTCCATCCTTTCATTTTCAACCTGTTTGTGTCTTTAGATCTAAAGTGAATGTCTT
[0542] ACAGACAGCATAAGCTATGTCATTAAAAAAATCCATTCTGCTTATCTCTGCCTTTTGACTGGGGAGTTTAATCCAT
[0543] TTGCATTTAAAGTAATCACTGATCATTAATATACTTTCAGTATTTTGTTGTTTTATGTATGTCTTATAACTCTTTTG
[0544] CTCTTCATTTCCTTCAATATTGCCTTTGTGTTTAGCTTATCTTTTTGTGTCACACTTTGATCCCCTTCTCATTTCT
[0545] TTTTTATATTTTCTTTGTGGTTACCAGGAGGACAATGTATCAACTTTTAAAGTTATTACAATTTTATTTTTTTAAA
[0546] TCTCTCCCATTCGGGGATTTTAGGAAGGTTAAATAATAATGTAAATGAGATACCTAGAACAATATAAGCATTCAGG
[0547] AATTATTAACTCAATTCCAATCCTTCCTCCACCTCCACCTCTTTCTCTGTGAGATTATAGAAAAGATGACAAAAAG
[0548] GATGTTTTCTGAGCCCTTTAATTGTTGAGAATGATCTTTGAGAAAAAGAAAAAAAATGAAAGCACTAGGAATGTAC
[0549] AACAGCCTGGAAGTATAATTAAGTGTAAATTAAATAGATAAAAGTTATAAGCAGAGGAAAGTATAGTAGAACTCAG
[0550] TATTTAAAAGAGAATCAATGTGAAAATTATATAAATTTATGTAAAATAAAACTACCAGACAAATCTGATATCCTTA
[0551] GGATTTTTCTTTCTTTCATGTGATTTCTAATTGCTACATATGACACTAAACCATTGATCTGAGCTGTAAGAGAAAC
[0552] TGGAAATTGTTCTGTTATCTTTTGTAAGATTTCTAGAACATTTTGCCCTCAGACTTAAATGCCAACGTATTTCTCA
[0553] CTTATTGTTTACTGCTTTTGGATTTACATATGATTTGATTCTTTCTTATCTCTTTATCCTTACAATGTAATTCAAAC
[0554] TGATGCCAATTTAAGTTCAATTGCGTACAAAAACTCTACTCCTATGCAGCTCCGCCCCCATCTAATTTACATTATTG
[0555] ATGTCGCAAATTCCATCTTTGTACATAGTTTACATATTAACATGATTTATACATTTTTATGTATTTGGTTTTAA
[0556] ATCCTGTAGAAAAATAAAAAGTCAACACACCAATATTAAAATAATACTGGTTTTATATTTGTCCATGTGCTTACCT
[0557] TTATCAGTGTTCTTTACATCTTTATACGGGTTTGAGTTACTGTCTTGTGTCCTTTAGTTCCAACCTAAAGAACTCC
[0558] CTTTAGCATTTTTATAGGGCAGGTCTAGTGGTAATGAACTCTCTGAGTTTTTATTTAGGGATGTCTTAATTTCTAG
[0559] CTCCTGTTTGAAGTAAATTTTTCTGGATATACAATTCTCTGTTGATTGATTTTTGTTCATTTTCCCTTCAGCTCTT
[0560] TTAAATACATTATCCCACTTTCTTCTGCCTTCCAAGGTTTCTATTAACAAAATTCAGCTTATAATCTTATTAAAGA
[0561] TCTCATGTACATGAGTGGCTTCTCTCTTGCTGTTTTCAAGATTCTGTGACTTTGGTTTCTGATAGTTTAAATATAA
[0562] TGTGTCTTATTGTGGGTCTCTTTGGATTTATCCTAGAGTTTCTTGGTCTTCTTACGTTGGTATATCCATGTATTTC
[0563] AAGACATTTGAGTAGTTTTCAGCCATTATTTCTTCAAACAATCTCTCCTCTTTTGGGGACTTCCATTTTACCTATAT
[0564] TGGTTCTTTTGATGGTGTGGCACCAGTCCCCTAGACTTTGTTCACTTTTTTCCAGTCTTTTATTTCTGCTTCTCAG
[0565] ACTCAACAAGCTTCAAGTGTCTGTATTCAAGTCTGCTGACTCTTTCTTCTTCCAGCTCAAATCTGCTGTTGGATCC
[0566] CCCCTTGTAAAATTTTTAATTCCATTTTAGTGTTTTTCAAGTTAAGTATTTTTATTAGGTTCCTTTTTATAATTTC
[0567] TTTTTGTTGATATTCTCATTTTATTACACATAATTTGTCTGATTTCCATTAGTTTTTTTCTTTGTTTTCCTTTAGC
[0568] TCTTTGAAAATATTTAAGACATTTTAAAAGTCTTTATCCAAGTTCAATTTCTATGGTTCGTAGAGATATTTTCTG
[0569] CCAGTTTATGTTCTTCTTTTCCATGGGCCATGTTTCCTGTTTCTTTGTATACTTTCTAATTTTGGTTGAAAACT
[0570] GAGCATTTGAAAATAGAGCCAACTTTCCCAGTTTCTGCAGAGAGTCTTTATGCCACAGTATTCGTTCACTGATTAA
[0571] CTGGGTATATCTAAGCTTAGGGAGCAGCTGAGTCAAAAGTTTAAGGTCTTCTCAGGTCTTTTCTGAGTATACATGT
[0572] TTCCTATGCCTGTGTGAAATGTTCTCAATTTCCCTATATAAACAGCTACTTCTTCTTTTTTTTTTTTTTTTGAGAT
[0573] GGAGTCTCGCTCTGTCACCCAGGCTGGAGTGCAGTCATCTCAGCTCACTGCATCCTCCACCTCCCAGGTTCAAACA
[0574] ATTCTCCTATACAGGTGTGTGCCACCACGTCTGGCCAATTTTTGTATTTTTAGTAGAGACAGGGTTTCGCCGTGTT
[0575] GGCCAGGCTGGTCTCAATCTCCTGACCTCAGGAGGATTACAGGCTTGAGCCACAGTGTCCAGCCTAAACAGCTACT
[0576] TTTGAATGCTTTAATTTCCTGAATAGTCTCAACCCAGTTTTTCCTTGAGGTCTTAGGTGGTCCATTGTATGTCTCC
[0577] ACCCATAGTTGCTTGCCCCAGGCATCTGTGGGTCTGTGGTACCACTGCAGCTTTCACCACCTGTAGCTGCCACCTT
[0578] TCCCTATCTGAGATCCAGGTTAGGTGAGAGAGATCATTCCTTCACGCAGTCCCATGACAGGTTGGAACATTTCAAA
[0579] TAAGGTCTGTTCTGCTCCTCTGGTTGAAGGGAGAAAATTGGGAACCGGTTTCCCACCTTCTACAAACCAAGATCTC
[0580] ATGTTGCCACGGGAGTGGCAGGGCAAGTGCAAGTGAAAATGCCATACAATTTTCTACCATTTTGAACGCGGGTTTT
[0581] TCTTCAATGGTCATTTGCTTGGTTGCTGTAGGCCTTTCACTGTTTTCCAGAGCTCCCATAAGATTACTTTAGCCAG
[0582] TTTTTTGTTCTTTCCTGATGCTTCCCTGGCAGAGTAAGGGTTGGAACTTCCACCATTTTGCTGATTCATAACTCTG
[0583] TAGTCAGTTTTAAATATATTGATACTTGAGTTTGTTTTATGGCCCAGAATATGGTCTTGGTAAATGTTTCACATAT
[0584] ACTCAGAAAGAATGTGTATTCTGATGTTGTTACATGGGCTGTTCTATAAATGTTACTTAAGGTGGTTAATAATGTT
[0585] GCTCAAGTCTTCTATATTCTTGCTGATTTTCTTTTATTTATTTATTTTATTTTTTTTATTATACTTTTAAGTTCTA
[0586] GGGTACATGTGCACAACATGCAGGTTTGTTATATATGTATACATGTGCCATGTTGGTGTGCTGCATCCATTAACTC
[0587] ATCATTTACATTAGGTATATCTCCTAATGCTGTCCCTCCCTGCTCCCCCCACCCCATGACAGGCCCCAGTGTGTGA
[0588] TGTTCCCCTTTCCTGTGTCCAAGCGTTCTCATTGTTCAATTCCCACCTATGAGTGAGAACTTGCGGTGTTTGTTTT
[0589] TTTGTCCTTGTGATAGTTTGCTGAGAATGATGGTTTCCAGCTTCATCCATGTCCCTACAAAGGACGTGAACTCATC
[0590] CTTTTTTATGACTGCATAGTATTCCATGGTGTATATGTGCTACATTTTCTTAATCCAGTCTATCATTGATGGACAT
[0591] TTGGGTTGGTTCCAAGTCTTTGCTATTGTGAACAGTGCTGCAATGAACATACGTGTGCATGTGTCTTTATAGCAGC
[0592] ATGATTTATAATCCTTTGAGTATATACTCAGTAATGGGATGGGTGGGTCAAATGGTATTTCTAGTTCTAGATCTTG
[0593] AGGAATCACCACACTGTCTTCCACAATGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAAAGTGTTCCTATTT
[0594] CTTCACATCCTCTCCAGCACCTGTTGTTTCCTGACTTTTTAATGATCGCCATTCTAACTGGTGTGAGATGGGATCT
[0595] CATTGTGGTTTTGATCTGCATTTTTCTGATGGCCAGTGATGATGAGCATTTTTTCATGTGTCTTTGGCTGCATAAA
[0596] TGTCTTCTTTTGAGAAGTGTCTGTCATATCCTTTGCCCACTTTTTGATGGGGTTGTTTTGTTCTTGTATATTTGT
[0597] TTGAGTTCTTTGTAGATTCTGGATATTAGCCCTTTGTCAGATGAGGAGATTGCAAAAATTTTCTCCCATTCTGTAG
[0598] GTTGGCTGTTCACTCTGATGGTAGTTTCTTTTGCTGTGCAGAAGCTCTTTAGTTTAATGAGACCCCATTTGTCAAT
[0599] TTTGGCTTTTGTTGCCATTGCTTTTGGTGTTTTAGACATGAAGTCCTCGCCCATGCCTATGTCCTGAATGGTATTG
[0600] CCTAGGTTTTCTTCTAGGGTTTTTTATGGTTTTAGGTCTAACATTTAAGTCTTTAATCCATCTTGAATTAATTTTT
[0601] GTATAAGGTGTAAGGAAGGGATCCAGTTTCAGCTTTTTACATATGGCTAGCCAGTTTTCCCAGCACCATTTATTAA
[0602] ATAGGGAATCCTTTCCCCATTTCTTGTTTTTGTCAGGTTTGTCAAAGATCAGATGGTTGTAGATGTGTGGTATTAT
[0603] TTCTGAGGGCTCTGTTCTGTTCCATTGGTTTATATCTGTTTTGGTACCAGTACCATGCTGTTTTGGTTACTGTAGC
[0604] CTCGTAGTATAGTTTGAAGTCAGGTAGTATGATGCCTCCAGATTTGTCCTTTTGGCTTAGGATTGTCTTGGCAATA
[0605] CAGGCTCTTTTTTGGTTCCATATGAATTTTAAAGTAGTTTTTTCCAATTCTGTGAAGGAAGTCATTGGTAACTTAA
[0606] TGGGGATGGCATTGAATCTATAAATTACCTTGGGCAGTATGGCCATTTTCACGATACTGATTCTTCCTATCCATGA
[0607] GCACGGAATGTTCTTCCATTTGTTTGTGTCCTCTTCTATTTCGTTGAGCAGTGGTTTGTATTTCTGCTTGAAGAGG
[0608] TCCTTCACGTCCCTTGTAAGTTGGATTCCTAGGTATTTTGTTCTCTTTGACGCAACTGTGAATGGGAGTTCACTCA
[0609] TGATTTGGCTCTCTGTTAGTCTGTTACTGGTGTATAAGAATGCTTGTGATTTTTGCACATTGATTTTGTATCCTGA
[0610] GACTTTGCTGAAGTTGCTTATCAGCTTAAGGAGATTTTGGGCTGAGACGATGGGGTTTTCTAAATATACAATCATG
[0611] TCATCTGCAAACAGGGACAATTTGACTTCCTCTTTTCCTAATTGAATACCCTTTATTTCTTTCTCCTGCCTGATTG
[0612] CCCTGGCCAGAACTTCCAACACTATGTTGAATAGGAGCGGTGAGAGAGGGCATTCCTGTCTTGTGCCAGTTTTCAA
[0613] AGGGAATGCTTCCAGTTTTTGCCCATTCAGTATGACATTGGCTGTGGGTTTGTCATAAATAGCTCTTATTATTTTG
[0614] AGATATGTCCCATCAATACCTAATTTATTGAGAGTTTTTAGCATGAAGGGCTGCTGAATTTTGTCGAAGGCCTTTT
[0615] CTGCATCTATTGAGATAAACATATGGTTTTTGTCTTTGGTTCTGTTTATATGATGGATTATGTTTATTGATTTGTG
[0616] TATGTTGAACCAGCCTTGCAACCCAGGGATGAAGCCCACTTGATCATGGTGGATAAGCTTTTTGATGTGCTGCTGG
[0617] ATTCAGTTTGCCAGTATTTTACTGAGGATTTTTGCATCAATGTTCATCAGGGAAATTGGTCTAAAATTCTCTTTTT
[0618] TTGTTGTGTCTCTGCCAGGCTTTGGTATCAGGATGATGCTGGCCTCATAAAATGAGTTAGGGAGGATTCTCTCTTT
[0619] TTCCTATTTACTGTACATTTATTCCACCAGTGACTAAAACAGGTGTATCAATAAAATCTGTTCCCTCAGGTTTTGC
[0620] TTCAGGTATTTTGAGGGTCTGTTATCAGGTGCATAAACAAGATTGTTATGTCCTATTCTTAAATTAATCCCTTAT
[0621] AATTATGAAGTTAATTTTTTTTTTCTTGAGATGCAGTTTTGCTCTGTCGCCAGGCTGGAGTGCAGTGGCACAATC
[0622] TCGGCTCAGTGCAACCTCTGCCTCCTGGGTTCAAGCATTTCTTTGCCTCAGCCTCCCGAGTAGCTGGGGTTACAGG
[0623] TACCTGCCACCACGCCGGCTAATTTTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATCTTGGCCAAGCTGGTC
[0624] TTGAACTCCTGAACTCTTGATCCACCCACCTTGGCCTCCCAAGGTGCTGGGATTACAGGTGTGAGCCACTGCGCCT
[0625] GGACCTGGCCCGAAGTAAACTTCTTTACCCTTGCTAATGATCTTTGCTCTGAAGCATGCTTTGCTGGTATTAATAT
[0626] AGTCATTCCTTCTTTCTTTGATTCATGTTTGCAGGGTATATCTGTTTCCATTCTTTTACTTTTAACCTATTGTCTT
[0627] TATATTTAAAGTGCATTTCTTGTAAGTATAATTGGTTTCTTAAATCAATTATCTGCCTTTTAAAATGTCATTTTT
[0628] ATATGATTTGCATAAATATGATTATTATTACAGCTAAATTGAAATCTGTCATCTTGCTATTTGGTTTCTATTTATC
[0629] CCATTTTTTTCCCCTCTTTTTTTGCTTTCCTTGAGATTGAACATTGTATTAGTTTTCTAGGGTTGCTGTAAGAAAG
[0630] TGACATAAAGTGGATGGCTTAAAACAACAGAAATTTATTGTTTCAGTTTGGAGGCTAGTCATCTGAAACCAAGGTG
[0631] TCATCAGGGCCGTATTCTCTCTGAAACCTGTAGGGAAGAATTCTTTCCTGCCTGTTCTAGCTTCTAGCATTTTCCA
[0632] GCAATTCTTGGCATTCCTTTGCTTGTAGATGTATCCCTCCAATCTCTGCCTCTATCATAACATAGCCATCTTCTCC
[0633] CTTTATCTGTCTATTCTTCTCATCTTATAAGAACATTAATTACTGAATTGGGGCCCAGCATAGATTAGGCCTAATC
[0634] TCATCTTGAATAGGTTACATCTGCCAAAGATTCTTCTTCCAAATAAGATCACTTTTACAGCTTTTACAGGTACTGA
[0635] GAGTTAGAACCTCAATATATCCTTTGGTGGGGACCGACCTCTTACCCATAAAAAGTATTTTATATGATTCCATTTT
[0636] ATCTCCTTTTTAGGTTATTAACTACAATTTTTTTTTCTTTTTTTTGAGATGGAGTTTTGCTCTTGTAGCCCAGGCT
[0637] GGAGCGCGATTTTGGCTCACTGAAACCTCTGCCTCCCGGGTTCAAGTGATTGTCCTGCCTCAGCCTCCTGAGTAGC
[0638] TGGGATTACAGGCATGTGCCACCGTGCCTGGCCAATTTTTGTATTTTTAGTAGAAACAGGGTTTCACCATGTTGGC
[0639] TAGGGTGGGTCTCAAATTCCTGACCTTAGGTGATCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGAG
[0640] AGCCACCACGCCTGGCTTTATAATTTTTTTTTAATTCAGTGGATGTTTTAGGGTTTATAGTATACATCTTTATCAC
[0641] AGTCTAGCTCCAAGTGATATATCCCTTTATGTATAGTACATGACCCTTACAGTAGTGCATTTCCATTTTTCCTCTC
[0642] TGGCATTTAGGCTATTGCACACACATACACTCAATTCATCCCTTTGTGTAGATCCGTATTTCCAGCTGCTATCTTT
[0643] TGCTTCTGTCTGAAATATATGTATGATTTCTTTTATGACTATTTTGAGAAATTTGGTTATGTGCATTTGTCTATTT
[0644] TTCTTATGTACTTTTAGCTCATCAATCTTAAGTCTGTGAGTTTATAGTTTTTAAAAACAAATTTGAAATTATTTGG
[0645] CTATTATTTCCTCAAATATTTTTTTCTGCCGCCCCTGCTTTCCCTTTCCTTAGGGATCTCTGATTTCCACCTATAT
[0646] TACTCTGATTGAAGTTGTTCCACGTCTCTTTTGAAAATCTCTGAAAAATCTTTTATCATTTGGATAATCTGTATTT
[0647] GTACATCTTCAAGTACATTAATATTTTCTTTTGCAATGTTTAATCTGCTGTTAATCCCATGTAGTGGATTCTTCAT
[0648] CTCAGGTATTGCTGTTTTAATCTCTAGAAAATTCCATTGAAGTCTTACTTGATGAAAAAGGCAGATAAAAACAAATG
[0649] TTGGCAAAGATATGGAGAAATCAGAATCTGCACACACTGATGATGGGAATGTAAAATGGTCAAGGCAATTTGGAAA
[0650] GCAGTCTGGCAGTTTCTCAAAAGGCTAAACGTAGTTCCCATATGACAGCAATCATTCATCTAGGTATATACTCCAG
[0651] AGAAATAAAAACATATCCACACCAGAACTTGAACATTAATTTTCATAGCAACATTATTCCTAGGGGTTTAAAATTT
[0652] TTTACATTATTTTTATTTAAAATAGAGACAGGGTCTCACTACGTTGCATAGGCTGGTCTGGAACTCCTGGAATTAA
[0653] GCATTCCTCCTGCCTTTGTCCTGTTTTCTCCACTGGAAAAGAATAAAACTTTGTACACTTGGACTAACAACTCCCG
[0654] ATTCCTCCTTTACCAACATGCCCCACAGCCTCTAGTAACTTACTCTCTACTTTCATGAATTCAACTTTTTTAAGA
[0655] TTCCACATATAAGTGAGATCATACAATATTTGTCTTTCTGTGCCTGGCTTATTTCTCTTAGCATAATGTCCTCCAG
[0656] ATTCATACATGTTGTCTTAAATGACAGGATTTACCTTCCTTTAAAGGCTGACTAGTACTTCATTGTGTATATGTAT
[0657] CACATTTTCTTTATCCACTTATCTGTTGATGGGCACTTAAATTGTTTCAATGTCTTGGCTACTGTAAGTAATGCTT
[0658] CAATAAACATGGGAATGAAGATATCCCTTCAACATATTGATTTCTGTTCTTTTGGATAATACTCAGAAGTGAGATT
[0659] ACTGGATCATATGGTTGTTCTATTTTTTTCAGAAACCTCCATACTGTTTTTCATAGCGGCTGTACTAATTTACATT
[0660] CCCACTAACAATGCATGAGTTCACTTTTCTGGACATCCTCCCCAACACTTGTTATCTTTCATCTTTTTCATAAAAG
[0661] CCATTATATAATAGGTGTGAAGTGACATCTCACTGTGGTTTTGATTTGCATTACTCTAATAATTAGTGTGAGCATT
[0662] TTTTTTTTTTCATGTACCGAATGTCTTTTGAGAAAGGTCTCTTCATTCCTTTGCCCATTTTAAAATCAGGTGGTTT
[0663] TCTTGCTCTTGAGTTGTTTGAGTTCCTTATGTATTTTAGATATTTACCCATTTCCAGATATATCATTTATATTTTT
[0664] TCCTATTCTTTGAGTTCCCTCTTCACTGTGTTGTTTCCATTGCTGTGCAGGTCTTTTATTTTGATGCCACCCCATT
[0665] TGTCTATTTTTGCCATGCTTTTGCAGTCATATCCAAAAAAATCATTCCCAAGACCAATGCTGTGGAGATTTCCCCC
[0666] TATGTTTTCTTCAGTAGGTGTACAGTTTTAGGTCTTATATGTTAAGTTTTAAATCTATTTTTTTATATGGTGTAAA
[0667] TAAGGGTCTAATTTAATTCTTTTGCATGTGGATATCCAGTTTTCCCAACACCATTTATTGAAGACCCTGTCCTTTT
[0668] ATACTTTTCAGTATGCAGATCTTTTACCTCCTTAAATTTACACCTCAGTATTTAATATTTGTTGCTATTATGAGAT
[0669] TTTCATAATTTCCTTTTCAGATAGCTCATTAATAGTAGATGGAAACACTACTGATTTCTGTAAGATGATTTTGTAT
[0670] TACGGAACTTTACTGAGTTTGTGTATCAGTTCTACCAGGTTTTAGTTTTGTTCTGGTGGAGACATTACAGTTTTTT
[0671] GTATATGGTTATGTCATCAGTAATTACAGATGATTTAACCTATTCCTTTCCTATTAGGATGCCTTTTTTTTCTTTC
[0672] TCTTGTCCAACTGCTCTGGTTAGGACTTCTAGTACTATGTCAAAAAGTGATGAGGGTCGTACATGGCCTCCATACC
[0673] TAATCTGTTGAGAGTTTTTACCATGAAACCAGGTTGAATTTTGTCAAATGCTTTTTCTGCATCCATTGAGATGATC
[0674] ATATGATTTGATTTACACCCTCCATTTTGTTATGTGGTATATCACACTTTTTGATGTGCATATGTTGAACCACCCT
[0675] TGCATCCTAAGGATAAATCCCACTTCATCATGGTGAATCATTCTTTGTATTCGTGAATCCAGTTTGCTAATATATT
[0676] GTTGAGGATTTTTGCATCCATGTTCATCAGGGATATTACTTTGTAAGTTTCTGTCCTTAAAGTGTCTTTCTCTGGC
[0677] TTTAATAACAGTGTAACACTACCCTTGTAAAATGAATTTAGAAGTATTCCCTCTGCTTCATTGTTTTGGAAAAGTT
[0678] TGAGAATTTTTTATTAGTTCTTTAAATGTCTGGTAAAATTCAGTAGTGAAGCTGCCTAATCCTGGGCTTTCCTTTGG
[0679] TGGGATACTTTTTATTACTGGCTCAATCTCTTTTCTTGTTATTGGCTTATTCAGATTTGTTTCTTCATGATTCACT
[0680] CTTTGTAGGTTGTATATGTCTAGGAATTTATTCATTTCTTTAGGTCATCCAATTTGATGGTGCATAACTTCATAGT
[0681] AGTTTCTTATAATCCTTTGTATTTTGGTGATATCAGTAGTAAATGTCTCCTCTTTCATTTCTGATCTTATTTGAGT
[0682] ACTCTTTTTTTCTCCTAGTCTAGGTAAGAATTTGTTGATTTTATCTTTCAAAAAAAAAAAAAACCAACTCTTAGCA
[0683] ACTCTTAGTTTTGTTCATTTTTTTCCAGTCTTTATTTCAACTGTGATCTTTGTTACTTACTTCTTTATGCTAACTT
[0684] TCGGGCTTAGTCTGTTCTTTTCCTAGTTCCTTTAGGTGAAAAGTGAGATTGTGATCCTTCTTCTTTATTGGCGTAG
[0685] GTTTGTATCGCTATAAATTTCCATTAGGACTGATTTTGCTGCATCACATAAGTTTTGTTTCCATTTTCATTTGTCT
[0686] CAAGGTAATTTTTTATTTACTTTTTGACTTCTTCTGTGAACTATTAGTTGTTTGGGAGCATATTGTTTAATTTCCA
[0687] CATATTGCTGTATTTTCCACCAGAATTGATTCTTGTTCTTGATTTCTAGTTTCACGCCATTGTAATCAGAAAAAGGG
[0688] ATTTGATATGATTTCTGTCCACTTAAACTTAAGATTAGTTTTGTGGACTAACATATATCCTGGAGAATGTTCCATG
[0689] GGCATTTGAGAACAAAATGTATTTTGCTGCTTCTGGATGGAATGTTTCATATATGCCTGTTAAGTCCGTTTGGTCT
[0690] AAAGTGTAATTGAAATCCATTGTTTCTTTATTGATTTTCTGTCTAGGTGATCAATCTGCCCATGGTGAAAAGTAGA
[0691] GTATTGAGGTCCCGTATTATAGTATTGCAGCCTATCTCCCTCTTCACATCATTTAAAAATTGCTTTATGTATTTAG
[0692] GTGGGTCAATGTTGGGTGCATATACTTTTACAATTGTTATGTCTTCTTGGTGAATTAATCCCTTTATCATTATATA
[0693] ACAAACTTCTTTCTTTTTATAGTATTGACTTAAAGTCTATTTTGTCTGATAGAAGTATAGCTACCCCTGCTCTCAA
[0694] TTTCCATTTATATAGAATATCTTTTTCCATCCCTTCACTTTCAGTCTATGTGTATGTTTAGTAGAAAAAGTGAATCT
[0695] CTTGCCGGGCGCAGTGGCTCACTCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGCGGGATCACCAGAGGTTGG
[0696] GAGTTAGAGACCAGCCTGACCAACATGGAGAAAACCTGTCTCTATTAAAAATACAAAATTAGCCAGGCGTGGTTGT
[0697] GGGCCCTTGTAATCCCAGCTACTCGAGAGGCTGAGGCAGGAGAATTGCTTAAACCCGGGAGGTGGAGGTTGCGGTG
[0698] AGCTGAGATCATGCCATTGCACTCCAGCCTTGACAATAGCAAAACTCCGTCTCAAAAAAAGAAAAAGAAAAAGAAA
[0699] AAAAAGTGAGTCTCTTATAGGCAGTATGTGGTTGTGACTTAAAAAAAAAAAAAAATCCATTCTGTCATTCTATGTC
[0700] TTTTTGTTGGAGAATCTAATCCGTTTACATTCAAGGTAACTATTGGTAAGAAACTGCTAGTGTCATTTTGTAATTT
[0701] GTTTTCTGATTGTTTTGTAGGTCCCTTGTTTCTTTTTTCCCTATTGCTACCTTCCTTTGTGGTTTGGTGGTTTTCT
[0702] GTGGTGGTGTGCTTTGAATCCTTTCTTTTATAGTATATGCGATTACCATTGTATTTGCTGTAAGGCTAACTTAAAA
[0703] CATTTTATCCTTAGGCTACTTTAAGCGATAAAAACTTGCCTTTAGTTGCATACAAAAACTCTACGCTTTCACAACC
[0704] CCCCCGCCTTTCGTGATTTTGATGTCAAAGTTTACACTTTTTTAAATTTGTATCTCTTATTGTAGCTACAGTTACA
[0705] ATTACTTCTTGTAGCTACAACTTATTGTAGCTACAGTTGTTTTTAATAGTTTCATCTTTTAAACCTCCTAATAGGA
[0706] ATAACATTGCTTTACCTGCCACCTTTACAATACTAGAGAATTCTGACTATGAATTACTTATACCATTTAGTTTTTT
[0707] ACTTTTATGTTTCTCATTAACTAGCAGTCTTTTATTTAAGCCTAAAGAACTCCCTTTTAGTAATTCCAGTAGAGCA
[0708] GGCCTAGTGAGGACAAACTCCCTTAGGCATTGTTTATCTGGAAAGTGTTTATTTCTCCCTTTGCCAAGTAAAGTA
[0709] TTCTTAATTAACAGCTTTGTTTCCTTCAGCACTTTGAATATACCATCCCACTCTCTACTGGCCTGTAAGGCTTTTG
[0710] CTGATAAAGCCACTGAATCTGTATTGGGGCTACCTTGAATGTGATGTTTCTTATCTTTGCTGCTTTCAGTATTCTT
[0711] TGTCTTTGATTTTTGATAACTTGGTTGTGATGTGTCTTGGTGAACTCTTTAGGTTGAATCTGATCGGTGACCTCAG
[0712] CTTCCTGTTCCTGAATTTTGTCATCTTTTCTCAGATTTGGGAATTTTTCAGCTATTACTTCCTTAAATATGCTTTC
[0713] TAGGCCTTTTTCTTTCTTTCTCCTTAAGGACCTCCTATTATGCAAAAGTTAGCTAGCTTGATGTGTCCTGTAATT
[0714] CTTATAGGCATTCTTTTTTGTTTTTGTTTCTCATTGGATAATTTCAAATGTCTTACCTTTGAGCTCATTGATTCTT
[0715] CTGCTTGATCAAGTCTGCTGTTGAAGCGTTCTACTTAGATTTTCAGTTCAGTTACTGTATTCTTTATCTTTAGAAT
[0716] TTCTATTGTTTTTGTTTATATTTGTTAAACTTCTCATTCTGTTCAGATGTTGTTTTCCAAATTTCATTTTTCTATC
[0717] CATATTTTCTTGTACTTTGTTGAACTTAAGAGGATTAGTCTAAATTATTTGTCATTTCACAGGTCTCCATTTCTTC
[0718] TGAGTCTGTTACTGGAGCTTTCATATCCAATGTACACCAGAAACTTTGCTAATTCCACAGTAAATGTTAGAAATGG
[0719] GTTTTTATTGATAAAATCAGTGGCTTGCTAATTAGTATGTTAGAAGCTGGCTTGCATTGGTGAAGTTGAGGGTATT
[0720] CGATATACGTATCCCGGCTAAAATACTTCTAAAGAACCTCTCCAGCTTTGCAAGAATAGAGTATAGGAATCTGAGG
[0721] AGGCCTTAACATGGCCCTCAGAAAGGACACACAGGGCTTGACCTCTAAACATATAAACATATACAGAAACGAGGT
[0722] CAGAACATGTTTTGACTGATGCCAGTAGTAACACAGCAGAGGCCTATTGCTGGTCACTGTTACCAATACCTTGTGTA
[0723] ATAAAACCTTTCATTTAAATTGAGAGGTTGTAAGCCCCGAAAGCAAAGGGCTTACAGTACCTCTTGCCTGAACAC
[0724] TCCTGTGTGTGCTTTCTAAGAAATGCTTTTAAAATAATGCCTGTGGCACAAATTGATTTGACACTGGCTCTCTTTA
[0725] TAAGCTGCTATCAAGGTTGTGGGGAATAGCTAACTCTTACCCACTTTCCCTGACAAATAGGAACCCGTAGTTACCT
[0726] ACCAAAAGTATGTAAAAGCTATATCCGACCCAAAGGCCAGTTAGGTCAAAACACCTTGAAAGGAGCTCAGTTTAAG
[0727] GAAATCAGTGGTGTCACAGTGCCCCACTAGCGTGTAAAAGTTTTCATAGTTTGACTATCGGATGTGCTTAGTTTCA
[0728] CAGCTGAGTCTTACCTTGTGATACTTTTAGAGCAAAAGTCAAATCAAAGATGATTTAAAAAAACATTTCAAAGATT
[0729] CATAAAGAATAAATGCCTCCTCAGGAAGTCTTCTGGAGTTCTGCCCACTTCCCTTAGGTGGCTCTTTACTGTGCCC
[0730] ATCTCATAGCCTGTCTCCTTCCACTTGGTGTATTGCAGAGTAAAGCTCACTGTTTACAGGGGTGGTAGAAAGTGTG
[0731] GTCCTTTCCCAGACTCCTTTTTCCCTTCCTCTTCTCATTTTTCAGAAGATGTGTTTGATAATAAACGAAACAAAAT
[0732] GACTAACACATTGAGCTGAGCTACATAAGCAGATGTCAGTTTGACGTGAAGAGTTTAAAAGATCTATGCATTATCT
[0733] GGGGACTCCTCCCCCAGACCTGAAGGATCAGGTGCTGCCTTCTATGCCACCTGTGCAGACAGCAAAAGAGGAAAAC
[0734] CATACCCACGTTCAGTATGAACAAAGGGGACATTTGAACTCTGTGTGGACCCCTCATTGGAAGGGTGTTTCTTCTC
[0735] CTGCTGCATCCACAAAGAGCACTCCTTAGCCTTGCCTTTTGTCAGTTCTCTCTCCAATAAGGCTTGAGCAGAGACA
[0736] ACCCAGTGCAGTTCAGAGAGACTGAAGTCTGGTGTTCCAGGTCTGAGTCCTAGCTCTAGCTCTCTGTGTAACTTTG
[0737] GGATGTCCCAAAGTAACTTTTCACAACTTGATAGGTGTTAACTTGAATTTTGGATACAGGTGACTCTTAGCCCATC
[0738] CCCTCTCTGTGCTTCAGATATGTCATCACTTGGGCCATATGACCTCTGGACACCTTTCCTACTTTCCACAATTTCA
[0739] GAGCAGCAGAGCAGACTGGAGCTCCTGCTGCCTCTGAGCTTCAGTGAATTATCACTCGTTGGAGGGAAGCTTCAAG
[0740] CATTTTGTTATCTTTCAAGAGCAAACACAGTGTCTGTCAGCAAGAATATGTAGCAGATGCTAGTGAACAGCAGTGA
[0741] TTAGGGTTGAATGCTGGATTTAAATATGGAGCTTAGGCTGTGAAGGAAGCCTGAAGAACCTAGAGCCCCATGAAGC
[0742] TGCCCTCTGTGAGATCTGACACCATTTCCCACTGATGAGCCATGGGTCTAATGGGTAGCACTGATTCCACATACAG
[0743] TATGTGAGTGCAATACAGTGAAAGCAAAGAGAATAAAATGATGGCTAACATGATGTTCCAAACTTTAAACAGGAGA
[0744] AAAACACACAATTCCATTATGTATAAGAACCCACACAGAGATCAGGAGAATAACCTCATTGGAGAATGAATGACCT
[0745] GTGTGGGGAATTTAGGGTAGAGTTGAGATTGAAAAAATGGGCCGAAGTCAGGTGGCCAAGGGCCTTAATACCTTGT
[0746] ATACAAGATGTGTAGTCAAGGAAGACCATGCCTTACTTATGCATCAATTCCCTTGGGCCTACAAAGAGCTGCCTAG
[0747] CCTGGGACTGTTGTAGAGAAAAGCTACAGTGTTCCAATGACACAGGGACTCCTCCATGTATGTATGAGTGCCCAGC
[0748] TGGCTCTGTAATAAATCTTATTTTTATTTATTAACTTTTCTTGCGCATTGGCTTGATGCATCAGTTGGAAGTCAGA
[0749] GGCCAAACGAAGTGAACACTGAGCCAAAGGAAGTTCTCAGCCTTTAGGGAGGCAGAATTCACTTTAAACACAATAA
[0750] ACAAATGAACTCACATTATACAGGAGAGAGTCAGAAGATCCCAGTGGCTGGTGTCATCGGGCCATATTTGCCCGAA
[0751] GTGCCTATTCCTTATAGGAACCCACTCCCAGGGTTGATGGGCTACATCCTTAGGAGGCTTTATGCCTATGTTCTCC
[0752] TGACCACTGGCTCCTCCAGGGCTGGCCTTTTTTAGTCTCTCTGTAGAGGTTCCTGTAGCTGGTTGGATATAGGCTT
[0753] TCACAGAAGGGTCAGTGCCTTGGGTCTGGTTACAGGACTGTTAATCTTGCTTTGTTAAGAGTAATGTTATTTCCCC
[0754] ATTTCCAAATTCTCCAGGGAGATGGAATGTCAAAGATAGTATGACTGTAGCACCTAAATCCTGGGTTCCAGAAGCA
[0755] GAGAAGAGAATACACTGAAGCTGTAGAAAGGCCTATTAGTCCATGTCAGAGATTAACTGGATGCGAGGACCATTTC
[0756] TGGGATGGTGTATACAGAACTGGAGAACTGGATAGGGAGTCAGAAACAAAGAGCTGAAGATGATGCCTTTGAAGTT
[0757] TCCAACGTGGATAACTAGGTCAACAGAATATTACTCAAGAAAGTATTAACATAGGATTGAGATGCAGTCAGTAGTA
[0758] ATGGAATTGAAATTTCAAAGTATATACCTCATGGATCTCAGGGGGTGTTGAGCTGATCACCTGGGCTAACACTCCT
[0759] ATGACCCTGGGGAAAATCAAATGACCTGGTACTGTAGCCATGGTAGGGGTGTCATCACCTTAATCCAACTGGGACA
[0760] GTGCTGTTTGATATTCATCTGGAACTTGGTGCAGACCCACATTTTGCTGGGTTTCACCACAACCAAGGCTTTTTTG
[0761] ATTCTTTTCTCTTTTAACATCAGTACATCACTGCAAAGTTAATCCTCATATAATAGGAGATGAAACTAATTGCTTA
[0762] TAAAAACAAGATTTTTACAACACTAAAATTGTTCAAGCATATGGGCATATTTATAGTTGCAGGCAGTGTTTCAGAT
[0763] GCAGACTGTTCTTGGCTGCAGTGGTTGTTTACAGGCAGCATCTGTTCTGATTAAATATTTGATGATTATCCCCGAA
[0764] TGTTTTAAAGCATAGTACTGGGCTCTGCTGACTGTACAACAAACTGGCATTTTTGACCTATAGGGCACTGGGCTAG
[0765] GAGATACAGTTCTGAGGGAAGTGAAAGATAGTTAACAACTGCACAACTGACCCTTTATTAGTTGCAATAAAGCAAT
[0766] CCAACCACCCAACCCACTGTGATGGCTTTCCTACTATTTAAGGTTGGTGGTGTCAAAGAGACACCCTCCTGTACAG
[0767] TGTGCAGTGAATCAACATCATTTCCACAAAACCTCCTTCCTGCACAAAGGAATTATCATACTTTGTTACGAAGTAA
[0768] AATTTTCCTGTATCAGTCACAGGAGTTCACCAGTTAAGATACTGTTAGTTGAAGACTTCTGGGGTGACTTAATGAA
[0769] ATAGCTCAGCCATCTGGTTTAAAAACTGGATTCTTCTATCCCTCCACACAGCTGTCCATGCACCTGCATCATCTCA
[0770] AGGCTGGTCTCCCTGGTGGTAGAAAGGCTGACAGTAAAAACTGGAGCCACATGATTCCTTGCTTAGGCAGTGTTTC
[0771] TTCATACTCTCACATGAGAGCAGGCATGTTCTTTCCCTAGGCTCACAGTAAACACTCTGTCAAATCTCACAGGCCC
[0772] AAAGTGCTTTTGGTTATCCCCATTCCAAGCCAATCTGTGGCATGGAAGATAGCATTACCCTGACTGCCTTAGACTA
[0773] ATATACCTACTCCACTTCTGGGGCTGGGAATAATTTGAGGTCAACCATCCAAACTGCATGACAGCCATTCCATGG
[0774] AAGAGGTATGGCCTAAATCTTTGGGGCAACCTGAATTCATGAAAACTCTCTTAGTTATGTAACTATTTTTGAA
[0775] TTCACTTCTGTATCATTTAATTTTACTAATAAAATACCCTTTACCCTAAATGTCAGCCAAGCGTAAGGCTCCG
[0776] TTGGGACAGAAGGAACTATCAAAGCTTTGTTTTTATACATTAGCAGCATTTGACAAAGAAATAACTCTGAAGGA
[0777] AGGAGAATAACCAGGCAGAGTCTAGATGCATGGAAAAGAAGTCTTTGAAGGCTTCGCAGGCTGAAGGAAAGGGC
[0778] AGGACTACTTCAGGAATACAACGTTTAAGTAAAAGAGGTTGGGGTCTGTTGATCTTGAGGAGAGATGAGGATGGAC
[0779] TGGAAAATAGGAGTGAGATAGTAGGAGGAAAGGATATGGATGTATATACTGTATGGGTAACCATCAGTC
[0780] GACCCTAAGAAGATAATAGTTGTTAAATGGTTAGCTATTTAATGAAAGAAACCTGAACAAGTAATAATCTTGAGTT
[0781] GCAAAGTGGCTGGAGTCACACAACAGACTAAATTTCTGGTAGAACAAATCCAGCAGCTTATGTGAAGGTTACCATG
[0782] TCTGAAGCTGGATAGAAAAGGTCTAACTTCCAACCAAAGTCACAGTTCTTGAGCTCGGTACACAGAGACAGACTGC
[0783] TAACAGCTGATGTGTCCTCAGCGAGAGTGTCCTCATTTATATCCTCGTTCTCTTCTGCCTCCTTTTTTTGTTTTAA
[0784] ACTTTTGGGAAGTCTCATCATTCAATACAGTTCTAATATATCACAATAACAGAGGCGGCCCAATTTCTACAAATTG
[0785] ACTAATTCTATCCCTGAAAAGTTCATACAATAAAACTATACAAAGCATCATTTTCAACCATCCTATAGAAAAATTT
[0786] CCCTATTAAATTTTAACTCTAAATCCTCTATCTCTGTTAATAACCTTACTAAAAACTTCCCCATCACTGCCTGCCA
[0787] GGGAGATCAAAAGAAACCAAATTTAAGAAACCTCCAACACCTGTACCTGACTGAAAAGCAAACATACAGACCTTTC
[0788] AGTCCTGCCCCTACTATTCAGCTCCTATCACAGAGACATGGTGGATGTCCCCTTGGGAAGCGGATAGCTCTTAGGT
[0789] GGAAGCTAGGCCTGCAATAAGCAGGCCAGGAAACATGTCTCCCAGGCCCCATACTCTTGGCAGAAGCACTTGGCCA
[0790] CCAGACAGCATGTCCTGTCAACCTACAGAGTTCTTAAAAACAAACACTGGGACCCAGAATAGTACCCTGTGGTCAT
[0791] AGTGCCCACAGTTCACTAAGCACCCTCACAGGTCTTTGACAGAACACTGACTGCCAGGTCACCTGGTGGGCAGAGA
[0792] AATGGAAGATTCCCAGGCCCAACTAGCATCTCAGGGAAGAACCACAAGCAGAGCAACTTTCAGAGCTGGTCGGCCA
[0793] GCGTTGGCACCCAGGGAAGCAAGTGCTATTCCATATTTGGAGAGAACATAAAACTCAAGGAAACAGAGAAGTCCTA
[0794] CTCAATACCGTTCTCAACTGAAAACAAGAGAACTTGCAAAAAAGAAACCCAGTTTTCTGGAGTCCATGGAGAAATA
[0795] TGAAGCCAATGCTCGGCTAACAGAGCAGAAAGCCTTTTATAAATAATGCCAGTCAAAGCTCCAAAGGTCAGAGCTG
[0796] ATGCATGCCGGATTGTTCTGACAATTTCTTAGGTTTCTAGGCAACAAGGAGCTGGTCAAACAGCTCACCTCCAAGG
[0797] ACATACTTTATAATACCACCCTGGTAGACGAGAGCGAGGCAGCAGTGAAGGCAATAGTCAAGAACAGGAGAGGGAG
[0798] GTAAAGAACAAGATGCTCTTCAGACAGTCTGGACAAAGACAGTCCCTACCCAGCTCTCAGGAGTTGCCTCCTTAAG
[0799] AAGGTGGAGGCCCAGGCAGCTCCCAGGGTGACCCTAAAGACAGACTCCAAGGAAAAGGGTGTGAGGGCAATGGTGA
[0800] ATATAAGGAGGTCCCCTTTCAGTAGGCAGAGCAAGTCAGTTCAGGTCTTATTTTTAGAGTCTCTGAACAGTGAAGA
[0801] GAAGCTTTCTGTGGACAGCATTCCACCACCATGGGAGGGGAAAGGTGCCATGAGAGACTTCTCCAGTGGGGCATAC
[0802] AAGCATTGTGCAGTGATCCCCAAGATCCAGCCACTGGCAGGAAATCGAAAGGCAAGCTTCTTAAATACATAGTATA
[0803] TGGAGACAGAAGTGTGGAGCACTCCCAAAATGAAAGGCCAAGACCCAGGAACAACCTCCACAACCTGGAGTATATA
[0804] CAAATGAACCCAGCCCTGCTGACTCAGATCCACACCATCCTAAAGCAGGGGTTTCTCATGAATGAAAGGGCTAAGT
[0805] ATTTGGTGGAGAGAATGAGAAGTCTCCCACTGCCCACACATTTTTTCTTCAGAGATTTCTTTTCCAAGAGCCCCTT
[0806] GAATAAAGGAAGGGAGGGAGCACTGAATGCCCCAGAAATCAGAATGCATGGTGCGGGAAGACGACAGGAAATAGTT
[0807] CTCAAAGAGATCAGAAAATAAATTGGAAGCAATTTCATTACCACAAAGAACAGACATTTTTTCTAAGGCACCCCTC
[0808] CCCTTTCCACCCAATTGTCATTCAGCAACTACTGAATACTTACCAATGAAAAACGTTACCCCTGACCTCAAGGCTG
[0809] CTCCTGAGCTCTGGTAGAAAATGCTTTCCTTGTCTATAAAACATGGCAAGCAAGGCAGGATTTAACAGTAAGGGCA
[0810] CAGTAGCACTGCAAGCCTTCAAATGGAAACCTGGAGACAAGCAGTGAGAACAGGAAGCAAAAGCAGGGCAGGTGAA
[0811] GCTAGGACCAGGGCATCTGGAACTTTCCACACAGGTTGGATCTCCATGCCAGACAACAGTTTTCAAGGAAAAATAT
[0812] CTAAGAGGAACATGACTTTGGGAAACTTTTTGGCAGTACTGCTTACTGTATACTAGAGAGTAAAAGAATTTGGGGA
[0813] ACATTCACCAATTTGCTTCTTCAGGGGCTTGGGTAGGGAACGTGAACAGGAACCTGGCTCTAATTTCTGAACTTTT
[0814] TTATCAGTAAAAACAATCCAACAAACGAAAGCTAGTCAGTGAGAGAACTGGGAGGGTCTGCCCTCCTTCCCTGAGT
[0815] CAAGCCTTCTGGGGGGACCTCCTGACATTTAATTAAGCAAAGACAACGCCCACTGAAGGAAGCTGACCTGAAAGTG
[0816] ACACGCTACTGTGAAATGAGCATGAAGTGGGAGCTTGTTACATATATGAAATGGCCAGCGATCCTGAGCAAAGCGC
[0817] TTCAGAGCTTGAGACCTAAGTCTTCTCATCTATATACTGAGGGCTGGACAAGATGATCTGTCAAGCCATTTTTATC
[0818] CCTAATCCACCAAAATCCAATGCTTTAGTTTATTGTCACAAAAGCAGGTATCGAATGGCTATCCTGCAGTGCCTCC
[0819] AATCAACATTCAGACTTTTTCCCTGAGGCAATATAAGATAACAGTTAACATGTTTTTATCAATTAGGTGGTCATGA
[0820] GATAAATATATATGGGAAGTGGTAGTTTTTCACTTAAATGCATATAATAATGGTACAGCTCTCTTTGAATAGTATT
[0821] TGTTTATTTCTTAAATATTTAAGTTCCTAAAGACGGTAAGAATAACCCAAGGAAGTGAAATCAATGTCACAAAGCA
[0822] CATGGCTAAATAACTGCAGGTTTGCAGTGCCATGTGTGAGATCAGATGACAGAAGGGAGAACTACCTTTAGGCAGA
[0823] GGCTTCTCATGTCCCCTGGAGTGGCCATGTGCTGTTCTACATGACTACTTCCACTTCGGTTATGTAGAAGCTATTT
[0824] AAAGCACACAGATGTTTGTGATGAGAAAAAAGCCACCCTTAATTGAATAATGGAAATTATAAGCATGATTTGAGGG
[0825] TGGGGGTGGAGGTGGGAGTAGAGATGGGTAGAAAGGAGTGCAATGGAAACAAAGGAGCCTTCATAAAATTCAAGTC
[0826] ACTTCTTAGGATAACGTGATTGATTTACTCACCACCTTCTTAGGAACATAAAGCAAACAAGTGGGTTTTCCTTTTA
[0827] CTGCTTTTCTGAAATGAGCTACACTCAAGAAAGCAGCACGGGGGTTGTGCTGTCCCTGCACAGTGGCAGGAGAGTA
[0828] TGAGGAGCAGGTGAATGCCACAACAGCTCCATCCAAGATCATTTTTCACATGCAGGAACCATTCTTATACTACCCT
[0829] TTACTGGTAATTTCTGTAGAAATCTGGAAGTCTGGTTGACACCCTCCTGTACAGTGTGCAGTGAATCAACATCATT
[0830] TCCCTTGGACTTTGCAATCACGGTGGCATTCATACATTCATTCAACAAGTATGTATGTACAGGACAGTGGAGTAAA
[0831] GAAAACAGATAGTTCTTACTCTCACGAGGCTTAAAATTTCAGGAGGGAACTAGGCAGTCATGAAGTAAACATAAAA
[0832] ACACAGATTGTAATAGGCACTAGAGAATAATGAAGACTTTGGGGAACACAATTTAAATTGGAAAAATATCTCAGTT
[0833] CCGTTAACACATGTTGAAGGGGAATAGCATTGTTTTGCTGGATTTGGGGCCTGGATGCAAGCATGTTGGGTATGCA
[0834] TTGTAGGGTAATGCATTTCCTTCCATTTGGGCCCAAGTGTATATTTACCACCCAGTTGTGATGAGCTGGGATCCTC
[0835] CTGCTCAATCTCAGCTTGAAGCACTTGGAGGTTATCTGCCTGCTGTGGGTGATTATTTTGGAGCAAGGTACTTCAT
[0836] TTGCCTCAAGAAACAGATTTGATACCACTACTGTGCCCTTTTGGAACAGAGAAGTAGGCAAGACCCCAGTGTGAGG
[0837] CAGAGTGATGGGATCTTTAGGGACATAATTGATGATGTAACTGATGATGATTTTGGAGTTTATACATTTCCAAAGT
[0838] TTCAAAATATTTTCACTTGGTTGATTTATCTTTATGGTGATGACACTACGTAGATATATGCCCTTCTTAAAAGTTA
[0839] CAGTAAGAGGCTGGGAGCGGTGGCTCACGCCTATAATCCCAGCACTTTGGAAGGCCGAGGTGGGCAGATCATGAGG
[0840] TCAGGAGATTGAGACCATTCTGGCTAACACGGTGAAACTCCGTCTCTACTAAAAATACAAAAAAATTAGCCGGGCG
[0841] TGGTGGCGGGCGCCTGTAGTCCCAGCTACTCAGGAAGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCT
[0842] TGCAGTGAGCTGAGATTCCGCCACTGCACTCCAGCCAGGGCAATGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAA
[0843] AAAAAAAAAAAAGTTACAGTGAGAGTTGACATTGAGAAAAGGGAGGCCCAGCCAGGGTTATGCAAAGACACAGTAG
[0844] GGAGGAGGATGGGAAGTTTCTGAGACACCCCAGTAACTGCATGGGTCCACAAAGCACATGTACAGTCTGCTCTATG
[0845] CACTGCAGGTACAGCCACGAATAAGACAAAGTCTCTGCCCTCATGGAGCTTGGTGTCTGTCTACTGGAGCAGACAA
[0846] AAACAAACCTGCTTTTTCTCATTTGCCTCTACTGTGGGTTCCGTGTATAACTCTCAAATGCTAGCATTTCCATGCA
[0847] TTCCATCCTTGTCCTTCTCTCCTCTCTGCCTTTTCCAGGAGAATTTTCCTAGCCACAGGTTCAGCTATGGTCTATG
[0848] TGCTGGAGTCATACATTTTTATCTTCTGTGTACGTTTTTCTCTAGACCCATATTTTTAATTGCCTTAGGACAGCTC
[0849] TCCCTGGATATCCCTCAGACACAACTAAAACATCATTCAATTGTACTATTAATAATTTTCCCTTCAAAATCCACTC
[0850] CTCTTCTCTATAGACCTAACAGCAACACTGTCCGTCCAGCTCTCAAAACCTGAAATGTGGGAGTTGTCTTTGACTC
[0851] TTATCTTTCCCATGCATGAGCACTGAATCAATCAGAGTCCCTAGCATGTCTTGGACTGTGGCCTCCCTTCTATCTT
[0852] CAGATTATCTGCCTTTTTAGAATTATGGCAATAACTTAACTGCAAAGACCACATGTGCACTTGTGCTCTTTCAGTT
[0853] TGTAATAAATATAAAATGAAAAGTGATTATGTCTTTGCTTAACGTCTGCAAAATAAAAGTCCAAAGTCCTTGGTAT
[0854] GGTCTATAAGGCCCTCATTATCTGACCTGCCTGCCTTCCCAATCTCATCTTAATCCCTTACAGCCTGACACTCAGA
[0855] CATACTAGACTTTCCACCTAACTCACTCACATACACCTATCCTGTATGTCAAGATTCGGCTTGACCTTCATCACCT
[0856] ACCTATCTGCAGTATTTTTGGATCTGAATTCTCTGCCCACATTGTACTTTCACATACTTCTTTTACCCTTAGTGGT
[0857] TTGTACTTATGCCTGGTCTAACTAGATTGTCTCCCTGTAACAGACTTCTTGATTCAACAAAGCAGCTCTGAATCAG
[0858] CCTGAAACCTATGGCACACTGCAAAATGGCAAACATTCAATAGGTATTGCCCAGTAAATGTTAATGAAAGGAAAA
[0859] AAATTCAAACTTCAGTTGGAATAGGATTAGAGCAAGTTAAAAAAAAGTTTCCCATAGAAAATCTTCCTCATCGTAA
[0860] ATATCATCATCCTAAATGTCCCGAGTCTTTCCATGGGTCTAATTTACCAAATCATGAAGACTCTCTTTCTCACTGT
[0861] GTATGTGTAGTGGGGAGAGGCAGAGACAGAACGGTTTTTTTTTTTTTGCAAGTCTGCTCTCTGGATTCGTTTTTC
[0862] TGGGGATGAAATCTCAGGCTATGTAGCTTTTCTGGTCCCTTTTTGGTAATCAACAAATCATCAGTTTCTCTAGGTA
[0863] TTAAAAAGCCTACACTTTTGAAACACCAAGAGGCCAAACTCTCTCTTAATTGAAAACATAATTCTGCCTCTTACTG
[0864] AGGTCTTTGGGTGGGAAGCTTAAAAGACAGCAGTTGGGGGCAATTGGTTTTTCTTTTCCTCCCTCCACCTTCTTTC
[0865] CCATTCAAGAGCTGTTGCTGCCCTTTCTGGAGGGGAGGGAATTAGAAAAAAGATCCTGCCTTACCCAGTCACTGT
[0866] TAATTATTACTTTGAGCCAGGGTGGGGAATGACTTTCTTTCCTGGAATACACCCTGCTGGAAACCACAGCTGAGAT
[0867] TCTCTAAGCTGGCAGCTTCCAACCTCTCCTCCCTCAACAGCTTCAACATTATATGGCACTCAGCTGCAGGGTGCCT
[0868] GGCTCCAGGCCGGCAGTCCATTTGTGCAGGGTAGTTTTCAAGATGGCTCATAGCCCATCTCTTTCAGTGACCAGCG
[0869] TGGCCTATGGGAAACATACATCTTGACTCCATTATTGGTAGGAGTACTCTTTAGTTAACTGCCACAGGCCAGTTCA
[0870] GACACGTCTTACCCTGAGAGCCTTTTCAGAGTCAGGTACCATCCCTGTGTCCCCCAGCATCTGAAGATCACAGGTG
[0871] AAGGTCTCCAAGTAGTTCACTTAAAAAATACCTCAGTAGGTTTAAGAACAGGGAAAGCTCCCAATTCATTCTGTCA
[0872] GGAGTATGACTCTCATCCCCAAACTGGACAGATATATAATATGAAAACTACAGACCAATATTCCTTATGAATATAG
[0873] ATGCAAACATTCTAAACAAAATACTAGCAAACCAAATCCAGCAGCATAGAACAAGGTTTATGTAGCATGGACAACT
[0874] GAGATTATCCCAGGAATGCAAAGTTAATTCAATATACAAAAGTCCATTAATACAACATATTAATAAAGGACAAAAC
[0875] AACATGAAAATCTTGATACAGAAGAAGCATTTAACAAAACCCACAGCCCCTCCTTTTTTTTTTTTTGATTAAAAAA
[0876] CACTCAGTAAACTAGGTTTAATAAAAGAATTTCCTCAACTTGAAGCAAACCCACAGCTAGCTAACATCATACTCAA
[0877] TGGTGAAAGACTGAATGCTTTCCCCTTAAAATCAGGAACAAGAAAAAGATGTCTGCTCTTGTCACTTCTATCCAAT
[0878] ATTGTACTGGAGGTGCTAGCCAGCACACTAAGGCAAGAAAATGAAATAATAGGAATCTAGACTGGAAAGGAAGAAG
[0879] TAAAGTATTTCTGTTCACAGATGCATGATCTCATATGCAAAAAATACTAAGTGACAAAAAAAAGAATTTTAGAAAA
[0880] GCTACAATATACAAAATCAATATACAAAAATTAATTTTATTTCTAACACCAGTGATGAATACAAAAATAAAAATTA
[0881] GAAAATAATCATATAATTAAAGTGGCATCAGTAAATACTTAGAAAAAAATTAAAGACGTCAAGACTTGCACACTG
[0882] AAATCTCTAAAACATCACTGAAATAAAGACCTAAGCAAATGCAAAGACATCCCACAGTCATGGAACAGAAAACCTA
[0883] ACACCATTAAAATAGCAGTTATTTCTCAAATTTATCTACCAATTCAACTAAATCCCTATCAAGATCCCAGCTGTTT
[0884] TGCAGGAATTGACACAATGATCATATAAAAATTCATATGCAATGCAAGGGACCCAAAACAGACAATGATTTTGG
[0885] GGAAAAAAAAAAAAAAAATGGAGGACTTGCACATCCCAAATCTAAACTTACTACCAAGCTACAGCCATCAAGACAG
[0886] TGCGGTGCTGGTATAACGACAGACATATAGGGCAATGGAGTAAGACTGAGAATCCAGAAAGTCTTATATTTATGGT
[0887] CAACTGTTCTTTGACAAGGGTACCAGGACCATTCATGGGGAAATAATAGTCTTTTCAACAACTGGGTGCTTGGGCAG
[0888] ATGGATATACAGATACCAATGCACTTATGCAAAAAATGGATGAAATAGGAAACTTCACTACATTCTACTGCATGCT
[0889] CGGTCATTTTCAATCATTTAGGTGGCAACACTGACAAGATAACAGAAAGATGGAGGTAATAACATGTGAAAGGCAA
[0890] AATGGTTTGTTTTTTTTTTTAAAAATGACAGTCTCTATCATGAATTTACTTACACTCCAGGCAAAGGTTATTAGAA
[0891] GAAAAAAGATGTAAGAAAATTCCTTAACTGAAATGTGGAAAGAGTATCAAGAGGAGACCCTAAGACACTCTGTAA
[0892] GAATCCCAGTGACTCCTCACTGTTCAACTAAGAAATGTACCCCATTATGCTGTGCTACCACGGAAGCATTGGAGGC
[0893] ACTTTGGGGGTTGATGAAGTCTTCATGGATGAGGTACTTTAAATATCTGGTCATGAAGAGTATTTGAGAAATATGA
[0894] CAAGTGAAGATGCTGGGTAGGAATGCAGCGAGGAAAGTGTGTAACACAAGGCCAAATTGGAAAGGTCAGTGAGGGG
[0895] GCAATCTGTGGAGGCACTGAATGCAGAGGATATTAAAAATTAGCAAGATAGTGTTCTAGCACAATGAAAAGGATTGG
[0896] AAGAGGGAGATGAGAGTCAGGGAGTGAAAATTGGCAGCTGCTAAGAATGTCCGGGTGAGTCAGAGGATCAGGACCT
[0897] GTAAGGGCAGTATAAAGAAGGAAGGAATGATGGGGAGAGGTTTAGGGGAAAGAAGTGACAACCTGTGACAATTGAG
[0898] GAATGAGAGATTTTGATGATTGGGGTGAAGGTTACATTTCTTAAAAAAGAAACAAGAATGGTCGGTCGATAGAGAT
[0899] GCAAGATGAAGAATTTTGTTTTTAGGACTACTGACTATGAGGTAACAAAGAAATCCCAGAGACAGAGGTCTGAGCA
[0900] AAAGATATGGGATTGGGGAAGAATCTTTGGGAGTGACTGAGGTTGACTAGAGGGGAACTGGGCAAGAACAGGTAAGG
[0901] ACTTTAAGCAGAATTGGAGGAGTATCCATCTAAAATCTGGGTAAACTGGGATGGAAAAACAAGTAGCCAGAGAAGC
[0902] AACAGCCCAAGCTAGGGTGTTGTCAAGGTTATAGATGTTACTGATTTTGGCAATGAGGAGATTATAAGGATCCTTG
[0903] AAGACTGTACTTTCGGTGAAACTACCATGCATTAGTAGCCTTTCACAGTGATATCTACCCCCACACCTGCATCAAAA
[0904] TCTTGCAGTGCCTATTAATAATGCCAACCCACTAACGGGGAGGGAGAAAAGACTTGGGACTCTGTACTTGTAAA
[0905] ACCCTCTACCCTCCCCAGGCAATTCTTTACACACTAACACTGTTGAGGTAAAAGGAGACAAGTGAGGGAGCAAATG
[0906] GAAGGTGTGTTTTTGGATTATACAGTGGCTCATGGAAGGGTGGGAGGGGTACAGATGGCCCTTAGACACTGGCGGA
[0907] AAGTCAGAGAAAAAAAAATTACAGTAAGCAGGTAAAGGGATCAAGCACAGGGACTAGTCTTGGGACGACATTT
[0908] CTTCCTCTGACAGTTTGTATGGAATTCTTGAGAAAATTCCTCGAAGGGGCCTGAAATTCTCAGAATGGTCATGTTT
[0909] TTAATGGGAATAGGGAGTGATGCTGCCCCATTACAACCATCTGTTCTAACAGAATGTCTGTACCGAGGAGGGATGA
[0910] GTAACATCGGCAAGTTCTGTTCGAAGCCTTTTTCAAGTTTCTTTTTGATATGTATCTATCTATCTATCATCTCCCT
[0911] ATACAAGCAAGCATCCCCAAGGTAGTTGTCTCAGGAAACCAGGGTTAGGATGACCAGCTCATTTGCTGGAGCTGC
[0912] CAAGGTCCAGAAAAGTTTGGCTGCAGGCTGTTTTCATGTTTTATGTATGTTTGAAATGTTCTATAATAATAAAAGG
[0913] TTAAAAAAGTTTACATTTATTTGGAAAACCAGTTACTTTAGTTTATGGTTCCTTTTTTTCCCTCCAGAGCTTCCTG
[0914] GAGATTGAGGTCTAATTCAAAGAAACCAAAATATAATATAGGTACCTGGGCAAAAAAAGTACTTTTATAACATA
[0915] ACATTTGGGTAGAGGAAGTATCCACTGTAGTCAAAATGTCTATGTTTTGCTCTTCCTTATTGTTCAGGGACATTC
[0916] CATTAAATAGTAATGAAAAGGCAGCAAAGTAAGAGGAGTGACAACATGCCCGGCATAATTAAGCAAGCTAGAGCA
[0917] GCTATTCTGTGCAACCGACGATTTTTTTTCTCTAAAATTTTAAGGGTAGGTTCATTCTGACTCTGTTAAAAGTCTA
[0918] CTTGATGTGAACAACTCTATATCTGATAACCTATTTCATTACCACTTTAAACTTGTCATATGGATACGTTATTA
[0919] CAATTGTAGAACTTTAATAAATACCATAATAATAAAACTTGAGAACTGAAGAGCACACATTTCTTCACGAATTTAT
[0920] TATATAAAACGCCCTCAGAGTATTTAATTTCTCCTCACTTTAATTACACTTAAGAAGCACAGTGGATGAGAAGCC
[0921] TTTAAGATGACTACAGTTGCACGAAGGTCCCTTTCATCAAGGTAGCGTATGTACCCTAACAGTGTTCTAAAGGCTG
[0922] GCCCAGAAAAACCCCATGTTACCTTATCACAATATGGAAAGCATTGTCTTCTTTTTCCACTAAATTAAATTATGGT
[0923] GAAAAGTGCCACAGTTTTATTTAGCATTATGGTACATAACAAACAGTTCTGTCTCAATTATGAAAAAATTAATTA
[0924] AAATAATCCTGAAAGACATCCTTTTTCTCCCCCCAATTTGAAAGCTGCATTTTTCCTGCCAATTTCAAACAAA
[0925] CAAATCATCAGGTTGATCTACAGTAATCAGTTAACAATCAGTCAATCAATCAATCACCAAGGCACAAGCT
[0926] CAGCACATTAGCTATAGCTTGTAGCAAAAGGATATCAATGTCTCACCTTAGTTAAAAATACATAATCCTTTTAT
[0927] TTTATAATGCAATAAAAGAAATTAACACACACATACACAGAAGACTAGGAAAGGGGAAACTACTTACTTCTGGA
[0928] AATCAGTAATGTAAACCTACTTGTACTTTTCCATAGTACATGAAAGTAACGTTTAACATGTTTTGAATTAATTAAT
[0929] TAAATTTAATCTGTGGGGCTATACAATGTAATTCTTAGGAGTAATAGTTTCATTCATTTCCAGGTCAGCTTACTGT
[0930] ATGATTAAGTAACAAGGCACAGTAGCCATCTTTTTCATTATGTTGCAACACTGATCACGTGCCTCGATAAAATG
[0931] GCTGATTCAACAAGATGGCAACACGAAGGGGAGACTTTGGATTGTCTATTTAAAATCTAGGTAATAAGTAAGT
[0932] AATTAATAAAACTCTATCTTAAGTGCACTTTCACATGCTTTTTGTTTATAATAAACAACAAACTTCCTAAC
[0933] TTTGTTGCAATAGGCTTGACTACCATTTCATTTGGCCAAATGCACTTTCCCCAGTAAACTTAACACAACAACGAGA
[0934] ACAACAAGAACAAATCCCTGTCCTTTCATATACTAAGAAAGAGGATTGGCTACTGAAACAGTTCATTGCAAGAC
[0935] ACATGAAGACGACATACTGTGGCATGAGTTGTTTTGTTTTTAATTTGTTGTGCTGTTACTAAAGTTCTGAGGGCT
[0936] GCAGTTAAAACATTCCAATTTCTCCCTTCCTTCCATCTTCTTTATTGATTGATTCTCAAGATTTTGCACAGAAAA
[0937] CTCTTTGGGGGCTAGAACAGCAGTAATTGCATCACACTGTTTTCAAGACTTCAAGTTTCAAAAGCAAATCATTAAA
[0938] AAAAATACAGTTCCTGATTTGAGTTAGATACAGGGACAAAAAAGTAGCACATACTTGAAGGTTACGTGGTCTACAA
[0939] ATGGTGGCAATATTTTCCTTGGGAGAGTAGTTCTGTTGGTATATATTTTTTAAATACTCAAAAGGCTCAACCTCAA
[0940] GCAGTAATAAACACAAGCAAAAGTGATTTAACCCTTAAAATAAATATTCAGAAAAACCTCTCTGTACATACAAGTG
[0941] AAAGAATATGTAACACTTTCACGCAAAAAAATAATTATAATAATAATAAAGGATTTGTTCATATATGTAGCTGAAA
[0942] TTCTGCTGTTCCAGCCCACATGTCCCCAATAAAGAAGGGAGGCACAGACATAGGTGACTACTGTGGTTGACTATCTT
[0943] ACAGCCTTTTTGTACTGGGACACTATCACCACCAAAAATTTATCCCTCGTTATATTTTTAAAATTTTTTAAATTTT
[0944] TTCTTTTTTTTTCCTTCCTTTTTTTTGTTTTATTTTGTTTTGTTTTGTTTTACAGCATGCCAAATCCTTTGGCATA
[0945] CGTGATGGCCTTCAACAATCTCTCTTTAAGTTTTTCTTTGCTTGAGTATTCCGGAAGTAAAAGCACATTAAAGCAA
[0946] GTATGAGATGTAGGTAACCTAATAGAGAAAAGGGGAAAAAAACAGGAAAACTGTAAGTCATGGGAAATACACTTA
[0947] GAATTAAATGCTCCTATTTTTAGATTGTATATAGTTGAGACGGTCTGCAATGCAAACTATACATTAATGCAAATCA
[0948] TAAAACTTTTTGTTGTGTAACTACCAAGTTGCCTTTATCCTATAAATTACTCAAAGCTAGTGACGATGATAAGATAC
[0949] TGTATCCATTGAGTTTTTACTACATAACAGATACCATTTTAGGTACTGAATTCTTACAGTTCATTTAACTAAATCT
[0950] TTCCACAACAAAACCACAGAGAGGACATCAGTAAATGCACTTTAGAGGTTAGGTCACTGAGAAGTCAAGTAACTTC
[0951] CTCTAAGGTGGAGAAAATACTCAAACCTGTTTTACAAGACTGCAAAGTGTGTGCTCTTAAATGCTTATTAGAAACA
[0952] CTGCTGGCAATATGACTAAGAAAATGATTTGATAACAGGATTCTAGCACAATCAAATGATAATCTTCCGAGCCTCA
[0953] ATGTAACCATTCTAAATAGATGATCATGTTATATGGCTTTCAATTAACAAGCTGGGAATCAAAAAAGTAAATGAAT
[0954] CACACTAATTTGATTCCAAACCAATGTGAGCCCCATAATAATTTTTAACTAGGGCAATTTCTTAAAAGTTTCCTCA
[0955] CACAATGACAGCAAAGTATTTTCTCAATTGTCTAATATGATTTGGGGATTTGTATATAAAATCACGAATGTGCTCA
[0956] GAAACTATAAAGACAGTTCATATGTATGTGACGAGGAATGCAAGGTTTTCGGTAGGTATACAGTCACAAGTTAATA
[0957] ATTACCTACCTTTCTGTGTCTGGGCCATTTTTGGCTATAATCATCTTTAATTTTCCTAGTCCTCCCACAGGTGCTC
[0958] TGTCTGTGCCCGTTGTAAACTGCAAGAAGAGTCTTTTCTGTTCATCTGTAAATGAATGAACGATTTCCCAGAACTC
[0959] CCTAATGAGAAAAAATACAATACTGGTTTCAGTTTGGCATTCATTATGACTGGTACTAACATAAGCTTATGATTTG
[0960] CATTAAAACTATATTAAGAGACAACTTGGAAGTTAATTATCAGGATAGTATCACTTCTGGTGATTTAAAAATTTCC
[0961] AAGCAAATTTATCCTGAACAGCTCTGAATACGTAAAAATTTAGATTAGATTACAATATAGTAAAATATTAGTACTA
[0962] CAATAGTAAAAATTGAGAAAACCCAAGTGTGTAGTAACAGGAAGTGACTATTTAAACTATGGTATAATCACATTA
[0963] TGCAGTCAGTAATGAGCAAAAGACAAATCCTATGAATTGAAAAAGACTGAAATGAATATTTGGAAAAATTAACTC
[0964] CAGGGTGCCTTTGGGTATATATTTTATTTATCCTTTCTCCTTTATTCTCCTGGTCTACTCATCCTTTAACTCAACTT
[0965] TGGGAGGAAAAGTGATACAGATTAAGGACAAAAGAAAAAAAGACCCCCTGCCCCAACCAACTGGCCCCAAATGCA
[0966] AACAACTACATACCTAATAGCAGTAATACAAAAGTTCAATTTTTATATGAACTAGAATACTTTAAACAAGTAATAT
[0967] GTGCTGTGTATGGAGGAGGAGAATTATTCTGACATTTCTGCCACCTGCAGTTATTTTAAGAGAATGATTTATCCTG
[0968] TGGCATTCCTAAAATCTATGTAATAAAAGCTATGTTTTAATGACACTTATGTTAGTTTGAGTTCTAAAAAACGAAA
[0969] TACAAGCTCATAAAGTGCAATCTTGAAGTTTATTTGAATAATCAGGCATCTATAAAACATATATACACTAGTTCAT
[0970] AGCTAAATAAATTTTTTTTTTTTTGAGACAGAGTCTTGCTCTGTCGCTCAGGCTGGAGTGCAGTGGCGCGATCTCG
[0971] GCTCATTGCAAGCTCCGCCTCCTGGGTTCGCGCCATTGTCCTGCCTCAGCCTCCCAAGTGGCTGGGACTATAGGTG
[0972] CCTGCCACCACGCCTGGCTAATTTTCTGTACGTTTAAGTAGAGGCAGGATTTCACCATGTTAGCCAGGATGGGTCT
[0973] CGATCTCCTGACCTCGTGATCCGCCCACCTTGGCCTCCCAAAGTGCTGGGATTGCAGGCATGAGCCACCGCGCCTG
[0974] GCCTATAGCTAAATAATGTTAAGATTAAAAAATTAAAAAAAAAATTAAAAGTATTTTTAGTTGCTTATATAATATA
[0975] AAATGCATTTTAATAGTTATTTAGAAAGTTCTTTCCAGAGCCAGGTGTGGTGGCTCATGCCTGTAATCCCAGCACT
[0976] TTGGGAGGCTGAGGCCAGTGGATCACCTGAGGTCAGGGGTTCAAGATCAGCCTGACCAACGTGGTGAAACCCTGTC
[0977] TCTACTAAAATACAAAAATTAGCCGGGCGTGGTGGCAGATGCCTGTAATCTCAGCTACTTGGGAGGCCAAGGCAGA
[0978] AGAATTGCTTGAACATGGGAGGCGGAGGCTGCAATGAGCTGAGATCACACCATTGCACTCTAGCCTGGGAAACATT
[0979] TTGAGCCATCTCAAAAAAAAAAAAAAATTTCATCTCAAAAAAAAAAAAAAAAAAAATTCCAGAATGTTAGCAGAGA
[0980] ACATCACACATCCCAAACCAGTAATTACAATTTTCTACCTTTTGATATTCTAATATCCCAACATACTATTTTTATT
[0981] ACCAAAATGCTGGCATTTTTGGTGCTGCAACACCATTTATCTGAAATAACTTAAAAGTTTTATTAGAATTCTTGGC
[0982] TTTCTCCAATCTCTTGCCACTTCCCTTCCCTGCCCCTTTACAAATCCACCAGTCAGCAAGAGAAAACAAAAAAGAA
[0983] ACACACAACAACAGAAAACTGGACATGAAACTTGCAGGAGCATCTCTCAGGTAAGGAGGAGAGGAATCGGACCCCA
[0984] GTTCATGATACTCCTTTTGGGGAGGCTGACAAGAGAAAACAAGTCTGCTGTAGCACAGAACCCTCCAACATAGCAG
[0985] AAAAGCTGCCCTGCAGTGGGTGGTAATAAAGCCTCCTCACACTGCAGGAGGGCTCTGAAGCTTAACTGAACCAGCT
[0986] ACACCTAAGGAGGTAGACCAAAGAGCACCACCGAAGAACAGAGACAGACCCTGCAGGAAGTGGCAGATCAGCAGTG
[0987] GTCACAATGACCAGTCTGGCTATATTATTACGGAGCTGTTTCTTTGGACTTTTAAACGAAACCTTTAAAAATTTTA
[0988] TACAATGAAAACAGGGAACAAAATGCATCTCTATTCCTATAAGTGTTATGTGTGTTACATTAACATTTTGAATTAA
[0989] ACAAGAATGCATATATTTAGAAAGCTGAAGAAAACACGAAGAAGCTTCCAGGTTTCCACATAAAAGTGGTGGCTGT
[0990] ATCGATCACATCCTACTCACATCTCTAAAAATCTACCCGGATCAAAAAGGGGAAAATAAAAAAAAAACCTATGACT
[0991] TAGGTCTAGAGTAAAACTAGGAGACAGAACAATAAACTCCAAATACCAAAGAAGTGGGGAAATGAGCAGGGTCCAG
[0992] CAGGAGCTACATCGAAGAGTGGCTTGTGCGGAATCATACTGATTAGGGATCACCCAAGGCCAGACCCCACCCCCTC
[0993] CACCACCTGCCCCTCAACAGAGCACTACTGAGTGTAGGTTAGAGCACTGGCAACAGGGTGGTTAAAGGAAGGACTA
[0994] CAGAAAAGTACTTGGGTCCAGCAATGGCAGGCTCAGGAAGGCACCATGCATGAAAGGAAGGGGGGTACCTTCAAAA
[0995] GCAGAAGTGTCCCTTAAGCGGCTGTAAAGGGGTGGAAGCAGCTAATGAAAAAGAGTCTTCATTAAGCTACATGGAG
[0996] CTGAAAAATCAGAAAGTGGTGATTCTGCCCTTACTAAAGCAACAGAAGAGGGATCCCTTCAACCAAGACCCCTAAA
[0997] GCCACACAATTCCTCCCTGCTCCACCATGAGGTCTAGTAATAACAGGTCCAGAAAAAAGTAACATCTGTTATAGAA
[0998] ACATAAACAAGAAAAACAGAATTCGGAAGTCTAAATAAAGTTATTATGGGAAGAGTCTGGCGAATGAGAAGCAAAA
[0999] CTTTCCGGTAGACAAAAGTAGACCAGAAAAATTCAGTCATAAACAATGGGAAACTAGTAACACCACATTCCAACAC
[1000] AAAAGGAGAATGCAGCAGCAGACAAGACAGACCACCAGTGATGAGAAATACAAATTCAGAAAGAAATGAGCACATC
[1001] TTAAAATAAAAATAAGAATACTAAAAAAATACTGAAGAAATATGCAAGGTAACTTTGGAAATAAAGGCTAATTTTATT
[1002] ATAAGGTGACCAAAGAAGAAGCAGTATGACTAAAATTTCTACTGAGGACAGACTCTAGAAAATTAAAAAACAAAGA
[1003] AAATGAATAAAATAAACATAACTAAAGAAATGCATATCAAAGCATAATAACGAAAAGATTAATAGCTAACTACAT
[1004] AAACATAAAACCTTTCATTTGGCAAAAATCCTATAAGCAAGGTTAAAGACAAATGACAAACTGGGAAAAAATA
[1005] TTTGCGAATTTACCAGCGTTAAAGGACTAATCTCCTTAACATATAAAGTTTCTAAAAGTGAAGAAAACGACCAGCT
[1006] GAGCAGCAATGAGCAAGACTATATAAAACTATAAACAGCTCTACAAGAAAAAATGTCCATTATCATTCATAA
[1007] TTGAGGTAAGCTCAAAAATTGTAACTATAGTAAAATACCATTTCTCAATTGGCAAATAAGTAAACATCCACATTTA
[1008] ACAACACATTCTGTTTGGAAAGTTTTAAGAAAAGAGATACTGTTGTAAACTGCTGGTGGGAATGCAAAATGTTATT
[1009] TTTCTGTGAAGGAGGATTTGGCAGTATCTAGCAAAATTACACATGCATCTACCATTTGATGCAACAATCCCACTTC
[1010] TAACAATTTATCTTAATGATACTTTACATATGTACGGAATAATGCATGAACATTAAGAGGATTCACTGTGACATTA
[1011] GTACTAACAGCAAAAGGTTAAAAATAACCTCGATGCCCATAAATATTGATAAGCTATGCTGCATCCACACAAAGGA
[1012] GCAGTATTCAGTCATACAAAACAAAATGGAAAACACCTCTGCAATAATGTGGGATGATTCTCAGGATACACTAGGA
[1013] AGATTATTTTCCTAGTTCTGTCCTCTGATAAGGCCTACAAGCAGTAACGTTCAAAAGCAAAGGCCATACTTTGCAT
[1014] CTAAAATCTGACTTCTAAATGCCATTCTCCAACAATTTATTGGAAAAATAACTTATTCCAGGCCTGAGAATGAATG
[1015] TTCGAGATTAGTTAGAAATCTCAAAATCTAATAGGGTCATTTTAAAAGCACACGATAGCTAAGCAATTTGAATATC
[1016] ATTTAGAGTAATGACTGTGAAACGTATTAAATACAAAAACATTCATTAGTTCGTAATATTCAAAAAGGCAGCAAAA
[1017] ACCAACCAAAAAACAAAATTAAATTGTCACTATTAAAATTATTACATTAACTCCTTACTCTAAAAACCTTAAATCT
[1018] ATTTTATCATGCCTTTTCTGTAGAACTGTTTTTCAAGGTAATCAAATGGCACCCAATGATGAGAAAAAAGAATGCC
[1019] AGGTATATATGTAGGACAAGCAGATGGAAATTTTTTTTCCCCAAACAGCCATTTTGCAATCCCCAATGAGATAACA
[1020] GATTAAGGTAATGATACTGATAAATACGAAAATCAGGTGAAGGGCAGGTAGCAGGTTCTGGAAAGATGATGATGGC
[1021] AACGACATAGTTATTATTATTATTATTTTTTGTTTTATTCCCTCCCAACCTCCCCTACAAAAACAGCAAACTGAAT
[1022] GAGAAAACCAAAGACCCAGAGACATTATCTACAACAAAACCATGAACCATTGCATATAATTGGACAGAAACAAAGC
[1023] TCTGACAACTACAAGACTGGTTAGTAAGGAAGCAGATGCAAGGTAACTGACTGGGTTTCTGACAGCCCTGAGAACA
[1024] CTGCCAACCCACTGGAAAGCACAGGCCAATCTGAAAACAGGGCTTAAAGTTTTAAAAAGTTCTACAGGATCTAATT
[1025] TGCAGATGATTACAAAGGGATCATGATGTAGTAAGCTCTGGGCCCTTAAAACACCCGAATACCAAACCCCCACCAG
[1026] AAACAAACCTTGTACCGAGGAAAAACTTCTGGGAATAACTTCCGAATGGACCAGGTCAGTAATAAAAACCAAAAAA
[1027] AAGTTCAAATATATGTGTGGGATAGAGGAGTAAAGAAGGCAGTTTCAGAAAGCACAAGGGCATATTTTTGACCATT
[1028] TTACAAAAACACAGACTTCTCCTCGTCCCTAAAAAGCGAAAAAAGTTATCTGGCCCATCTCTCCCTCGTCCAAGT
[1029] ATGAGAAACTCATTTCACTCACACACACACACACACACACAAATAAATAAATAACAGAACAGAGTGAAACAGTG
[1030] TAATTATTAGAGAAAAAGTATGTGCATATACATGAGAATGGTGTCCCTACAGAAAATCAAAGTACATGAAACAATA
[1031] TGCAAATAAAACATGAAAACTGTAAACAAATTTCAAACTGAGCTAAAAAGAATTTAAAAAATAACAAATCATTAGA
[1032] AATGGGAAATTTCTGAATGAGGGTAACTGAAAAAAAGGAAGACATGACACAACTAAGGAGTAATTAGAAATGCAAG
[1033] GAAAAAATCCCATCAAATACAAAGAAACTAAAACTAAACTAGAAGAAACATAAAGGTGAATAAAAACAGAACAATA
[1034] ATACCAGAACCTGAAGGCAGAAGAAAAATCTTAAATCAAAAAAGAAACAAACCCATGCTTGAGACTCTCCTTGCTG
[1035] GTCCAGAGCCACAGTGCTGCTGTGTACTGGCAGGAGGAATTCTGCTATAATTGGTCCTGGCAGTGTTCACCTTTCC
[1036] TGCAAGTGTTCCACAGCCCAGGGACACAATGTGGTCAGGAGCACTGCCAGGAACACCAGCAAGGGGGAGCCTGCCA
[1037] CAACAGGCACAAGGCTCAGGAAGCACTCTCCAGCCCACGAAATCTAGTGGGGGTCCTCTTCCCTCACCCAAACAC
[1038] ACTCTGCGCAGCT
[1039] SEQ ID NO:2
[1040] shRNA artificial / synthetic sequences.
[1041]
[1042] SEQ ID NO:3
[1043] UBE3A-ATS artificial / synthetic target sequence.
[1044] 5'-GATATCACCTTACAGAAATTA-3'
[1045] SEQ ID NO:4-489
[1046] UBE3A-ATS artificial / synthetic sequence.
[1047] 4.CTGAAGTGCACATGGAATATT
[1048] 5.TCTTCAGGATGACACATATTA
[1049] 6.CACAATGATATGGAGATTTAA
[1050] 7.CTCAATCCAATAACCTAATTT
[1051] 8.GTAAACAGAAGGAAGAAATAA
[1052] 9.AGGTCCGTATTACCCTTATAT
[1053] 10.CATCTAGCCTTTCTGATTTAT
[1054] 11.ATCTAGCCTTTCTGATTTATA
[1055] 12.TCTAGCCTTTCTGATTTATAT
[1056] 13.CTAGCCTTTCTGATTTATATTA
[1057] 14.AGTCACAACTCAGATTTATTT
[1058] 15.GGCCTCACAACTCAGATTTAA
[1059] 16.GAACAGAGCCCTCAGAAAATAA
[1060] 17.GGAAAGGATTCCCTATTTAAT
[1061] 18.GAAAGGATTCCCTATTTAATA
[1062] 19.GACAAACGGGATCTCATTAA
[1063] 20.CATCTGACAAAGGGCTAATAT
[1064] 21.ACAATGAACTCAGACAAATTT
[1065] 22.CAATGAACTCAGACAAATTTA
[1066] 23.GTTAGAATGGCGATCATTAA
[1067] 24.CAGCCATCCCATTGCTATATA
[1068] 25.AGCCATCCCATTGCTATATAT
[1069] 26.GCCATCCCATTGCTATATATA
[1070] 27.CCATCCCATTGCTATATATAT
[1071] 28.CATCCCATTGCTATATATA
[1072] 29.ATATACCCAAAGGACTATAAA
[1073] 30.TATACCCAAAGGACTATAAAT
[1074] 31.ATATGCACAGGTATGTTTTATT
[1075] 32.GAAAGACACTGATTGTATTTA
[1076] 33.ACATAGCCCTAACCATATAAA
[1077] 34.CCTCACACCAAAGACCTATTAT
[1078] 35.TGGCAGAGATTTGGCAATTAT
[1079] 36.GGCAGAGATTTGGCAATTATA
[1080] 37.AGAACAACAAGGAGGAAATTT
[1081] 38.GAACAACAAGGAGGAAATTTA
[1082] 39.GAATGGAGTGAAATGTTTAAA
[1083] 40.TCTGATTTCCTTGGGTTTATT
[1084] 41.CTGATTTCCTTGGGTTTATTT
[1085] 42.TGCTCTTCTTTCTACTTTATT
[1086] 43.GTAAGCATTTAGTGCTATAAA
[1087] 44.TTAGTCACATCCCACAAATTT
[1088] 45.ATGGTCTGTGCTGTGAATATT
[1089] 46.TTGAAGTCTCCAACCATAATT
[1090] 47.CAGTTTGTGCATCACATATTT
[1091] 48.TGCCCTCTTGGTGGCTTATTT
[1092] 49.TCCTAGGTCATAATGATAATT
[1093] 50.CTCCACATCCTTACCAATATT
[1094] 51.CGCTTATCAGATATGATTTAT
[1095] 52.GGTCTATACATGTAGATTATT
[1096] 53.TCATAGATGTATGGGATTATT
[1097] 54.CATAGATGTATGGGATTATTT
[1098] 55.CTTGTAACTCCTTGGTTAAAT
[1099] 56.TTGTAACTCCTTGGTTAAATT
[1100] 57.TGTAACTCCTTGGTTAAATTT
[1101] 58.GTAACTCCTTGGTTAAATTTA
[1102] 59.TCCTTTCTGATGCTGTTTAAA
[1103] 60.CCTTTCTGATGCTGTTTAAAT
[1104] 61.CTGAAACTTTGCTGCATTTAT
[1105] 62.TGAAACTTTGCTGCATTTATT
[1106] 63.GAAACTTTGCTGCATTTATTA
[1107] 64.TTGCTCTGTGAATAGATAATT
[1108] 65.TGCTCTGTGAATAGATAATTT
[1109] 66.ATATGTTGATCCACCTTTA
[1110] 67.TATGTTGATCCACCTTATAT
[1111] 68.ATGTTGATCCACCTTTATATT
[1112] 69.TCTTTGGCTACTTTGTATAAT
[1113] 70.CTTTGGCTACTTTGTATAATA
[1114] 71.TAAGTGCATAGAGCCAATAAA
[1115] 72.ATGCACATGATCTTCTTAATT
[1116] 73.TGCACATGATCTTCTTAATTT
[1117] 74.TGGCTTAAACAAGAGAAATTT
[1118] 75.GGCTTAAACAAGAGAAAATTTA
[1119] 76.AGGTATCAGAGTGTATATTT
[1120] 77.TTAAAGAGTTGCCACATTATA
[1121] 78.GTTGCCACATTATACATAATA
[1122] 79.AGACATTGAACCAGCTAATTAA
[1123] 80.GACATTGAACCAGCTATTAA
[1124] 81.AGGGTTAAAGGAAGGTATAAA
[1125] 82.ATACCCGAGATGACCCAAAA
[1126] 83.CAAATCCACGAGAAGAAATAA
[1127] 84.ACTTGTGTTGATGGTATTATA
[1128] 85.CTTGTGTTGATGGTATTATAT
[1129] 86.ATTCATTGGAAAGGGTATAAA
[1130] 87.CAGTAACAAGAGCCCATTATT
[1131] 88.AGTAACAAGAGCCCATTATTT
[1132] 89.GCCCAAGAGATCCCACTTTATT
[1133] 90.CCCAAGAGATCCACTTTATTT
[1134] 91.TTTCATCTCACCCAGAATATT
[1135] 92.TGTTATGAGATCCAGTTATTT
[1136] 93.ACTGAACTGTGAGCCAATTAA
[1137] 94.CTGAACTGTGAGCCAATTAA
[1138] 95.AGTCTTAGGTAGTTCTTTATA
[1139] 96.CAAAGGCAGCAGACACAATAAT
[1140] 97.AGACTGGCTATTTGAAATTAT
[1141] 98.GACTGGCTATTTGAAATTATT
[1142] 99.CACCATCAAGAGAACTAATAT
[1143] 100.ACCATCAAGAGAACTAATATA
[1144] 101.CCATCAAGAGAACTAATATAA
[1145] 102.GGAAAGTACATAGTCAAATTT
[1146] 103.CAATGCATACTACAGTATAAA
[1147] 104.AGTCCTTACGTGTCAATAATT
[1148] 105.GTCCTTACGTGTCAATAATTA
[1149] 106.GACACATACAGGCTGAAATTA
[1150] 107.ACACATACAGGCTGAAATTAA
[1151] 108.CACATACAGGCTGAAATTAAA
[1152] 109.CAATATTGAAGCACCTAAATA
[1153] 110.ATGGATCTAACAGACATTATA
[1154] 111.CATTCTCCAGGATAGATTATA
[1155] 112.ATTCTCCAGGATAGATTATAT
[1156] 113.CAAGATGGAAACTGGAAATTT
[1157] 114.TTCTATGAGGTAAGCTTATAT
[1158] 115.TCTATGAGGTAAGCTTATATT
[1159] 116.SUMMERSUMMARY
[1160] 117.SUMMERSUMMARYAAAA
[1161] 118. ATTACKAttackAttackAttack
[1162] 119.TGAAGACTGCCAACCATTTAA
[1163] 120.SIGHTGCCAACCATTTAAA
[1164] 121. CTAATTCWATERSTORM
[1165] 122.GATGCAGGATAGTTCAttach
[1166] 123.ATGCAGGATAGTTCAATATAA
[1167] 124. TGCAGGATAGTTCAATATAAT
[1168] 125.GTGTCTGTTGGCTGCATAAAT
[1169] 126.CTTTGTAGATTCTGGATATTA
[1170] 127.GCAGAAGCTCTTTAGTTAT
[1171] 128.SECAGCTCTTTAGTTATTATT
[1172] 129.CATCCTGTTACTGGGTATATA
[1173] 130. GTATACCCAGGGGATATA
[1174] 131.TATACCCAGATTATAA
[1175] 132.ATACHGGROUPTAAA
[1176] 133.TACCCAGATTATAAAT
[1177] 134.CCCTTAGGETTAGET
[1178] 135.TGACAAACCTGGAGGTAATAT
[1179] 136.GACAAACCTGGAGGTAATATA
[1180] 137.GTCCATTCTCACCACTTATAT
[1181] 138.TCCATTCTCACCACTTATATT
[1182] 139.CCATTCTCACCACTTATATTT
[1183] 140.CATTCTCACCACTTATATTTA
[1184] 141.GTAGATGACATGATCTTATAT
[1185] 142.GAATAGAGAGCCCAGAAATAA
[1186] 143.ATGCTTGACATCACTAATAAT
[1187] 144.TACACTGTTGGTGTGAATTTA
[1188] 145.ACACTGTTGGTGTGAATTTAA
[1189] 146.CACTGTTGGTGTGAATTTAAA
[1190] 147.GGTATTTGCACACTCATATTT
[1191] 148.GTATTTGCACACTCATATTTA
[1192] 149.ATAAAGAGAACGTGGTATATA
[1193] 150.AGACACAGTGGAATCTATTTA
[1194] 151.GGTACAAACTTTCAGTTATAA
[1195] 152.GAAGGCACTGATATGTTAATT
[1196] 153.AGGCACTGATATGTTAATTAT
[1197] 154.ATCCATTCAAGCTAGATTATT
[1198] 155.TCCATTCAAGCTAGATTATTT
[1199] 156.GGCATGGTGGCCCTCAATTAT
[1200] 157.GCATGGTGGCCCTCAATTATA
[1201] 158.CATGGTGGCCCTCAATTATAT
[1202] 159.ATGGTGGCCCTCATTATATA
[1203] 160.TGGTGGCCCTCAATTATATAT
[1204] 161.GGTGGCCCTCATTATATA
[1205] 162.GTGGCCCTCAATTATATATAT
[1206] 163.TGGCCCTCATTATATATA
[1207] 164.GGCCCTCAATTATATATAA
[1208] 165.ATGAACAAATGGGATTTAA
[1209] 166.TGAACAACAATGGGATTTAAA
[1210] 167.GAACAACAATGGGATTAAAT
[1211] 168.AGCAATAGTGGAGAAATATAA
[1212] 169.GACCTAAACCCTATCTTAA
[1213] 170.ACCTAAACCCTATCTTATAAT
[1214] 171.CCTAAACCCTATCTTAATT
[1215] 172.CTAGGCAGCAATACTAATAT
[1216] 173.GTGTAGCTATGACTGATATTT
[1217] 174.TGTAGCTATGACTGATATTTA
[1218] 175.GTAGCTATGACTGATATTTAT
[1219] 176.TAGTCTTTGCTTGCCTATTTA
[1220] 177.AGTCTTTGCTTGCCTATTTAT
[1221] 178.GTCTTTGCTTGCCTATTTATT
[1222] 179.CTGTGTTTAGTTGTCTTTAT
[1223] 180.CTACCCTGGATAGGGAATATA
[1224] 181.TTCTATTTGCAACAGGATAAAT
[1225] 182.TCTATTGCWEATHERATATA.
[1226] 183.CTATTGCATTAAA
[1227] 184.ACTGGTGAACTCCTCATCHED.
[1228] 185. TWOWAVES BETWEEN WEATHER
[1229] 186.THE SEASONS BETWEEN SEASONS
[1230] 187. SUCCESSFUL TAOT
[1231] 188.TGCCTGTATGAATTA
[1232] 189.GCCTGTGATTAGATTATE
[1233] 190.GAACCAATCTTGTGCTTTATT
[1234] 191.GCATTCTCTGATCTGATTTAT
[1235] 192.CATTCTCTGATCTGATTTATT
[1236] 193.AGAGGCTTAAAGGAGATTATT
[1237] 194.TTGTTCAAGGATTCCTTATTA
[1238] 195.TGTTCAAGGATTCCTTATTAT
[1239] 196.GTTCAAGGATTCCTTATTATT
[1240] 197.TGTGGAGAATCATTGATATAT
[1241] 198.GTGGAGAATCATTGATATATT
[1242] 199.GTATATGAGAGTTCCATTATT
[1243] 200.TGGCTGTGGAAACGCTTATTT
[1244] 201.TGGATCGATGATGAGAATAAT
[1245] 202.GGATCGATGATGAGAATAATT
[1246] 203.GCCCTCCAATAGGACAAATAA
[1247] 204.TGACCCAAGACTTGCTTTAAT
[1248] 205.GACCCAAGACTTGCTTTAATT
[1249] 206.TGTGCTGAAAGAAGGAAATAT
[1250] 207.ATATGGCATGCCTCTATTAAA
[1251] 208.TATGGCATGCCTCTATTAAAT
[1252] 209.ATGGCATGCCTCTATTAAATA
[1253] 210.TGGCATGCCTCTATTAAATAA
[1254] 211.GGCATGCCTCTATTAAATAAT
[1255] 212.GACAGTGGAACCAAGTTTATT
[1256] 213.GAGACTCCATGGTTCATAATA
[1257] 214.AGACTCCATGGTTCATAATAT
[1258] 215.TTGTGGTCATACTACATTATA
[1259] 216.TGTGGTCATACTACATTATAT
[1260] 217.GTGGTCATACTACATTATT
[1261] 218.TTGCAACAAGGTAAGTTATAT
[1262] 219.TGCAACAAGGTAAGTTATATA
[1263] 220.TTGATTGATGCCCTCATAATA
[1264] 221.TGAAGTTGGGTAAAGTATAAA
[1265] 222.GTCAATACACAACTGATAAAT
[1266] 223.CAAAGAGTTTCAGCCATAAAT
[1267] 224.CATGCTTTCCAGGAAATAT
[1268] 225.TCCAGAGGAAATATGTTTAAT
[1269] 226.TTTAATCATCTGCCCTATATT
[1270] 227.TTAATCATCTGCCCTATTA
[1271] 228.TGCAAGATACCATACATTTAT
[1272] 229.GCAAGATACCATACATTTATA
[1273] 230.GGTCCATGTGATTTCTTTAAT
[1274] 231.TGCCATAACTATAGCATTTAT
[1275] 232.GGATACCATCCCACTATAAA
[1276] 233.TGTGTTTCCTTCCAGATAATT
[1277] 234.GTGTTTCCTTCCAGATAATTT
[1278] 235.GTGTGCTGAAAGGGCTATAAA
[1279] 236.TTGAACCAACCACCCTATAAA
[1280] 237.TAAACGTTGTATGGCTTATTT
[1281] 238.ATCCCTGTGTACACAATATTT
[1282] 239.ATGTGTGGTAAATCCATTATT
[1283] 240.TGTGTGGTAAATCCATTATTT
[1284] 241.ATGAGCATTTGGCAGTAATAT
[1285] 242.TGAGCATTTGGCAGTAATATT
[1286] 243.GAGCATTTGGCAGTAATATTA
[1287] 244.AGCATTTGGCAGTAATATTAT
[1288] 245.GCATTTGGCAGTAATATTATT
[1289] 246.GAGACTCTGCTGAAGTTTATA
[1290] 247.AGACTCTGCTGAAGTTTATAA
[1291] 248.CAGTTATAGAAGTGCTAATTT
[1292] 249.TATGATGACCTCCTGAATTAT
[1293] 250.GGGTCTGGTGTTTCATTTATT
[1294] 251.GGTCTGGTGTTTCATTTATTT
[1295] 252.GGGTCTCATTATAGTTAATAT
[1296] 253.TAACAGCATGTCAGGTAATAA
[1297] 254.GCAGAGCCCTATTCCTTTAAA
[1298] 255.CTCCTAAATGTTTGGAAATTT
[1299] 256.TTAGCATTTCTGACCTATTTA
[1300] 257.TAGCATTTCTGACCTATTTAT
[1301] 258.AGCATTTCTGACCTATTTATT
[1302] 259.ACAGGATATAGGGAATAATTT
[1303] 260.CAGGATATAGGGAATAATTTA
[1304] 261.TAGCACTGAAATGCCTATATT
[1305] 262.AGCACTGAAATGCCTATATTA
[1306] 263.GAGCAGAAATCAATGAAATAT
[1307] 264.ACTTGTAACCAGACCAATTTA
[1308] 265.CTTGTAACCAGACCAATTTAA
[1309] 266.ACTCAGTGAACAAGTAAATAA
[1310] 267.TAGCCCTGTATCAAGTAAATT
[1311] 268.ACAAGATTCCAGAACATTTAA
[1312] 269.CAAGATTCCAGAACATTTAAA
[1313] 270.GAGAGTTACCCAAAGAATTTA
[1314] 271.AGAGTTACCCAAAGAATTTAA
[1315] 272.AGAAGAAAGGTTTGGAAATTT
[1316] 273.AGCCCAATCTATAGGATTTAT
[1317] 274.GCCCAATCTATAGGATTTATA
[1318] 275.CCCAATCTATAGGATTTATAT
[1319] 276.AGTTCATCGTTAGTGTTATAT
[1320] 277.GTTCATCGTTAGTGTTATATA
[1321] 278.ACCACCATGCCCAGCTAATTT
[1322] 279.ATGACCCATTTGAAGTTAATT
[1323] 280.TGACCCATTTGAAGTTAATTT
[1324] 281.ATGCTGGCCTCACTGAATAAA
[1325] 282.TGCTGGCCTCACTGAATAAAT
[1326] 283.GCTGGCCTCACTGAATAAATT
[1327] 284.TGTTCCCTCCTCTTCAATTAT
[1328] 285.GTTCCCTCCTCTTCAATTATT
[1329] 286.TTCCCTCCTCTTCAATTATTT
[1330] 287.TTGGTAGGTTGTGCGTATTTA
[1331] 288.ATTAGTTGGCATGCAATTATT
[1332] 289.ATTCGTAGTTCTCTGAATAAT
[1333] 290.TTCCTTCTGTTGGCCTTTAAT
[1334] 291.TCCTTCTGTTGGCCTTTAATT
[1335] 292.CCTTCTGTTGGCCTTTAATTT
[1336] 293.GAAAGCATTTAGAGCTATAAA
[1337] 294.CTTTCACTACCTGCCATAAAT
[1338] 295.TTTCACTACCTGCCATAAATT
[1339] 296.TTCACTACCTGCCATAAATTT
[1340] 297.TCCTTGACCTATTGGTTATTT
[1341] 298.CCTTGACCTATTGGTTATTTA
[1342] 299.CTTGACCTATTGGTTATTTAA
[1343] 300.TTGTGATCACAGAAGATATTT
[1344] 301.TGTATAATCGCAGTCTATTAA
[1345] 302.TCGCAGTCTATTAACATTTAT
[1346] 303.CGCAGTCTATTAACATTTATT
[1347] 304.GAGTGGTAAAGTCTCTATTAT
[1348] 305.AGTGGTAAAGTCTCTATTATT
[1349] 306.AGCATAAGCTATGTCATTAAA
[1350] 307.CTCTTCATTTCCTTCAATATT
[1351] 308.TGAGATACCTAGAACAATATA
[1352] 309.GAGATACCTAGAACAATATAA
[1353] 310.CTCTTTCTCTGTGAGATTATA
[1354] 311.ACAACAGCCTGGAAGTAAT
[1355] 312.CAACAGCCCTGGAAGTAATT
[1356] 313.ACAGCCTGGAAGTATTAA
[1357] 314.ATTCAAACTGATGCCAATTTA
[1358] 315.TTCAAACTGATGCCAATTTAA
[1359] 316.AGTCAACACCAATTAAA
[1360] 317.AGCTCCTGTTTGAAGTAAATT
[1361] 318.GCTCCTGTTTGAAGTAAATTT
[1362] 319.GCCTTCCAAGGTTTCTATTAA
[1363] 320.TGTGGGTCTCTTTGGATTTAT
[1364] 321.TATGGTTCTGTAGAGATATTT
[1365] 322.TGTTCTCAATTTCCCTATATA
[1366] 323.GTTCTCAATTTCCCTATAA
[1367] 324.AGGTTGGAACATTCAAATAA
[1368] 325.TTACATGGGCTGTTCTATAAA
[1369] 326.TACATGGGCTGTTCTATAAAT
[1370] 327.TGTTACTTAAGGTGGTTAATA
[1371] 328.GTTACTTAAGGTGGTTAATAA
[1372] 329.GTTGCTCAAGTCTTCTATATT
[1373] 330.CAACATGCAGGTTTGTTATAT
[1374] 331.ACATGCAGGTTTGTTATATAT
[1375] 332.ACGTGTGCATGTGTCTTTATA
[1376] 333.CTTTATAGCAGCATGATTTAT
[1377] 334.TGTGTCTTTGGCTGCATAAAT
[1378] 335.CTTTGTAGATTCTGGATATTA
[1379] 336.GCAGAAGCTCTTTAGTTTAAT
[1380] 337.TTTCCCAGCACCATTTATTAA
[1381] 338.TTCCCAGCACCATTTATTAAA
[1382] 339.TCCCAGCACCATTTATTAAAT
[1383] 340.CCCAGCACCATTTATTAAATA
[1384] 341.GTTGTAGATGTGTGGTATTAT
[1385] 342.TTGTAGATGTGTGGTATTATT
[1386] 343.TGTAGATGTGTGGTATTATTT
[1387] 344.GTTCTGTTCCATTGGTTTATA
[1388] 345.TTCTGTTCCATTGGTTTATAT
[1389] 346.GGATGGCATTGAATCTATAAA
[1390] 347.GATGGCATTGAATCTATAAAT
[1391] 348.CCTAATTGAATACCCTTTATT
[1392] 349.GGCTGTGGGTTTGTCATAAAT
[1393] 350.GCTGTGGGTTTGTCATAAATA
[1394] 351.TGTCCCATCAATACCTAATTT
[1395] 352.GTCCCATCAATACCTAATTTA
[1396] 353.TCCCATCAATACCTAATTTAT
[1397] 354.CCCATCAATACCTAATTTATT
[1398] 355.TTGTCTTTGGTTCTGTTTATA
[1399] 356.TGTCTTTGGTTCTGTTTATAT
[1400] 357.AGCATGCTTTGCTGGTATTAA
[1401] 358.GCATGCTTTGCTGGTATTAAT
[1402] 359.CATGCTTTGCTGGTATTAATA
[1403] 360.ATGCTTTGCTGGTATTAATAT
[1404] 361.TGCTTTGCTGGTATTAATATA
[1405] 362.GAGAGTTAGAACCTCAATATA
[1406] 363.AGAGTTAGAACCTCAATATAT
[1407] 364.CCACCACGCCTGGCTTTATAA
[1408] 365.CACCACGCCTGGCTTTATAAT
[1409] 366.ACCACGCCTGGCTTTATAATT
[1410] 367.CCACGCCTGGCTTTATAATTT
[1411] 368.GTCTAGCTCCAAGTGATATAT
[1412] 369.TTTGCTTCTGTCTGAAATATA
[1413] 370.TTGCTTCTGTCTGAAATATAT
[1414] 371.TCTTAAGTCTGTGAGTTTATA
[1415] 372.TCTCTGATTTCCACCTATATT
[1416] 373.CTCTGATTTCCACCTATATTA
[1417] 374.GTATATACTCCAGAGAAAATAA
[1418] 375.CACCAGAACTTGAACATTAAT
[1419] 376.ACCAGAACTTGAACATTAATT
[1420] 377.CCAGAACTTGAACATTAATTT
[1421] 378.GTCTGGAACTCCTGGAATTAA
[1422] 379.CTTTCTGTGCCTGGCTTATTT
[1423] 380.CAGGATTTACCTTCCTTTAAA
[1424] 381.TCTGTTGATGGGCACTTAAAT
[1425] 382.CTGTTGATGGGCACTTAAATT
[1426] 383.TCATAGCGGCTGTACTAATTT
[1427] 384.CATAGCGGCTGTACTAATTTA
[1428] 385.TTTACCCATTTCCAGATATAT
[1429] 386.GTGTAAATAAGGGTCTAATTT
[1430] 387.TGGTTATGTCATCAGTAATTA
[1431] 388.CCTTGCATCCTAAGGATAAAT
[1432] 389.GTGAATCCAGTTTGCTAATAT
[1433] 390.TGAATCCAGTTTGCTAATATA
[1434] 391.GAATCCAGTTTGCTAATATAT
[1435] 392.CCATGTTCATCAGGGATATTA
[1436] 393.GTGTCTTTCTCTGGCTTTAAT
[1437] 394.TGTCTTTCTCTGGCTTTAATA
[1438] 395.GTCTTTCTCTGGCTTTAATAA
[1439] 396.TTGTGATCCTTCTTCTTTATT
[1440] 397.GTAGGTTTGTATCGCTATAAA
[1441] 398.TAGGTTTGTATCGCTATAAAT
[1442] 399.AGGTTTGTATCGCTATAAATT
[1443] 400.GGTTTGTATCGCTATAAATTT
[1444] 401.TCATTTGTCTCAAGGTAATTT
[1445] 402.TTTGGGAGCATATTGTTTAAT
[1446] 403.TTGGGAGCATATTGTTTAATT
[1447] 404.TGGGAGCATATTGTTTAATTT
[1448] 405.TGGATGGAATGTTTCATATAT
[1449] 406.AGTATTGAGGTCCCGTATTAT
[1450] 407.GTATTGAGGTCCCGTATTATA
[1451] 408.CTCCCTCTTCACATCATTTAA
[1452] 409.TCCCTCTTCACATCATTTAAA
[1453] 410.TATGTCTTCTTGGTGAATTAA
[1454] 411.ATGTCTTCTTGGTGAATTAAT
[1455] 412.CTGCTCTCAATTTCCATTTAT
[1456] 413.TGCTCTCAATTTCCATTTATA
[1457] 414.GCTCTCAATTTCCATTTATAT
[1458] 415.TCCTTCAGCACTTTGAATATA
[1459] 416.TCAGCTATTACTTCCTTAAAT
[1460] 417.CAGCTATTACTTCCTTAAATA
[1461] 418.TCCTTAAGGACCTCCTATTAT
[1462] 419.GCTTGACCTCTAAACATATAA
[1463] 420.CTTGACCTCTAAAACATATAAA
[1464] 421.ACCAATACCTTGTGTAATAAA
[1465] 422.TTGACACTGGCTCTCTTTATA
[1466] 423.TGACACTGGCTCTCTTTATAA
[1467] 424.CAGAAGATGTGTTTGATAATA
[1468] 425.GTTTGACGTGAAGAGTTTAAA
[1469] 426.CTCTGAGCTTCAGTGAATTAT
[1470] 427.AGGGTTGAATGCTGGATTTAA
[1471] 428.GGGTTGAATGCTGGATTTAAA
[1472] 429.GGTTGAATGCTGGATTTAAAT
[1473] 430.GTTGAATGCTGGATTTAAATA
[1474] 431.AGTGAAAGCAAAGAGAATAAA
[1475] 432.CATGATGTTCCAAACTTTAAA
[1476] 433.AGGTGGCCAAGGGCCTTAATA
[1477] 434.GCCCAGCTGGCTCTGTAATAA
[1478] 435.CCCAGCTGGCTCTGTAATAAA
[1479] 436.CCAGCTGGCTCTGTAATAAAT
[1480] 437.TGGTGTCATCGGGCCATATTT
[1481] 438.TAACTAGGTCAACAGAATATT
[1482] 439.GCAAAGTTAATCCTCATATAA
[1483] 440.GCAGCATCTGTTCTGATTAAA
[1484] 441.CAGCATCTGTTCTGATTAAAT
[1485] 442.AGCATCTGTTCTGATTAAATA
[1486] 443.GCATCTGTTCTGATTAAATAT
[1487] 444.CTGCACAACTGACCCTTTATT
[1488] 445.TGCACAACTGACCCTTTATTA
[1489] 446.TGATGGCTTTCCTACTATTTA
[1490] 447.GATGGCTTTCCTACTATTTAA
[1491] 448.AGCTCAGCCATCTGGTTTAAA
[1492] 449.CTGACTGCCTTAGACTAATAT
[1493] 450.TGACTGCCTTAGACTAATATA
[1494] 451.CAGCATTTGACAAAGAAATAA
[1495] 452.AGGATATGGATGATGTATATA
[1496] 453.GTCGACCCTAAGAAGATAATA
[1497] 454.AGAAACCTGAACAAGTAATAA
[1498] 455.GAAACCTGAACAAGTAATAAT
[1499] 456.AGTCACACAACAGACTAAATT
[1500] 457.GTCACACAACAGACTAAATTT
[1501] 458.AGCGAGAGTGTCCTCATTTAT
[1502] 459.GCGAGAGTGTCCTCATTTATA
[1503] 460.CGAGAGTGTCCTCATTTATAT
[1504] 461.ATCCTCTATCTCTGTTAATAA
[1505] 462.AGCAAGTGCTATTCCATATTT
[1506] 463.CTGGAGTCCATGGAGAAATAT
[1507] 464.CCTCCAAGGACATACTTTATA
[1508] 465.CTCCAAGGACACTTTATAA
[1509] 466.TCCAAGGACACTTTATAAT
[1510] 467.CCAAGGACATACTTTATAATA
[1511] 468.GTGAGGGCAATGGTGAATATA
[1512] 469.TGAGGGCAATGGTGAATATAA
[1513] 470.CGAAAGGCAAGCTTCTTAAAT
[1514] 471.GAAAGGCAAGCTTCTTAAATA
[1515] 472.GGCAAGCAAGGCAGGATTTAA
[1516] 473.ACAGGAACCTGGCTCTAATTT
[1517] 474.GGGACCTCCTGACATTTAATT
[1518] 475.GGACCTCCTGACATTTAATTA
[1519] 476.GACCTCCTGACATTTATTAA
[1520] 477.GTGGGAGCTTGTTACATATAT
[1521] 478.CTAAGTCTTCTCATCTATATA
[1522] 479.TTAGGTGGTCATGAGATAAAT
[1523] 480.TAGGTGGTCATGAGATAAATA
[1524] 481.AGGTGGTCATGAGATAAAATAT
[1525] 482.GGTGGTCATGAGATAAAATA
[1526] 483.GTGGTCATGAGATAAAATATAT
[1527] 484.CACAAAGCACATGGCTAAATA
[1528] 485.ACAAAGCACATGGCTAAATAA
[1529] 486.CGGTTATGTAGAAGCTATTTA
[1530] 487.GGTTATGTAGAAGCTATTTAA
[1531] 488.AGCCACCCTTAATTGAATAAT
[1532] 489.ACTACCCTTTACTGGTAATTT
[1533] SEQ ID NO:490
[1534] Stem-loop artificial / synthetic sequences.
[1535] CTCGAG
[1536] SEQ ID NO:491
[1537] Stem-loop artificial / synthetic sequences.
[1538] TCAAGAG
[1539] SEQ ID NO:492
[1540] Stem-loop artificial / synthetic sequences.
[1541] TTCG
[1542] SEQ ID NO:493
[1543] Stem-loop artificial / synthetic sequences.
[1544] GAAGCTTG
[1545] SEQ ID NO:494
[1546] shRNA artificial / synthetic sequences.
[1547]
[1548] SEQ ID NO:495
[1549] shRNA artificial / synthetic sequences.
[1550]
[1551] SEQ ID NO:496
[1552] shRNA artificial / synthetic sequences.
[1553]
[1554] SEQ ID NO:497
[1555] shRNA artificial / synthetic sequences.
[1556]
[1557] SEQ ID NO:498
[1558] shRNA artificial / synthetic sequences.
[1559]
[1560] SEQ ID NO:499
[1561] shRNA artificial / synthetic sequences.
[1562]
[1563] SEQ ID NO:500
[1564] shRNA artificial / synthetic sequences.
[1565]
[1566] SEQ ID NO:501
[1567] shRNA artificial / synthetic sequences.
[1568]
[1569] SEQ ID NO:502
[1570] shRNA artificial / synthetic sequences.
[1571]
[1572] SEQ ID NO:503
[1573] shRNA artificial / synthetic sequences.
[1574]
[1575] SEQ ID NO:504
[1576] shRNA artificial / synthetic sequences.
[1577]
[1578] SEQ ID NO:505
[1579] shRNA artificial / synthetic sequences.
[1580]
[1581] SEQ ID NO:506
[1582] shRNA artificial / synthetic sequences.
[1583] wherein nnnnnnnn can be CTCGAG (SEQ ID NO:490), TCAAGAG (SEQ ID NO:491), TTCG (SEQ ID NO:492) or GAAGCTTG (SEQ ID NO:493).
Claims
1. A polynucleotide sequence comprising: 5'-GATATCACCTTACAGAAATTA CTCGAG TAATTTCTGTAAGGTGATC-3'(SEQID NO:2)。 2. An expression vector comprising the polynucleotide sequence according to claim 1.
3. The expression vector according to claim 2, further comprising a promoter. The expression vector according to claim 3 , wherein the promoter is a neuron-specific promoter.
5. The expression vector according to claim 4, wherein the neuron-specific promoter is neuron-specific enolase (NSE), synapsin I (Syn) or Ca 2+ / CaM-activated protein kinase IIα (CaMKIIα). The expression vector according to claim 3 , wherein the promoter is U6 promoter or H1 promoter.
7. The expression vector of claim 2, wherein the expression vector is an adeno-associated virus (AAV) vector or a lentiviral vector.
8. The expression vector of claim 7, wherein the expression vector is AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10.
9. A pharmaceutical composition comprising the polynucleotide sequence according to claim 1 and a pharmaceutically acceptable carrier.
10. The pharmaceutical composition according to claim 9, wherein the polynucleotide sequence is contained in an expression vector.
11. The pharmaceutical composition according to claim 10, wherein the expression vector is an AAV vector or a lentiviral vector.
12. A polynucleotide encoding a shRNA comprising a nucleotide sequence that is at least 85%, at least 90%, at least 95% or 100% complementary to an RNA encoded by any one of SEQ ID NOs: 3-489.
13. The polynucleotide of claim 12, wherein the polynucleotide is SEQ ID NO:
2.
14. The polynucleotide of claim 12, wherein the shRNA results in activation or increase in expression of paternal UBE3A.
15. The polynucleotide of claim 12, wherein the shRNA results in decreased expression of paternal UBE3A-ATS.
16. An expression vector comprising the polynucleotide of claim 12 and a promoter. The expression vector according to claim 14 , wherein the promoter is a neuron-specific promoter.
18. The expression vector according to claim 17, wherein the neuron-specific promoter is neuron-specific enolase (NSE), synapsin I (Syn) or Ca 2+ / CaM-activated protein kinase IIα (CaMKIIα). The expression vector according to claim 16 , wherein the promoter is a U6 promoter or a H1 promoter.
20. The expression vector of claim 16, wherein the expression vector is an adeno-associated virus (AAV) vector or a lentiviral vector.
21. The expression vector of claim 20, wherein the expression vector is AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10.
22. The expression vector of claim 16, wherein the polynucleotide is a DNA polynucleotide.
23. A pharmaceutical composition comprising the polynucleotide sequence according to claim 12 and a pharmaceutically acceptable carrier.
24. The pharmaceutical composition of claim 23, wherein the polynucleotide sequence is contained in an expression vector.
25. The pharmaceutical composition of claim 24, wherein the expression vector is an AAV vector or a lentiviral vector.
26. A method for treating Happy Puppet Syndrome, the method comprising administering the polynucleotide according to claim 1 to a patient in need thereof.
27. The method for treating Happy Puppet Syndrome according to claim 26, wherein the polynucleotide encodes a shRNA that results in decreased expression of paternal UBE3A-ATS.
28. The method for treating Happy Puppet Syndrome according to claim 26, wherein the polynucleotide encodes a shRNA that results in activation or increase in expression of the paternal UBE3A gene.
29. A method for treating Happy Puppet Syndrome, the method comprising administering the polynucleotide according to claim 12 to a patient in need thereof.
30. The method for treating Happy Marionette Syndrome according to claim 29, wherein the polynucleotide encodes a shRNA that results in decreased expression of the paternal UBE3A-ATS.
31. The method for treating Happy Puppet Syndrome according to claim 29, wherein the polynucleotide encodes a shRNA that results in activation or increase in expression of the paternal UBE3A gene.
32. A polynucleotide comprising SEQ ID NO: 2 encoding a shRNA, wherein the shRNA is capable of inhibiting the silencing of paternal UBE3A.
33. A method for inhibiting silencing of a paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO: 1, the method comprising administering to a patient in need thereof an amount of the polynucleotide of claim 1 encoding shRNA effective to cleave the RNA antisense transcript encoded by SEQ ID NO:
1.
34. The method of claim 33, wherein the polynucleotide is contained within an expression vector.
35. The method of claim 34, wherein the expression vector is an AAV vector or a lentiviral vector.
36. The method of claim 33, wherein the polynucleotide is administered to the brain of the patient.
37. The method of claim 33, wherein the polynucleotide is administered to neurons of the patient.
38. The method of claim 33, wherein the shRNA reduces or terminates transcription of a polynucleotide comprising the sequence of SEQ ID NO:
1.
39. The method of claim 33, wherein the shRNA reduces the level of the RNA antisense transcript encoded by SEQ ID NO:
1.
40. A method for inhibiting silencing of a paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO: 1, the method comprising administering to a patient in need thereof an amount of the polynucleotide of claim 12 encoding shRNA effective to cleave the RNA antisense transcript encoded by SEQ ID NO:
1.
41. The method of claim 40, wherein the polynucleotide is contained within an expression vector.
42. The method of claim 41, wherein the expression vector is an AAV vector or a lentiviral vector.
43. The method of claim 40, wherein the polynucleotide is administered to the brain of the patient.
44. The method of claim 40, wherein the polynucleotide is administered to neurons of the patient.
45. The method of claim 40, wherein the shRNA reduces or terminates transcription of a polynucleotide comprising the sequence of SEQ ID NO:
1.
46. The method of claim 40, wherein the shRNA reduces the level of the RNA antisense transcript encoded by SEQ ID NO:
1.
47. The polynucleotide of claim 1 for use in treating Happy Puppet Syndrome, for use in activating paternal UBE3A, or for use in inhibiting silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO:
1.
48. The polynucleotide of claim 12, for use in treating Happy Puppet Syndrome, for use in activating paternal UBE3A, or for use in inhibiting silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO:
1.
49. Use of the polynucleotide according to claim 1 in the preparation of a medicament for treating Happy Marionette Syndrome, for activating paternal UBE3A, or for inhibiting the silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO:
1.
50. Use of the polynucleotide according to claim 12 in the preparation of a medicament for treating Happy Marionette Syndrome, for activating paternal UBE3A, or for inhibiting the silencing of the paternal UBE3A gene by an RNA antisense transcript encoded by SEQ ID NO:
1.
51. An shRNA encoded by a portion of SEQ ID NO:2, wherein the portion of SEQ ID NO:2 defines a first segment and a second segment, the first segment is defined by bold nucleotides, the first segment is shortened by one, two, three or four nucleotides at either end, and the second segment is defined by italic nucleotides, the second segment is shortened by one, two or three nucleotides at either end of the italic nucleotides.
52. The shRNA of claim 51, wherein the shRNA is encoded by SEQ ID NO:494, SEQ ID NO:495, SEQ ID NO:496, SEQ ID NO:497, SEQ ID NO:498, SEQ ID NO:499, SEQ ID NO:500, or SEQ ID NO:
501.
53. A polynucleotide sequence comprising: 5'-GATATCACCTTACAGAAATTA nnnnnnnn TAATTTCTGTAAGGTGATATC-3' (SEQ ID NO: 506), wherein nnnnnnnn Can be CTCGAG (SEQ ID NO: 490), TCAAGAG (SEQ ID NO: 491), TTCG (SEQ ID NO: 492) or GAAGCTTG (SEQ ID NO: 493).
54. A polynucleotide sequence comprising a first part, a second part and a third part, wherein the first part comprises any one of SEQ ID NO:3-489, the second part comprises any one of SEQ ID NO:490, 491, 492 or 493, and the third part comprises a corresponding nucleotide sequence complementary to the nucleotide sequence in SEQ ID NO:3-489.
